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ABSTRACT
Alongkronrusmee, Doungkamol Ph.D., Purdue University, May 2018. Identiﬁcation
of Novel Therapeutic Targets for Chronic Pain. Major Professor: van Rijn, Richard
M..
Chronic pain is a debilitating disorder associated with various diseases such as
arthritis and diabetic neuropathy and is also commonly observed during withdrawal
from chronic use of opioids or alcohol. Mu opioid receptor (MOR) agonists have
become a mainstay of pain therapy for thousands of years. While opioids are eﬀective
for acute pain, they are not useful for chronic pain and carry several adverse eﬀects.
This poor control of chronic pain urges a need for developing novel targets for chronic
pain relief. Here we have examined diﬀerent promising targets including delta opioid
receptor (DOR), DOR-MOR heteromers and adenylyl cyclase type I (AC1) which
have all been shown to be associated with chronic pain processing. Our studies
are providing important insights into mechanisms and eﬃcacy of these targets for
development of drugs for chronic pain with fewer side eﬀects.
In chapter 2, our aim is to identify the DOR as a possible target for treatment
of alcohol withdrawal-induced mechanical allodynia (AWiMA). One of the hallmarks
of chronic pain is mechanical allodynia (pain responses to normally innocuous stimuli). Mechanical allodynia is also a component of the alcohol withdrawal syndrome,
consisting of several separate symptoms including anxiety and depression, that can facilitate alcohol relapse. The currently available drug treatments for alcoholism rarely
combat the complexities of the withdrawal syndrome. Yet, the mechanisms underlying alcohol withdrawal symptoms speciﬁcally allodynia are still not well understood,
hampering development of novel medications that could treat the alcohol withdrawal
syndrome and reduce relapse. Here we propose that the DOR could be a novel target

xiii
for AWiMA therapy, particularly considering that DOR agonists also reduce alcohol
consumption and attenuate anxiety and depression in alcohol-withdrawn mice. To
study AWiMA, adult male wild-type and transgenic DOR knockout C57/BL6 mice
were exposed to alcohol either by a voluntary drinking or oral gavage exposure. The
DOR-selective agonist TAN-67 and antagonist naltrindole were used to examine the
involvement of the DOR in AWiMA, which was measured using a von Frey nociception
test.
We found that AWiMA was exacerbated and prolonged in DOR knockout mice as
well as by pharmacological blockade of DORs compared to control mice, indicating
a protective role of the DOR in the establishment of AWiMA. However, analgesia
induced by TAN-67 was attenuated during withdrawal in alcohol-gavaged mice, suggesting that DORs appear to be desensitized once mice reside in a state of severe
alcohol withdrawal. While this data supports the DOR as a drug target for prevention but not treatment of AWiMA, it is important to consider that DOR agonists
alleviate other components of the alcohol withdrawal syndrome and decrease the risk
of relapse.
In chapter 3, our aim is to identify a novel interaction site of the DOR-MOR heteromers using a multipronged approach. Evidence suggests that MORs can interact
with DORs to form DOR-MOR heteromers which display unique functions relative
to MOR or DOR monomer, and may contribute to side eﬀects of long-term mu opioid therapy for chronic pain. Our goal is therefore to develop drug-like compounds
that disrupt the heteromers to lessen the side eﬀects and increase the eﬀectiveness of
mu opioids. Yet, a lack of tools to selectively investigate the role of DOR-MOR heteromers in preclinical and clinical models is stiﬂing our ability to target the heteromers
with drugs. To aid in the development of such tools, it is important to comprehensively understand interactions between MORs and DORs; i.e., determining which
amino acids in the heteromer interface play major roles in the DOR-MOR formation.
Biochemical studies and insights gained from the crystal structures of the MOR and
DOR reveal that their transmembrane domains ﬁve and six may be essential for the

xiv
DOR-MOR interaction. We then constructed mutants spanning these domains of the
DOR to probe for destabilization of the DOR-MOR heteromers. We used a multipronged approach including heteromer-selective calcium signaling assay, bimolecular
ﬂuorescence complementation, co-immunoprecipitation and computational model to
investigate the impact of mutations on the stability and function of the heteromers.
We conﬁrmed that amino acid positions Ser5.67 , Val5.68 and Arg5.69 located in the
intracellular loop, which had been previously proposed by other labs, were crucial
in stabilizing the heteromers. Intriguingly, we identiﬁed novel amino acid positions
Tyr5.33 , Trp5.34 , Ile6.53 and Asp6.62 of DOR to be necessary for the heteromer formation. These discrete amino acids are located on the extracellular regions, thereby
providing a promising new target for heteromer disruption. These ﬁndings will move
us closer to our goal to develop small molecule protein-protein interaction inhibitors
that can be used with opioid analgesics to prevent or delay adverse eﬀects of chronic
opioid therapy.
In chapter 4, our aim is to study the eﬀectiveness of AC1 inhibition in a model
of (opioid resistant) inﬂammatory pain. Arthritis which occurs in 20% of US adults
is a major source of chronic inﬂammatory pain. Although opioids are commonly
prescribed for acute pain, they are not recommended for use in treating arthritic pain.
Recent studies have suggested that AC1 may be a new target of chronic pain. This is
supported by evidence showing a signiﬁcant decrease in chronic pain responses in AC1
knockout mice. Moreover, AC1 is the enzyme that synthesizes cAMP which functions
as a second messenger in opioid receptor signaling. Chronic opioid use can lead to
so-called cAMP superactivation which has been suggested to contribute to opioidinduced abnormal pain sensitivity and tolerance. We thus hypothesize that inhibition
of AC1 will reduce (opioid resistant) pain associated with chronic inﬂammation. Our
studies have demonstrated that a recently identiﬁed AC1 inhibitor ST034307 is able
to provide analgesia in a Complete Freunds Adjuvant model of acute inﬂammatory
pain and may reduce withdrawal signs observed in opioid-dependent mice.

1

1. INTRODUCTION
1.1

Chronic pain
As published in
An integrated perspective on diabetic, alcoholic, and drug-induced

neuropathy, etiology, and treatment in the US. Journal of Pain Research
(2017) 10:219-228.

1.1.1

Basic anatomy of pain

Comprehending the pathophysiology of chronic pain and the mechanism of action
for drugs requires a basic appreciation of the anatomy of the somatosensory system.
Noxious stimuli, such as thermal, chemical, and high-threshold mechanical stimuli,
are detected in the periphery and conducted to the spinal cord via two types of small
ﬁbers. The C ﬁbers are unmyelinated, slow-conducting, and localize pain poorly.
The Aδ ﬁbers are thinly myelinated, faster-conducting, and localize pain better [1,2].
Larger and more thickly myelinated than Aδ ﬁbers are Aα and Aβ ﬁbers, which
primarily transmit information about proprioception and vibration [3]. It is primarily the Aδ and C ﬁbers that are indiscriminately aﬀected in the diﬀerent types of
chronic pain (Figure 1.1). Measuring which type of ﬁbers are impacted is not trivial,
but can be attempted by clinical examination; loss of tactile or vibratory skin sensation or tendon reﬂexes are indicative of large-ﬁber neuropathy, whereas alterations in
lower-limb pinprick sensation and a visual analog scale pain score >40 suggest smallﬁber neuropathy [5]. Small-ﬁber neuropathy can also be determined by measuring
intraepidermal nerve-ﬁber density following biopsy [6]. Aδ-ﬁber neuropathy can be
measured noninvasively by laser evoked-potential [7, 8] and contact heat-evoked po-
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Fig. 1.1. Overview of neuropathies aﬀecting pain pathways. Notes:
C and Aδ ﬁbers are aﬀected by diabetes, drugs, and alcohol (and its
metabolite acetaldehyde), whereas large, myelinated Aα and Aβ ﬁbers
are aﬀected by drugs and thiamine deﬁciency. Channels (sodium,
calcium) and receptors (NMDA, serotonin, adrenergic, opioid) along
the pain pathway serve as drug targets for treatment of chronic
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transient receptor potential; CGRP, calcitonin gene-related peptide.
Reprinted from [4].
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tential [9, 10]. Nerve-conducting studies are a useful technique for neuropathic pain
(NeuP) research, but less relevant for clinical studies, as they primarily measure Aβﬁber function, which supersedes small-ﬁber neuropathy [11] and is laborious [12].
Receptors on primary sensory neurons convert environmental stimuli, such as pain,
into an electrical signal that is transmitted to the dorsal root ganglia, with an important role for sodium channels [13,14]. In the terminals of the dorsal root ganglia, neurons subsequently convert this electric signal into chemical signals by releasing neurotransmitters and neuropeptides, including glutamate, substance P, and calcitonin
gene-related peptide into the dorsal horn (Figure 1.1). A signiﬁcant event that occurs
during the development of a chronic pain state is central sensitization, where postsynaptic glutamate (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA]
and N-methyl-d-aspartate [NMDA]) receptors become increasingly more adaptive in
transmitting pain signals [15–19]. Activation of presynaptic calcium channels can
reduce the release of neurotransmitters and dampen central sensitization (Figure
1.1) [20, 21]. In the spinal cord, this nociceptive signal can be modulated by inhibitory interneurons using γ-aminobutyric acid (GABA) and glycine as their main
neurotransmitters. Following the reception of a pain signal in the cortical structures
of the brain, the experience of pain can still be suppressed by a descending system that
originates from the brain stem. This eﬀerent system attenuates the aﬀerent signal via
neurotransmitters, such as endogenous opioids, serotonin, and noradrenaline [22–24].

1.1.2

Major types of chronic pain

Diabetic neuropathy
Peripheral neuropathy is one of the most common microvascular complications
of diabetes. It has been estimated that ∼50% of diabetics suﬀer from peripheral
neuropathy [25], and 50% of these neuropathies are considered at least moderate in
severity [26–28]. Histological studies suggest that primarily small C ﬁbers are aﬀected
by diabetes and glucose intolerance [29–32], although Aδ ﬁbers have also been shown
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to be aﬀected by type 1 and type 2 diabetes [33–35]. Morbidities associated with
diabetic neuropathy amount to more than $10 billion in the US [36].
Diabetes or glucose intolerance can impair vasodilation and lead to ischemia,
which is thought to be central to the pathogenesis of peripheral neuropathy, including
trigeminal neuralgia [37,38]. A recent study demonstrated that patients with glucose
intolerance, even without carrying the diagnosis of diabetes, exhibited C-ﬁber neuropathy, highlighting the devastating eﬀect of prolonged hyperglycemia on neuronal
health [39]. On a molecular level, there are at least ﬁve prevailing mechanisms of how
hyperglycemia leads to diﬀerent complications of diabetes, with the polyol and PARP
pathways being the most relevant to neuronal death [40]. In the polyol pathway, the
inﬂux of glucose into the cell activates aldose reductase to convert glucose to sorbitol.
Sorbitol is then converted to fructose via sorbitol dehydrogenase. Both of these steps
generate oxidative species that contribute to neuronal injury [40, 41]. In Schwann
cells, endothelial cells, and sensory neurons, PARP is stimulated by oxidative species
and induces further oxidative stress in a feedback mechanism [42–46]. PARP is a nuclear enzyme that can also alter gene expression, leading to impairment of neuronal
conduction velocity, small-ﬁber neuropathy (Figure 1.1), hyperalgesia, and allodynia,
as well as other diabetic complications [40, 42, 47–51].

Alcoholic neuropathy
The prevalence of alcohol-related peripheral neuropathy has been estimated to
occur in two-thirds of chronic alcoholics [52]. Alcohol-related peripheral neuropathy
is historically regarded as a large-ﬁber neuropathy from thiamine deﬁciency (Figure
1.1) [53–57]. In contrast to small sensory ﬁbers, large ﬁbers are responsible for vibration and proprioception. However, advances in scientiﬁc techniques have reshaped
the pathophysiology of alcoholic neuropathy. Observations that neuropathy can develop even in the setting of normal thiamine levels [58] and that the early stages of
alcoholic neuropathy are characterized by painful paresthesia [59] have led scientists
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to postulate that alcohol and its metabolites have direct neurotoxic eﬀects on small C
ﬁbers (Figure 1.1) [60, 61]. Acetaldehyde is a known neurotoxin that is formed when
alcohol is metabolized by alcohol dehydrogenase. The precise mechanism underlying
alcoholic neuropathy is yet to be fully elucidated. Some proposed explanations include direct neurotoxic eﬀects of alcohol or its metabolite acetaldehyde [58] through
activation of spinal cord microglia [62], involvement of metabotropic glutamate 5 and
opioid receptors [62,63] in the spinal cord, promotion of oxidative stress by the activity of alcohol-metabolizing enzymes in the liver [64], and release of proinﬂammatory
cytokines coupled with phosphorylation of protein kinase C [65] and extracellular
signal-regulated kinases [66]. Taken together, these diﬀerent initiating events may
ultimately lead to DNA fragmentation and neuronal apoptosis [67]. Once formed,
acetaldehyde is metabolized by aldehyde dehydrogenase (ALDH) into a much less
harmful acetate. Interestingly, pharmacological and genetic data suggest that reducing ALDH activity can precipitate peripheral neuropathy, whereas increasing its
activity may carry therapeutic potential. As such, an ALDH inhibitor disulﬁram has
the side eﬀect of causing NeuP [68].

Medication-induced neuropathy
Disulﬁram is not unique in causing NeuP; in fact, many and more commonly
prescribed drugs, which span the spectrum of chemotherapy to cardiovascular medications, are known to induce neuropathy. This section focuses on taxanes, with
mention of statin-induced neuropathy. Paclitaxel and docetaxel are antineoplastic
taxanes used to treat numerous types of solid tumors, including ovarian, breast, lung,
and head and neck malignancies. Paclitaxel has its chemotherapeutic eﬀect by promoting microtubule assembly in a disorganized manner, thereby prohibiting mitotic
division. It is by this very same mechanism that paclitaxel causes peripheral neuropathy, one of the most common and limiting side eﬀects of the drug. In vivo studies have
demonstrated that paclitaxel causes abnormal microtubule accumulation, leading to
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demyelination [69, 70], and inhibits the regenerative capacities of neurons [71, 72]. In
a non-dose-dependent manner, paclitaxel causes hyperalgesia and allodynia without
aﬀecting motor performance [73]. Clinically, patients have complained of sensory
neuropathy and decreased vibration and proprioception, indicating that both small
C and Aδ ﬁbers are aﬀected (Figure 1.1) [74–77]. One of the original articles on
paclitaxel-induced neuropathy studied paclitaxel infusion at three doses, and found
that neuropathy developed in >80% of the patients at all doses and was dose limiting
in 70% of patients at the highest dose [78].
It is noteworthy that diabetes is a predisposition to drug-induced neuropathy.
In a retrospective study comparing the rates of taxane-induced neuropathy, chronic
diabetics (deﬁned by >5 years) developed neuropathy more frequently compared to
nondiabetics [79]. With regard to treating chemotherapy-induced peripheral neuropathy, SNRIs have been shown to be superior to placebo [80]. These drugs are also used
in the treatment of diabetic neuropathy. Together, these data suggest that taxanes
and diabetes act diﬀerently but synergistically in causing peripheral nerve damage
and NeuP.
Statins are prescribed to >40 million patients in the US alone (https://meps.ahrq.gov),
and are frequently prescribed to diabetics to reduce their cardiovascular risk. It is
interesting to note that there have been reports of statin-induced peripheral neuropathy [81, 82]. Though statins are demonstrated to have pleiotropic eﬀects, preclinical
studies suggest that they can attenuate NeuP by potentiating antioxidation [83, 84].
Promising data have also been found in human studies where rosuvastatin improved
both the intensity of diabetic neuropathy pain and nerve conduction [85]. In combination with the rarity of statin-induced neuropathy, these data suggest that this
potential side eﬀect of statin should minimally inﬂuence the physicians decision to
prescribe statins for vascular protection.
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1.1.3

Current chronic pain therapies

Based on a 2015 analysis of a systemic review and meta-analysis performed by
the Neuropathic Pain Special Interest Group on clinical studies of neuropathic pain
pharmacotherapy, a new guideline for treatment of neuropathic pain was recently
proposed [86]. The guidelines highlight the diﬃculty in adequately treating neuropathic pain, but recommend the use of tricyclic antidepressants (TCAs), serotoninnorepinephrine reuptake inhibitors (SNRIs), pregabalin, and gabapentin as ﬁrst-line
treatment options for neuropathic pain [86].

Tricyclic antidepressants
A number of randomized controlled trials have shown that TCAs may exert their
NeuP-relieving eﬀect via multiple mechanisms of action [87, 88]. The potential of
TCAs in pain relief is primed by their inhibition of presynaptic reuptake of serotonin
and norepinephrine [89,90] and activity at NMDA receptors and sodium channels [91],
all of which are involved in pain transmission. Amitriptyline and nortriptyline are
two of the oldest TCAs on the market. Although their use to treat depression has
declined with the increased popularity of SNRIs, they continue to be used oﬀ-label
to treat NeuP. However, according to recent Cochrane meta-analyses, no high-quality
evidence exists to support the analgesic eﬀect of both amitriptyline and nortriptyline,
despite an extensive history of anecdotal success [92, 93]. A factor for the declining
use of TCAs, whether for depressive disorders or NeuP, is that TCAs have a high
risk for fatal overdose and require careful dosing. Therefore, TCAs should not be
advocated for use as ﬁrst-line treatment of NeuP.

Serotonin-norepinephrine reuptake inhibitors
Venlafaxine and duloxetine are SNRIs that are prescribed to treat depression,
anxiety, and NeuP. Serotonin and norepinephrine play integral parts in the descend-
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ing pain pathway to suppress pain [94–96]. Preclinical and clinical research has
shown that drugs that increase serotonergic and noradrenergic neurotransmissions
exert antinociceptive properties. For example, SNRIs signiﬁcantly attenuated painrelated behaviors in the formalin model of persistent pain and the L5-L6 spinal nerve
ligation model of NeuP in rats [97]. SNRIs are also eﬃcacious in the treatment of
pain and functional impairment associated with ﬁbromyalgia, as per a number of
randomized controlled trials [98–101].
Pharmacological studies have demonstrated that for certain SNRIs, serotonin
reuptake inhibition predominates at low drug concentration, whereas inhibition of
norepinephrine reuptake occurs only at much higher doses [102]. Unlike treating depression, the treatment for NeuP with SNRIs is achieved at higher doses and more
rapidly. For venlafaxine, the usual antidepressant dosage is much lower than what is
needed for pain relief [103], suggesting that norepinephrine contributes more strongly
to attenuating pain. The importance of norepinephrine is further exempliﬁed by the
eﬀect of clonidine, an adrenergic receptor agonist, in alleviating pain [104]. However, a Cochrane review found that venlafaxine had limited eﬃcacy compared to
placebo [23]. Despite relatively similar pharmacology, duloxetine was eﬀective for the
relief of NeuP [105]. Duloxetine is a much more potent inhibitor of the serotonin
and norepinephrine reuptake transporters than venlafaxine [102]. Therefore, when
choosing a SNRI, we would favor the use of duloxetine.

Calcium-channel blockers
Changes in the expression and activity of voltage-gated calcium channels are
known to modulate neuronal excitability and synaptic plasticity in the dorsal horn,
culminating in pain processing [106–108]. The Cav α2 δ 1 subunit, an important accessory subunit for calcium channels, plays an important role in NeuP development,
based on reports of increased expression in the dorsal root ganglia and spinal neurons
during NeuP states [109–111]. Further supporting evidence shows that blockade of

9
the Cav α2 δ 1 subunit could reverse tactile allodynia in nerve-injured animals [112,113].
Interestingly, the Cav α2 δ 1 subunit is the binding site for pregabalin and gabapentin
[114]. Pregabalin and gabapentin were developed and US Food and Drug Administration (FDA) approved for treatment of epilepsy, but have become ﬁrst-line treatments
for NeuP.
A Cochrane review using randomized double-blind trials found pregabalin to be effective for the treatment of NeuP. Pregabalin at doses of >300 mg provided moderate
pain relief (50% improvement from baseline) in diﬀerent types of pain [115]. Another
Cochrane review investigated the eﬃcacy of gabapentin on NeuP using randomized
double-blind controlled studies, and concluded that 1,200 mg daily was needed to
achieve 50% pain relief. This eﬀect was found in 35% of study participants compared
to 21% in the placebo group [116]. To avoid sedating eﬀects, gabapentin is divided
into three doses, and patients are routinely instructed to titrate the dose, starting at
300 mg daily. However, compliance is a major issue in patients on gabapentin, usually as they dismiss the medications as ineﬀective and discontinue the medications
before reaching the therapeutic dose. Therefore, it is prudent to educate patients
of this therapeutic range. Moreover, a recent study has shown that the endogenous lipid palmitoylethanolamide has synergistic eﬀects with gabapentin to relieve
chemotherapy-induced allodynia in mice, which makes it possible to reduce the dosage
of gabapentin and lower its side eﬀects [3].
To further illustrate the vital role of calcium channels in pain transmission, ziconotide is a selective calcium-channel blocker and potent analgesic. Ziconotide is
FDA approved for the treatment of refractory chronic pain [117]. As ziconotide is a
large peptide that cannot readily cross the blood-brain barrier, it can thus only be
administered intrathecally. Intrathecal drug delivery can be used to manage chronic
pain eﬀectively, and may provide the most targeted approach with the fewest side
eﬀects [118–121].
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Opioids and drug development
Although opioids are intended for short-term use for acute pain, they have repeatedly been used to treat chronic pain. For example, tramadol has been used to treat
chronic pain, in part due to its dual action as a µ-opioid agonist and SNRI [86]. Patients frequently cite failures of diﬀerent adjunctive therapies to alleviate their pain,
and revert to the use of opioids. In light of the rapid increase in patients suﬀering
from opioid dependence/use disorders, the Centers for Disease Control and Prevention
(CDC) has recently published guidelines to avoid routinely prescribing narcotics for
the management of chronic pain. In addition to dependence, opioids also cause other
serious side eﬀects including tolerance, ileus, and respiratory depression. The latter
side eﬀect explains the high hospitalization and mortality rate associated with opioid overdose, which has increased concomitantly with the rise in opioid dependence.
Moreover, prolonged use of (escalating doses of) opioids can lead to paradoxical pain,
also known as opioid-induced hyperalgesia, and discontinuation of opioids leads to
withdrawal hyperalgesia. While the CDC guidelines are helpful for guiding narcotic
use, it will be challenging to unearth the culture of pain management that is heavily rooted in narcotics. The CDC currently excludes these guidelines from patients
with active malignancy, which remains a challenge to treat, despite rapidly escalating
doses of opioids. Clearly, safer, more potent and selective therapeutics are necessary
and overdue. Although the CDC raised concerns regarding the use of µ-opioids in
chronic pain, it is important not to dismiss completely their analgesic potential for
acute pain and palliative care [122]. Importantly, other opioid-receptor subtypes like
µ are also expressed along descending pain pathways, and increasing research eﬀorts
have identiﬁed these non-µ-opioid receptors as potential analgesic targets for chronic
pain.
While current analgesic opioids target µ-opioid receptors, there are three other
opioid-receptor subtypes. One of the most intriguing new developments in the use
of opioids for NeuP comes from work focused on δ-opioid receptors (DORs), κ-ORs

11
(KORs), and nociceptin ORs (NORs). DORs, KORs, and NORs are expressed in
several levels of pain pathways, including the periphery, spinal cord, and supraspinal
regions [123–129]. The expression of opioid-peptide messenger RNA also increases under conditions of chronic pain [130–132]. Preclinical evidence has demonstrated that
inhibition of DORs or KORs via either opioid antagonists or genetic ablation in mice
enhances allodynia and hyperalgesia following spinal cord injury [133–136]. Additionally, both DOR and KOR agonists have elicited antinociceptive and antiallodynic
eﬀects in animal models of NeuP [130,137–139]. An intriguing recent study identiﬁed
6-methoxyﬂavanone as a positive allosteric modulator of GABAA channels that can
alleviate streptozotocin-induced diabetic NeuP in female rats in a naloxone-reversible
manner, potentially via direct interaction with DORs and KORs [140]. In contrast,
the role of NORs in nociception is less linear: analgesic actions of the nociceptin
system in rodents are bidirectional, depending upon the doses and assays [141–143].
Encouragingly, the activation of NORs produces only attenuated and not intensiﬁed pain in primates regardless of experimental conditions [144, 145], and thus their
therapeutic potential in humans remains.

1.2

Delta opioid receptors
As published in

Delta Opioid Pharmacology in Relation to Alcohol Behaviors. Handbook
of Experimental Pharmacology (2016).
Delta opioid receptors (DORs) are heavily involved in alcohol-mediated processes
in the brain. In this section we provide an overview of studies investigating how alcohol directly impacts DOR pharmacology and indicating DOR modulation of alcohol
behavior, types of alcohol behaviors modulated by DORs, the relationship between
alcohol and DORs in analgesia, a link between DOR expression in speciﬁc brain regions and diﬀerent alcohol behaviors, two models explaining how endogenous opioids
acting at DORs may inﬂuence alcohol behaviors, new aspects of DOR pharmacology,
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including the formation of heteromers and biased signaling, and, ﬁnally, the potential
of using DOR-based therapeutics for treatment of alcohol use disorders (AUDs).

1.2.1

Direct impact of alcohol on delta opioid receptor pharmacology

Acute and chronic alcohol exposure can impact DOR pharmacology on several
diﬀerent levels: (1) by changes to endogenous opioid levels, (2) changes in DOR
expression level, or (3) modifying aﬃnity or potency of endogenous and exogenous
ligands for DORs in particular brain regions. Acute alcohol exposure has been shown
to reduce the aﬃnity of DOR by various mechanisms. Hiller and Hoﬀman have
demonstrated that alcohol and other aliphatic alcohols selectively inhibit the binding of enkephalins, the DOR preferring endogenous opioids, to DOR binding sites as
observed by a reduction in the aﬃnity or by an increase in the ligands dissociation
rate [146, 147]. This reversible inhibition may result from the cell membrane perturbation by alcohols since the potency of inhibitory eﬀect and the degree of membrane
disorganization are correlated with the alcohol chain length [146]. Acute alcohol treatment also decreases the binding of the DOR agonist [3 H]DPDPE, agonist-stimulated
[35 S]GTPγS binding, and rate of receptor internalization in brain tissue or in N18TG2
cells expressing mouse DOR [148–150]. However, the eﬀects of acute alcohol on DOR
pharmacology may be more pronounced when directly administered to the tissue as
brains from rats with prior exposure to a single dose of alcohol did not exhibit changes
in DOR aﬃnity [151].
While the eﬀects of acute alcohol exposure may be detectable only in vitro, chronic
alcohol exposure has been reported to modify DOR aﬃnity and expression both in
cell lines and in animal tissue. Chronic alcohol exposure in neuronal cell lines endogenously expressing DORs has been reported to increase DOR levels [152–154] in part
due to increasing DOR mRNA levels [154, 155]. Ex vivo, functional studies on brain
tissue from chronic alcohol-exposed rats found decreased DOR agonist-stimulated
[35 S]GTPγS binding in the alcohol-exposed rats compared to controls, possibly as a
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consequence of receptor internalization and phosphorylation [156]. A small number
of studies have reported minor changes in DOR aﬃnity, expression, and/or functionality with chronic alcohol exposure [157, 158]. On the other hand, several studies
found that chronic alcohol exposure increased DOR expression levels, either without
aﬀecting aﬃnity [159] or while slightly decreasing aﬃnity [160]. In vivo experiments
have also found evidence for increased expression of DORs after chronic alcohol exposure [161,162]. Some of the diﬀerential DOR expression in response to chronic alcohol
exposure may be ascribed to diﬀerent species, strains, or age of animals, speciﬁc brain
regions studied, and alcohol intake paradigms (e.g., duration, dose/concentration
used). Previous studies have shown that young rats express higher levels of DORs
than older rats [159, 163]. The inﬂuence of stress, for example, stress induced by
alcohol withdrawal [164], may be another factor that can impact DOR expression
in some of the animal models. It has been shown that stressful events can increase
DOR expression [165–167], whereas stress prior to alcohol consumption may prevent
an increase in DOR aﬃnity for DPDPE [168].

1.2.2

Initial behavioral evidence for a role of delta opioid receptors in
alcohol use

Initial behavioral evidence for an interventional role of opioid receptors in alcohol
use came from studies using the non-selective opioid receptor antagonists naloxone
[169] and naltrexone [170]. In order to identify which of the opioid receptor subtypes
is involved in alcohol consumption, various groups have tested antagonists selective
for diﬀerent subtypes of opioid receptor. Betafunaltrexamine, an irreversible muopioid receptor (MOR) antagonist, did not decrease alcohol consumption at a dose
previously shown to antagonize various eﬀects of morphine [170]. On the other hand,
selective DOR antagonists, ICI 174,864 and naltrindole, did reduce voluntary alcohol
consumption [170]. ICI 174,864 is a peptide and thus susceptible to endogenous
proteases [171], whereas naltrindole is a nonpeptide small molecule, which has a
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longer period of eﬀectiveness in vivo [172, 173]. Naltrindole also has greater potency,
selectivity, and binding aﬃnity for DOR than ICI 174,864 [173] and is therefore more
commonly used as a tool to study DOR pharmacology. However, naltrindole has been
reported to decrease saccharin intake as well as alcohol consumption, suggesting that
intake of sweet solutions may also release endogenous opioids [174]. Studies using the
enkephalinase inhibitor thiorphan provided another line of support for a role of DORs
in alcohol intake. Thiorphan, by enhancing endogenous activation of DORS through
their ability to increase enkephalin tone, can elevate alcohol intake in rats [169]. To
better understand the mechanism of action behind the opioid modulation of alcohol
intake, Widdowson and Holman looked at alcohol’s eﬀect on dopamine release in the
brain. Basal dopamine release from striatal slices is dose-dependently increased in the
presence of DOR agonist. Bath application of alcohol onto the striatal slices raised
the dopamine level in a dose-dependent manner. This eﬀect is reversible by the use
of the DOR antagonist ICI 174,864, linking this response to DORs [175].
Additional data supporting a role for DORs in alcohol consumption came from
studies performed by de Waele et al. (1996, 1997) using a portacaval anastomosis
(PCA) model in rats. In this model, a cirrhosis-like state was induced using portalsystemic shunts causing portal-systemic encephalopathy [176]. PCA rats exhibited
enhanced voluntary alcohol consumption compared to sham controls, and PCA rats
also had a reported increased density of DORs in the nucleus accumbens [176]. These
increases in alcohol consumption due to PCA are also reversible by the use of naloxone [177].

1.2.3

Delta opioid receptor modulation of alcohol behaviors

There are many facets to what constitutes as well as what causes AUDs. In order
to understand the therapeutic potential of a drug target in the treatment of AUDs, it
is important to model these diﬀerent aspects of alcohol use. The therapeutic potential
of DORs has been studied in a diverse set of alcohol paradigms.
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Volitional alcohol intake
Alcohol use in rodents is frequently studied using a two-bottle choice paradigm,
in which mice or rats are given a choice between water and alcohol with a certain
percentage, usually in the range of 1-20%, for a speciﬁed period of time per day. Frequently these studies are performed under a reversed light cycle to enable the animals
to drink the alcohol during their active cycle (drink in the dark, DiD paradigm). It
has been shown that DOR antagonists like ICI 174,864, naltrindole and naltriben,
and SoRI-9409 can reduce voluntary alcohol intake in these models [174,178–181]. In
a similar mouse model, the DOR agonist TAN-67 has also been reported to decrease
alcohol intake [182], whereas the DOR agonist SNC80 increased alcohol consumption [183]. Some studies however report not ﬁnding that naltrindole signiﬁcantly
decreases volitional alcohol intake in rodents [182, 184]. This may be due to diﬀerences in endogenous opioid tone based on the age, genetic background, and alcohol
history of the animals tested. For example, naltrindole was found to decrease alcohol
intake when, during alcohol exposure, no water is available [185].

Conditioned place preference
Alcohol, at non-sedating doses, can cause release of dopamine from dopaminergic
ventral tegmental area (VTA) neurons. This dopamine is thought to valuate alcohol
as a pleasurable and rewarding substance worth seeking [186–188]. A commonly
used paradigm to study the rewarding properties of drugs is the conditioned place
preference (CPP) test [189]. In rats the expression of alcohol-induced CPP could
also be blocked by naltrindole [190]. In C57BL/6 mice the expression of alcohol CPP
can be blocked by the DOR agonist SNC80 but can be slightly enhanced by another
DOR agonist TAN-67 [191]. This corresponds with earlier ﬁndings showing that
SNC80 increases but TAN-67 decreases alcohol consumption [182, 183]. Van Rijn et
al. (2010) proposed that, by reducing the rewarding eﬀects of alcohol, mice treated
with SNC80 will need to drink more alcohol to obtain the same rewarding eﬀects they
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would normally obtain when drinking alcohol. Not only can DOR agonists modulate
alcohol CPP, alcohol exposure can also impact CPP of DOR agonists. Mitchell et
al. (2014) found that rats exposed to alcohol, but not alcohol-naive rats, displayed
conditioned place preference to the DOR2 agonist deltorphin II. It has been shown
that stress (induced by foot shock) increases the rewarding properties of alcohol, which
can be blocked by naltrindole, suggesting the involvement of endogenous enkephalins.
In this paradigm TAN-67 enhanced stress-induced alcohol place preference [192,193],
consistent with the ﬁnding that TAN-67 enhances alcohol CPP [191].

Reinstatement of alcohol-seeking behavior
Like other types of drug addiction, alcoholism is characterized as a chronic relapsing condition. One method of studying alcohol relapse is to train mice to selfadminister alcohol followed by a period of abstinence and then use either drugs,
stress, or contextual cues to reinstate alcohol-seeking behavior. In this paradigm
the DOR antagonists naltrindole and SoRI-9409 were able to inhibit drug seeking
in rats [163, 194, 195]. Reinstatement can also be measured in a CPP paradigm. A
study by Gibula-Bruzda et al. (2015) found that the enkephalin derivative cUENK6
(cyclo[N, Nbeta-carbonyl-D-Lys2,Dap5] enkephalinamide) could reinstate alcohol
CPP in a naltrindole reversible manner.

Alcohol withdrawal-induced seizures
One of the well-known consequences of alcohol withdrawal is the occurrence of
potentially life-threatening seizures [196, 197]. Even though both DOR agonists [182,
183, 191, 198] and DOR antagonists [163, 174, 178, 180, 199] are considered possible
options for reducing alcohol use, a potential limiting side eﬀect of some DOR agonists
is that they can produce seizures in naive animals [200–205]. However, this is not
the case for all DOR agonists [206, 207]. It is thus more encouraging than surprising
that certain DOR agonists are able to reduce alcohol withdrawal-induced audiogenic
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seizures [208]. Given that enkephalin levels are decreased during alcohol withdrawal
[209], the use of DOR agonists to prevent alcohol withdrawal-induced seizures can be
considered a form of replacement therapy.

1.2.4

Impact of alcohol use and withdrawal on delta opioid receptormediated analgesia

Certain doses of alcohol produce analgesia [210], potentially through the release
of endogenous opioids. Indeed alcohol-induced thermal analgesia can be blocked by
opioid receptor subtype-selective antagonists [211]. Additionally, alcohol exposure
can modulate opioid-induced antinociception. For example, chronic but not acute
alcohol consumption decreases thermal analgesic potency of MOR (morphine) and
DOR (DSLET) agonists without changes in opioid receptor expression or aﬃnity in
both brain and spinal cord [212].
Recent studies have revealed that, under naive conditions, DORs are selectively expressed in non-peptidergic pain circuits that regulate mechanical sensitivity, whereas
MORs are localized in peptidergic pain circuits that process thermal nociception [213].
Van Rijn and coworkers have illustrated that chronic alcohol may increase DOR cell
surface expression in the spinal cord neurons modulating thermal pain [161]. The
newly translocated DORs could potentially modulate MOR analgesia by forming
DOR-MOR heteromeric complexes [161, 214, 215] or potentially by competing for
downstream mediators or by synergistic cross talk [216, 217]. Given that alcohol dependence and alcohol withdrawal can induce a state of hyperalgesia [218–221] and
upregulate DOR cell surface expressions, DORs may serve as a promising target to
treat hyperalgesia caused by alcoholic neuropathy or alcohol withdrawal. Yet, surprisingly few studies have investigated the role of opioid receptors in the mechanism
by which alcohol dependence modulates analgesia. Further investigations are thus
needed to understand how DORs and other opioid receptor subtypes impact the dynamic process of alcohol modulation of pain states.
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1.2.5

Neuroanatomical analysis of delta opioid receptor-induced modulation of alcohol behaviors

The dopaminergic neurons in the VTA play a central role in the mechanism of action of drugs of abuse and alcohol [222,223]. VTA dopaminergic neurons project to the
NAcc, striatum, prefrontal cortex, hypothalamus, amygdala, and hippocampus [224].
Studies using autoradiography and in situ hybridization or using a transgenic DOR
receptor linked to a green ﬂuorescent protein (DOR-eGFP) have provided evidence
that DORs are expressed in these important brain areas [177, 225–235]. Diﬀerent
studies have investigated the role of DORs on alcohol behaviors in each of these brain
regions. Here we summarize the unique functions of DORs in these brain regions in
relation to alcohol behaviors (Figure 1.2).

Ventral tegmental area
Opioid receptors located on presynaptic GABA terminals in the VTA are well
known for their ability to disinhibit dopaminergic neurons upon activation [224, 245].
It is known that rats will lever press to receive intra-VTA infusions of not only morphine and other MOR agonists but also DOR agonists [246]. This indicates that
DORs, like MORs, play a role in drug reinforcement of opioid self-administration.
Interesting evidence of DOR function modulating dopamine release from VTA neurons came from a study investigating the use of acupuncture in alcohol withdrawal.
Alcohol withdrawal increases the excitability of the VTA GABA neurons [247], which
can be reduced by acupuncture in rats in a naltrindole reversible manner [248], suggesting that acupuncture releases DOR-selective endogenous opioids in the VTA.
Studies by the Fields group have provided important insight into the role of DORs in
alcohol consumption. They found that low alcohol-drinking rats exhibited stronger
DOR inhibition of GABAA signaling in VTA slices. In these low-alcohol-drinking
rats, intra-VTA injection of a DOR agonist decreased alcohol intake, whereas injection of the DOR antagonist TIPP-ψ signiﬁcantly increased alcohol intake in low but
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Fig. 1.2. Impact of local modulation of DORs on alcohol behaviors.
In the ventral tegmental area (VTA), the DOR agonist DPDPE decreases and the DOR antagonist TIPPψ increases alcohol intake [236],
although naltrindole reportedly had no eﬀect [237]. The DOR agonist SNC80 increases and the DOR antagonist naltrindole decreases
alcohol intake in the dorsal striatum [163]. In the nucleus accumbens (NAcc), the DOR agonist DALA increases alcohol intake [238]
and naltrindole decreases alcohol intake [237] and alcohol-induced
dopamine release [239], whereas the DOR antagonist ICI 174,864 attenuates alcohol-induced loss of righting reﬂex [240]. Naltrindole decreases alcohol intake [237] and alcohol place preference [162] in the
amygdala. The DOR agonist DALA increases alcohol intake [241] in
the paraventricular nucleus (PVN) but decreases alcohol intake [242]
in the perifornical lateral hypothalamus (PF/LH). Naltrindole injection in the ventral pallidum (VP) does not modulate alcohol intake [243]. Reprinted from [244].
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not in high-alcohol-drinking rats [236]. This result could explain how microinjection
of naltrindole in the VTA of alcohol-preferring rats and high-alcohol-drinking Wistar
rats did not aﬀect alcohol intake [237]. It appears that rats that are more anxious,
more stressed, and/or more intoxicated by alcohol express higher levels of DORs in
the VTA [165, 249]. It remains uncertain how translatable the ﬁndings of an association between DOR expression and stress levels in alcohol-consuming rodents are to
humans as results from PET study using the DOR radiotracer in alcohol-dependent
patients found no correlation between [11 C] methyl-naltrindole-binding potential and
cortisol or adrenocorticotropin [250].

Nucleus accumbens
The nucleus accumbens plays a critical role in processes of drug reinforcement
and stress [251]. Mesolimbic dopamine projections connecting the VTA with the
NAcc also play a facilitatory role in alcohol self-administration. The DOR agonist
deltorphin II directly infused into the NAcc has been shown to mimic the eﬀect of
alcohol-induced dopamine release [239]. This eﬀect can be inhibited by using naltrindole, suggesting that endogenous opioids are involved and that DORs are locally
expressed on the terminals of dopaminergic neurons, as previously suggested by Borg
and Taylor [252]. Microinjection of naltrindole into the NAcc also decreases alcohol
responding in alcohol-preferring Wistar rats [237]. Several studies have reported that
DOR and enkephalin expressions are lower in the NAcc of alcohol-preferring animals
compared to alcohol-non-preferring subjects [253–255]. However, alcohol exposure
can increase pro-enkephalin [256] and enkephalin mRNA levels in the NAcc of the
alcohol-preferring but not of the alcohol-non-preferring animals [251, 257–259]. Despite release of endogenous opioids upon alcohol use, Turchan found no changes in
DOR expression in the NAcc and striatum after access to 1-6% alcohol over a 1-month
period [260]. It seems that genotype has a substantial inﬂuence on whether or not
alcohol exposure increases endogenous opioid levels in the NAcc and whether those
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endogenous opioids will impact DOR expression levels or can be eﬀectively blocked
by a DOR antagonist to modulate alcohol responding.

Striatum
Already early on, DORs in the striatum were identiﬁed to modulate dopamine
release [261,262]. These striatal DORS are involved in the dynamic interplay between
alcohol and the delta opioidergic system. For example, acute alcohol can increase metenkephalin levels in the striatum [263, 264]. Prolonged alcohol exposure on the other
hand decreases met-enkephalin levels in the striatum of rats [263,264], but will return
to baseline after withdrawal [264]. However, in mice, relatively short access to 7%
alcohol did not have a large eﬀect on DOR expression or activity in the striatum [265].
Still, in rats, endogenous opioids acting on DORs in the striatum are suggested to
increase alcohol intake. For example, microinfusions of naltrindole into the dorsal
striatum inhibit alcohol intake in Long-Evans rats, whereas microinjection of the
DOR agonist SNC80 increases alcohol intake [163]. While striatopallidal neurons are
known to contain enkephalins, naltrindole injection into the ventral pallidum did not
aﬀect alcohol intake in AA rats [243].

Hypothalamus
The paraventricular nucleus (PVN) of the hypothalamus plays a coordinating
role with regard to neuroendocrine responses. The PVN neurons are involved in
stress management and appetitive behavior and are innervated by enkephalinergic
ﬁbers [266]. It has been shown that dietary fat releases endogenous opioids in the
PVN [267]. Alcohol similarly increases enkephalin levels in the PVN [268]. In an
apparent positive feedback loop, direct microinjection of the DOR agonist DALA in
the PVN increases alcohol intake [241]. The actions of this feedback loop were also
apparent by ﬁndings showing that ingestion of a fatty meal can increase alcohol intake
[269]. Interestingly, microinjection of DALA in the perifornical lateral hypothalamus
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decreases alcohol intake. This may be caused by local inhibition of orexin function in
the perifornical lateral hypothalamus that indirectly controls opioid action in other
brain areas [242].

Amygdala
The amygdala is important for processing fearful as well as rewarding stimuli [223,
270]. Studies have revealed that in the absence of DORs, alcohol increases GABAA
inhibitory postsynaptic currents (IPSCs) in the central amygdala. This eﬀect could
also be mimicked using a DOR antagonist [271]. These results suggest that in wildtype mice, alcohol causes release of endogenous enkephalins in the central amygdala
that block GABA release by acting on inhibitory coupled DORs. On the other hand,
the DOR agonist DPDPE could decrease GABA IPSCs [271]. Interestingly, functional
DORs in the central amygdala are only detectable in alcohol-exposed, but not naive,
rats [162]. This may be an underlying reason why microinjection of naltrindole in
the amygdala of alcohol-preferring Wistar rats can decrease alcohol responding [237].
Microinjection of naltrindole into the central amygdala could also decrease alcoholconditioned place preference in rats [162], highlighting the important role of DORs
in reward processing in the amygdala of alcohol-dependent subjects.

1.2.6

Role of enkephalins and endogenous opioids on delta opioid receptor
modulation of alcohol use

Endogenous opioids are thought to play an important role in the development of
AUDs. Two hypotheses exist to describe the association between endogenous opioids
and alcohol use. The opioid compensation hypothesis of alcoholism presumes that
subsequent alcohol intake can compensate a lack of endorphinergic activity during
alcohol withdrawal [272]. The second hypothesis which we will call the opioid reward
hypothesis of alcoholism proposes that alcohol-increased release of endogenous opioids
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in response to alcohol can enhance dopamine release in the NAcc by disinhibiting
dopaminergic neurons [273].

The “Opioid compensation hypothesis of alcoholism”
This hypothesis is supported by evidence showing that intracerebroventricular
injection of met-enkephalin into rat brains decreases alcohol consumption [274]. Additionally, increased enkephalinase activity is associated with increased alcohol consumption [275]. Chronic alcohol consumption seems to decrease levels of met-enkephalin
in the striatum of Sprague-Dawley rats [257,273,276]. Lower levels of met-enkephalin
in the nucleus accumbens (NAcc) and lower levels of leu-enkephalin in the VTA
have been observed in alcohol-preferring AA rats and C57BL/6J mice relative to
alcohol-avoiding ANA rats and C57BL/6N mice [257, 277]. Alcohol has been shown
to elevate levels of met-enkephalin in these rats, which may, in turn, regulate its reinforcement [257]. The mRNA expression of preproenkephalin in the striatum and
NAcc of alcohol-preferring FH rats has also been demonstrated to be lower than that
of alcohol-non-preferring WKY rats [278].

The “Opioid reward hypothesis of alcoholism”
This hypothesis is supported by the fact that medications used to manage alcohol dependence such as the non-selective opioid antagonist Revia (naltrexone) block
the eﬀects of endogenous opioids released by alcohol intake [279–282]. The selective
DOR antagonists naltrindole and naltriben, which block endogenous opioids binding to DORs, have been reported to decrease alcohol consumption [174, 178, 182].
Concordantly, elevated endogenous enkephalin tone using the enkephalinase inhibitor
thiorphan [169], microinjection of enkephalin analogues into mesolimbic and hypothalamic regions [238, 241], or microinjection of SNC80 in rat striatum [163] increases
alcohol consumption. It has been suggested that alcohol-induced endogenous opioid
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peptide release may counteract the aversive eﬀects of alcohol and ultimately lead to
high alcohol drinking [169].

Potential reasons for the bidirectional eﬀect of enkephalins on alcohol behaviors
It appears that the role of the endogenous opioid system in alcohol reward is
still not unequivocally understood. Interpretation of studies investigating the role of
the endogenous opioid system in alcohol behaviors may be complicated by anxiety
[249,283] or stress [284] mechanisms, dissimilar distribution patterns of enkephalins in
the brain [285], or a joint action of enkephalins and beta-endorphin [286]. The DORs
have been implicated in modulating anxiety-like behavior; for example, DOR KO mice
are reported to have enhanced anxiety-like behavior relative to wild-type mice [287],
and DOR agonists can reduce anxiety-like behavior [183, 288]. The anxiety-like response in DOR KO mice can be reversed by the self-administered alcohol [283]. The
increased anxiety-like state of the DOR KO mice could be a major reason why DOR
KO mice show increased alcohol intake and alcohol self-administration [182, 283], a
result which would not have been predicted based on the observed decrease in alcohol
intake by several DOR antagonists. In addition to anxiety, stress may also modulate DOR responses by potentiating the eﬀect of DOR agonists [284]. Despite no
changes in alcohol consumption or alcohol place preference between preproenkephalin
knockout and wild-type mice [289], stress-induced alcohol intake was decreased in
preproenkephalin knockout mice, suggesting the importance of stress in the interpretation of these results [290]. Thus it may be diﬃcult to dissociate the individual
contribution of opioids, anxiety, stress, and dopamine from each other for their effect on the reinforcing eﬀects of alcohol [273, 291]. Furthermore, alcohol exposure
does not unidirectionally alter enkephalin levels throughout the brain. Lugo et al.
(2006) found that alcohol exposure increased met-enkephalin levels in the VTA, but
decreased them in the central nucleus of the amygdala . Moreover, even though the
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single enkephalin or endorphin knockout mice did not show altered alcohol CPP, mice
lacking both enkephalins and beta-endorphin exhibited a decrease in alcohol-induced
CPP when compared to wild-type controls, suggesting that alcohol may at least exert
its rewarding action through a joint action of enkephalins and beta-endorphin [286].
These results are supported by data showing that only a high dose of naloxone that
blocks both DORs and MORs attenuates alcohol CPP [286].

1.2.7

Impact of heteromerization and biased signaling of the delta opioid
receptor on alcohol use

Before the DOR was cloned, suggestions of the existence of two DOR subtypes
had appeared based on diﬀerential behavioral responses of a set of DOR agonists
and DOR antagonists. Responses that were induced by DPDPE and blocked by 7benzylidenenaltrexone were labeled DOR1, whereas eﬀects stemming from deltorphin
II activation that could be blocked by naltriben were labeled DOR2. However, the
pharmacology of these DOR subtypes has been diﬃcult to reproduce in vitro and
remains unclear [198]. Still that has not prevented researchers from investigating
how these DOR subtype-selective compounds modulate alcohol behaviors. Initial
studies showed that the DOR2-selective antagonist naltriben could reduce alcohol
intake in rats [178] and in mice [182]. Interestingly, there appears to be a dichotomy
between DOR subtype-selective ligands and their ability to modulate alcohol intake as
the DOR1 agonist reduces alcohol intake in mice [182]. DOR1 and DOR2 modulate
alcohol intake through diﬀerent mechanisms as co-administration of naltriben and
TAN-67 synergistically decreased alcohol intake [182]. Margolis and coworkers found
that the DOR1 agonist DPDPE when injected into the VTA decreased alcohol intake
in rats [236]. Later, van Rijn et al. reported that the DOR-selective agonist SNC80
increased alcohol intake in mice and labeled this as a DOR2 response [183]. This
was conﬁrmed by data showing that intra-striatal microinjection of SNC80 in rats
led to an increase in alcohol consumption [163]. The opposing alcohol modulatory
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responses of TAN-67 and SNC80 were conﬁrmed in alcohol CPP studies [191]. A
similar distinction in DOR1 and DOR2 modulation of alcohol behavior came from a
CPP study by Mitchell et al. showing that alcohol-exposed rats displayed CPP for
the DOR2 agonist deltorphin II, but not the DOR1 agonist DPDPE when the drugs
were injected directly into the VTA [292].
Three hypotheses, which are not necessarily mutually exclusive, have been proposed to explain the DOR subtypes: the “location hypothesis,” the “receptor hypothesis,” and the “drug hypothesis.” The “location hypothesis” originates from ﬁndings
that in the VTA DOR1 actions are primarily presynaptic, whereas DOR2 eﬀects are
most likely both pre- and postsynaptic [165]. Moreover, Mitchell et al. have proposed
that alcohol exposure can change expression and function of the presynaptic DORs
with time [249].
The “receptor hypothesis” suggests that the existence of the DOR subtypes arises
through receptor dimerization. More precisely DOR1 are DOR-MOR heteromers,
whereas DOR2 are DOR homodimers. Studies using knockout animals revealed that
the eﬀects of TAN-67 on alcohol intake, but not those of naltriben, were abolished in
MOR KO mice [182]. Both compounds were ineﬀectual in DOR KO mice [182].
The “drug hypothesis” proposes that diﬀerences in ligand-induced signal transduction pathways underlie the diﬀerential responses of DOR agonists and antagonists.
This hypothesis is based on the notion of biased G protein-coupled receptor signaling,
where certain drugs may only activate G-proteins, while other drugs solely signal by
recruiting beta-arrestins [293, 294]. A very recent publication has shown that there is
a very strong correlation between the degree of beta-arrestin 2 recruitment and the
ability of a DOR-selective drug to decrease or increase alcohol intake [295]. Chiang et
al. proposed that SNC80 and drugs with similar chemical structures increase alcohol
intake in mice because of their strong degree of beta-arrestin 2 recruitment. On the
other hand, TAN-67 is a very weak recruiter of beta-arrestin 2 and decreases alcohol intake in a mechanism that is not beta-arrestin 2 dependent [295], most likely
G-protein mediated.
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1.2.8

Therapeutic potential of DOR agonists for treatment of alcohol use
disorders

Alcohol, enkephalins, and DORs are dynamically linked making drugs that target
DORs interesting therapeutics for treatment of AUDs. Interestingly both DOR antagonists and agonists are capable of decreasing alcohol intake. Yet, we hypothesize
that DOR1-selective agonists like TAN-67 are the most suitable option for developing eﬃcacious therapy for alcohol dependence [198]. In particular DOR agonists have
anxiolytic-like, antidepressive-like, and antinociceptive properties [198, 296], which
would help reduce alcohol relapse [297–299]. Whether TAN-67 is particularly effective because it has limited beta-arrestin 2 eﬃcacy [295] or it can preferentially
engage DOR-MOR heteromers [182], or both, remains under investigation. While
certain DOR agonists may decrease seizure threshold [200–205], several DOR agonists are available that have limited to no observable seizure activity at therapeutic
dose [206, 207]. Moreover, DOR agonists may have less abuse potential, based on
several reports showing absence or limited place preference [191, 292, 300].
The variability in alcohol behaviors observed with DOR agonists and antagonists
is most likely due to the dynamic nature of the relationship between alcohol and
the delta opioid system. In mouse and rat models, there appear to be important
diﬀerences in DOR functionality depending on age, genotype, environmental factors
(e.g., stress), and history of alcohol exposure. We believe that there is a great potential
for DOR-selective drugs to be beneﬁcial in the treatment of AUDs. However, at
this point in time, only a handful of studies have modulated DORs in primates to
investigate the impact on alcohol behavior. Given the weak association of DOR single
nucleotide polymorphisms with alcohol-dependent patients, it is crucial to perform
more primate studies to obtain a better sense of the translatability of the rodent
ﬁndings. In particular studies using primates with a history of alcohol use and/or in
a subset of high-alcohol-drinking primates will be valuable additions to the current
knowledge on DOR modulation of alcohol behavior.
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1.3

Mu/delta opioid receptor heteromers
Opioid receptors are a member of inhibitory G protein-coupled receptors (GPCRs).

Opioid receptor agonists inhibit the activity of adenylyl cyclase and production of
cAMP, negatively modulate voltage-gated calcium channels, and positively couple to
potassium channels, resulting in an inhibition of tonic neural activity, with additional
eﬀects on kinases and transcription factors [301]. Pharmacological studies have shown
that GPCRs can synergize and interact with each other [302]. This process is known
as dimerization, for two interacting proteins or oligomerization, for interactions between more than two proteins; when identical proteins interact with each other this
is referred to as homodimerization, whereas if the interactions occur between different proteins it is called heteromerization. As brieﬂy alluded in our discussion of
DORs and modulation of alcohol use, opioid receptors also undergo heteromerization.
Particularly the DOR-MOR heteromers received much attention because the DORMOR heteromers appear to be associated with opioid system modulation following
long-term opioid therapy in chronic pain.

1.3.1

Evidence for the DOR-MOR formation

G protein-coupled receptors are membrane proteins consisting of seven transmembrane (TM) domains, connected by alternating intracellular (ICL) and extracellular
(ECL) loops, which is why they are sometimes referred to as 7TM receptors or serpentine receptors. To study the opioid receptor heteromer function, ﬁrst we need
to understand the molecular nature of the heteromers speciﬁcally which regions, i.e.
loops and or TM domains, make up the dimer interface. To predict the dimer interface computational modeling and experimental disruption studies are valuable tools.
Initially the computational model of DOR-MOR heteromers exploited the homology modeling of rhodopsin crystal structure. It was not until 2012 that the crystal
structures of the opioid receptor monomers and homodimers of MOR and KOR were
solved, which help to reﬁne the interface prediction [303–308]. Particularly, because
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the crystals for MOR and KOR were packed such that dimer interfaces were part of
the resolved structure. It is unknown as of yet whether this is an artiﬁcial interface
caused by the process of producing the crystals.

In vitro and in vivo detection of the DOR-MOR formation
For the assembly of DOR-MOR heteromers, both opioid receptors need to be
coexpressed in the same cells. The ﬁrst biochemical evidence that detected the coexpression of MOR and DOR was a coimmunoprecipitation study using anti-Myc for
immunoprecipitation and anti-FLAG for immunoblotting. Only immnuprecipitates
from cells coexpressing Myc-tagged DOR and FLAG-tagged MOR showed a signal in
western blot analysis [309,310]. Coimmunoprecipitation was also performed in mouse
spinal cord membranes and revealed a signal detection in samples prepared from wildtype mice but not from DOR knockout mice [311]. However coimmunoprecipitaion
assay does not illustrate the direct interaction and selective opioid receptor antibodies have been notoriously diﬃcult to come by. Researchers also used bioluminescence
resonance energy transfer (BRET) by tagging luciferase at C-tail of one receptor and
yellow or green ﬂuorescent protein at C-tail of another potential interacting partner.
MOR and DOR were demonstrated to be in close proximity enough to interact with
each other in BRET assay [311–313].
Anatomical evidence have also indicated the existence of DOR-MOR heteromers
in nervous system. Studies using radioligand binding assays showed the coexpression of endogenous MOR and DOR in human neuroblastoma cell lines [314–317].
Several studies using single-cell PCR, in situ hybridization, immunohistochemistry,
and single-cell electrophysiology revealed the coexpression of MOR and DOR in neurons [318–320], the spinal cord [321–323], striatum [324], and the central nucleus of
the amygdala [325]. The colocalization of endogenous MOR and DOR was reinforced
by studies from the Devi group who developed a monoclonal antibody targeting an
interface epitope of DOR-MOR. They determined the existence of endogenous DOR-
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MOR heteromers in neurons from wild-type animals but not from both MOR- and
DOR-knockout mice [326].
The colocalization of MOR and DOR in the brain was also determined by using the knock-in mice expressing enhanced green ﬂuorescent protein (eGFP)-linked
DORs and red ﬂuorescent protein-linked MORs [327]. It was shown that most of
MORs and DORs were separately localized. MORs were expressed on small unmyelinated C-ﬁbers whereas DORs were expressed on large myelinated nerve ﬁbers. Only
a limited number of colocalized DOR and MOR were found in DRG neurons [213],
which warrants the question if that is suﬃcient for the DOR-MOR heteromers in
these neurons to have a detectable impact on pain transmission. The lower amounts
of DOR-MOR heteromers detected in eGFP-linked DOR knock-in mice may be due to
the diﬀerential distribution of epitope-tagged receptors [323, 328–331]. Even though
the eGFP-linked DOR knock-in mice are useful to discern the localization of MOR
and DOR, these transgenic mice may be less suited to study DOR-MOR heteromerization and functional signaling because eGFP tag may interfere interactions between
endogenous DORs and other interaction partners.

Experimental disruption of the DOR-MOR heteromer interface
Over the years many attempts have been made to characterize the DOR-MOR heteromer interface. Previous study has shown that the replacement of TM1 with TM3
in MOR results in no interaction between mutant MOR and DOR as observed by coimmunoprecipitation [215]. This is in agreement with the computational prediction in
regards of transmembrane domains involved in the DOR-MOR interaction. Moreover,
a gene construct of TM1 of MOR fused to an intracellular GFP tag could form an
interaction with DOR [215], suggesting that MOR TM1 was involved in DOR-MOR
heteromerization. The importance of the MOR TM1 was further identiﬁed in a study
where membrane-permeable TAT peptides fused to MOR TM1 were administered
in vivo and able to disrupt DOR-MOR heteromers and increase morphine-mediated
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analgesia [215]. Not only the TM1 of MOR but also the carboxyl tails of MOR and
DOR have shown to be involved in the DOR-MOR interaction. Membrane-permeable
TAT peptides fused to the distal portion of the C-tail of DOR was able to disrupt
DOR-MOR heteromers [332]. Another study showed that truncation of MOR or DOR
at the carboxyl terminal domains co-expressed with DOR or MOR did not aﬀect
the binding proﬁles of DOR or MOR agonists, while co-expression of non-truncated
MOR and DOR did [333]. This suggests that carboxyl terminal domains play a role
in the heteromer pharmacology. Another evidence using an approach reliant on cotraﬃcking of MOR and DOR in which a nuclear localization signal was inserted into
one of the receptors demonstrated that three glycines (GGG) in the carboxyl terminal
tail of DOR and a series of amino acids (serine, valine and arginine; SVR) located at
the third intracellular loop of both MOR and DOR were crucial for the DOR-MOR
interaction. Consequently, the diversity in the observed dimer interfaces may arise
from the use of diﬀerent approaches.

1.3.2

Signal transduction and regulation of the DOR-MOR heteromers

Signaling of the DOR-MOR heteromers
Typically the MOR or DOR activation can couple to Gαi/o and inhibit intracellular calcium release, causing a hyperpolarization of the cell [301]. Despite the canonical signaling pathway, DOR-MOR heteromers have a distinct downstream coupling.
Pharmacological studies illustrated that low doses of MOR agonists were able to allosterically increase DOR radioligand binding in cells coexpressing MOR and DOR
but not in cells expressing MOR or DOR alone [334], supporting the diﬀerences in
signaling properties between heteromers and monomer/homodimers. Using GTPγ 35 S
and immunoprecipitation studies one group was able to show that DOR-MOR was
able to couple not only to Gαi , but also Gz . The authors were unable to ﬁnd any signs
of Gz coupling to MORs or DORs when expressed alone [309, 313, 333] (Figure 1.3).
This is supported by a study showing that MOR fused to luciferase protein could in-
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teract with Gz fused to GFP protein when coexpressed with DOR in the BRET assay,
whereas MOR interacted with Gαi instead in the absence of DOR [313]. Moreover,
the MOR agonist DAMGO could inhibit Ca2+ signaling in cells expressing MOR,
while increase Ca2+ signaling in cells coexpressing MOR and DOR. This enhanced
signaling could be blocked by pertussis toxin, suggesting that DOR-MOR heteromer
signaling is also involved in the activation of pertussis toxin-sensitive G-protein [335].
Other studies have also shown another unique downstream coupling of DOR-MOR
heteromers. DOR-MOR heteromers constitutively recruit β-arrestin 2 as shown by
colocalization or coimmunoprecipitation of β-arrestin 2 with MOR and DOR in MOR
and DOR coexpressing cells but not MOR or DOR expressing cells alone [336]. βarrestin 2 has been demonstrated to be associated with the ERK signaling pathway
in particular a slower and more sustained ERK phosphorylation, peaking within 5-10
minutes [337]. In cells coexpressing MOR and DOR, ERK phosphorylation occurred
at later time points, while a rapid phosphorylation, peaking within 2-5 minutes and
associated with G-protein activation [337] was present in cells expressing MOR alone.
Another diﬀerence between rapid and slow ERK phosphorylation is that the rapid
ERK phosphorylation depends upon PKC, while the slow ERK phosphorylation does
not (Figure 1.3). The DOR antagonist when coadministered with the MOR agonist
shifts the characteristics of DOR-MOR heteromers to MOR alone as observed by
shifting the downstream signaling pathway from β-arrestin 2 recruitment to non-βarrestin 2 mediated signaling and subsequently reducing ERK phosphorylation signaling [336]. This is in agreement with chronic morphine treatment that would increase
DOR-MOR availability, thereby reducing total MOR responses and contributing to
morphine tolerance. The DOR antagonist in combination with MOR agonist could
then normalize DOR-MOR signaling and reverse MOR tolerance (Figure 1.3). Still,
the detailed downstream coupling of DOR-MOR remains unclear, and it is not understood if the observed signaling pathways as described above, are context-speciﬁc
and only occur in subpopulations of cells and neurons.
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Fig. 1.3. Downstream coupling of MOR and DOR monomers and
DOR-MOR heteromers. Activation of MOR or DOR monomers couples to Gαi/o and activates PKC, resulting in rapid ERK phosphorylation. Activation of DOR-MOR heteromers by DOR-MOR ligand
signals through Gz and β-arrestin 2, contributing to slow ERK phosphorylation. However ligand combinations of MOR agonists and DOR
antogonists can shift the pattern of DOR-MOR activation from rapid
to slow ERK phosphorylation as observed in monomer activation.
Adapted from [338].
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Traﬃcking of the DOR-MOR heteromers
Thus far there is less information pertaining to the location of DOR-MOR formation. One study using a heterologous co-expression of wild-type MOR or DOR and
mutants of DOR or MOR deﬁcient in cell surface transport activities elicited that
neither wild-type opioid receptor was capable of rescuing its cell surface-transport
deﬁcient counterpart. This indicates that DOR-MOR formation may take place at
the plasma membrane [339]. However, this is inconsistent with other studies showing
that exogenous compounds like chronic but not acute in vivo administration of morphine or the DOR antagonist naltriben can regulate the DOR-MOR abundance by
translocating them from intracellular sites to the cell surface [326]. The traﬃcking is
thus vital process that help to facilitate the DOR-MOR formation. Coexpression of
MOR and DOR in heterologous systems revealed a reduction of MOR abundance on
the cell surface. This reduction was correlated with an elevation of MOR and DOR
coexpression within the Golgi complex [331]. Colocalization of receptor transporting
protein (RTP) 4, a member of RTP family of chaperones, with MOR and DOR promoted the traﬃcking of MOR and DOR assembly in the Golgi complex to the cell
surface [331, 340]. These results are in agreement with other studies showing that
chronic morphine administration is able to translocate DORs from intracellular pools
to the cell surface of central nervous system neurons [325,341,342], resulting in an increase in DOR-MOR formation. In contrast, one study has shown that DRG neurons
from DOR knockout mice display lower expression of MOR on the cell surface when
compared to DRG neurons from wild-type mice [343]. These contradictory results
may be explained by the methodological diﬀerences.

Internalization of the DOR-MOR heteromers
Opioid receptors commonly internalize in response to agonist exposure. GPCRs
can be categorized into two classes upon the endocytosis. Class A is recycled back to
the plasma membrane called re-sensitization like MOR. Class B is traﬃcked to lyso-
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somes and is ﬁnally degraded called down-regulation like DOR. The factor determining the division process relies upon ubiquitination signals, such that increased receptor
ubiquitination, increased the number of receptors destined for degradation [344–347].
Several reports have demonstrated that DOR-MOR internalization depends upon
types of ligand banding. The DOR agonists deltorphin II or SNC80, or the MOR
agonists DAMGO or methadone, but not the DOR agonists DPDPE or DSLET could
promote endocytosis of DOR-MOR heteromers [313, 339, 348, 349]. The DOR-MOR
endocytosis induced by MOR agonists was blocked by pretreatment with the DOR
antagonist naltriben [349]. However naltriben was more eﬀective at inhibiting endocytosis in cells expressing only MOR than in cells coexpressing MOR and DOR [349],
raising the question of the selectivity of naltriben at the concentrations used in this
study.
Another study elucidated that the DOR agonist deltorphin I but not the MOR
agonist DAMGO co-internalized MOR and DOR into the similar locations inside the
cells [215]. The authors revealed that DOR-MOR frequently cointernalized in the
lysosomes [215].

1.3.3

DOR-MOR heteromer-biased ligands

DOR-MOR speciﬁc and bivalent ligands
Many DOR-MOR speciﬁc ligands still have aﬃnity for DOR or MOR monomers/
homodimers due to the similar/shared binding sites between DOR-MOR and DOR
or MOR. Using high throughput screening, a novel molecule, CYM51010, was identiﬁed to have higher potency in DOR and MOR coexpressing cells compared with
MOR or DOR expressing cells alone, suggesting it may bind to the DOR-MOR heteromers. The CYM51010 also exerted antinociceptive property in vivo, which could
be completely blocked by the MOR antagonist naltrexone and the DOR-MOR antibody [350]. The reversal of analgesic eﬀects by the DOR-MOR antibody further
conﬁrms that CYM51010 functions as a heteromer speciﬁc ligand.
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Another approach to study receptor dimers has been to utilize bivalent ligands.
Bivalent ligands comprise of two moieties connected by a linker of optimal distance
to bridge the binding pockets of the two receptors comprising the dimer. Each moiety is a receptor selective drug, but can be either agonist or antagonist. The ﬁrst
bivalent ligand created for the DOR-MOR heteromers was MDAN (MOR-agonistDOR-antagonist). It was generated based upon combinations of the MOR agonist
oxymorphone and the DOR antagonist naltrindole pharmacophores. Acute administration of MDANs showed less potency than that of the monovalent MOR ligand. This
is in agreement with earlier evidence of ligand combinations indicating low DOR-MOR
availability in naive animals [351]. However, when administered chronically, MDAN21 (MDAN with spacers of 21 atoms) elicited analgesic eﬀects with reduced tolerance
and dependence when compared with the monovalent MOR agonists or coadministration of the monovalent MOR agonist with the DOR antagonist. Moreover MDAN-21
did not internalize DOR-MOR heteromers while the monovalent ligands induce the
DOR-MOR endocytosis [352]. This further supports the nature of bivalent ligands
of MDAN-21 and the importance of speciﬁc length of spacer. Other bivalent ligands than MDANs that had been generated were based upon combinations of high
aﬃnity at MOR and low aﬃnity at DOR e.g. the MOR agonist oxymorphone with
the DOR antagonist ENTI or the MOR antagonist naltrexone with the DOR agonist
SNC80 [353]. However these bivalent ligands are not characterized in in vivo studies
yet.

Coadministration of MOR agonists and DOR antagonists
Studies have indicated that DORs (alone or potentially as DOR-MOR heteromers)
can negatively impact MOR agonist analgesia. Thus, many studies have investigated
the therapeutic eﬀect of co-administering combinations of MOR agonists and DOR
antagonists. Coadministration of the MOR agonists with the DOR antagonists was
able to rescue morphine tolerant mice to baseline non-morphine tolerant levels or
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increase antinociceptive eﬀects of morphine in vivo [354]. Other supporting evidence
has indicated that coadministration of the MOR agonist DAMGO with the DOR agonist DPDPE reduced the potency of DAMGO antinociception in morphine tolerant
mice [354]. The modulation of MOR-mediated analgesia by DOR is also reinforced
by another study showing that mice injected with antisense oligodeoxynucleotides for
DORs to reduce the DOR levels in the brain displayed decreased morphine dependence [355]. Moreover DOR knockout mice exhibited loss of morphine tolerance [356].
However, one study has shown that the DOR antagonist naltrindole reduced the potency of MOR antinociception in opioid naive mice in a dose-dependent manner.
These contradictory results with other reports could be reconciled by the diﬀerences
in the state of animal models used between opioid- naive and tolerant mice.

1.4

Overview of adenylyl cyclases
Adenylyl cyclases (ACs) are enzymes that catalyze ATP (adenosine triphosphate)

to cAMP, which is an important mediator in the intracellular signaling. The membranebound adenylyl cyclases comprise two transmembrane regions, M1 and M2. Each regions contains six transmembrane spanning helices. There are three intracellular regions including N-terminus, cytoplasmic region (C1), and C-terminus (C2) [357–360].
To date, nine isoforms of membrane-bound ACs and one soluble AC have been
found [357, 358]. Each of them has discrete regulation and tissue distribution. The
membrane-bound ACs can be categorized into four groups; Group 1 contains AC1, 3,
and 8, which can be stimulated by calcium in a calmodulin-dependent manner. Group
2 contains AC2, 4, and 7, which is activated by Gβγ subunits. Group 3 contains AC5
and 6, which is inhibited by calcium. Lastly, group 4 contains only AC9, which is the
only AC that is insensitive to the AC activator forskolin [357,361]. The generation of
knockout and overexpression animal models have assisted in identifying the physiological functions and tissue distribution of each adenylyl cyclases [358] which we will
brieﬂy discuss below.
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1.4.1

Function

Adenylyl cyclases in learning and memory
AC1 and AC8 expression is highly conﬁned to the hippocampus where is responsible for learning and memory [358, 362]. Long-term potentiation (LTP), a persistent
strengthening of synaptic communication, is considered to play a role in learning and
memory formation [363,364]. AC1 and AC8 double knockout mice showed disruption
of their hippocampal late phase LTP and long-term memory [362, 365]. The loss of
hippocampal LTP could be reversed by the adenylyl cylcase activator forskolin, suggesting that cAMP is an essential mediator of the LTP. The importance of the role
of AC1 and AC8 in learning and memory is further highlighted by the ﬁnding that
AC1 and AC8 double knockout mice elicited an impairment in both passive avoidance and contextual fear-conditioning tests, paradigms used to assess learning and
memory. However, mice lacking either AC1 or AC8 exhibited normal behaviors in
both passive avoidance and contextual fear-conditioning studies [365]. Indeed, compared to wild-type controls, AC1 single knockout mice rapidly lost remote contextual
fear memories [366] that engage in multiple cortical regions including the anterior
cingulate cortex. While AC1 single knockout mice had normal paired-pulse facilitation (PFF), a short-term form of synaptic facilitation, AC8 single knockout mice
had declined PFF [367, 368]. This represents that genetic ablation of both AC1 and
AC8 in mice can deplete the memory formation, whereas genetic deletion of either
AC1 or AC8 will have moderate eﬀects on learning and memory in a subset of animal
behavioral studies.

Adenylyl cyclases in analgesia
The development of chronic pain has been proposed to be accompanied by mechanisms underlying the learning and memory formation which is a long-lasting strengthening of synaptic connections (LTP) [362, 369]. AC1 and AC8 are expressed in the
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central nervous system that is related to pain processing including the anterior cingulate cortex and spinal dorsal horn neurons [369–371]. Compared to wild-type mice,
AC1 knockout mice but not AC8 knockout mice displayed signiﬁcantly reduced pain
responsiveness in acute muscle pain [372], chronic inﬂammatory pain evoked by formalin and complete Freund’s adjuvant [373], and neuropathic pain models [369, 372].
The small molecule AC1 inhibitor NB001 also exerted analgesic properties against
inﬂammatory and neuropathic pain. NB0001 was also able to abolish LTP in the anterior cingulate cortex and spinal dorsal horn but not the hippocampus [374]. Moreover AC1 knockout mice exhibited decrease cortical lesions evoked by N-methyl-Daspartate (NMDA), suggesting that AC1 may play a role in prevention of the neuronal
excitotoxicity [375].

Adenylyl cyclases in drug dependence
Opioid tolerance and dependence following chronic µ-opioid receptor results from
an upregulation of adenylyl cyclase activity [376–379]. There are three AC isoforms
(AC1, AC5, and AC8) thus far that are involved in opioid dependence. AC1 and
AC8 knockout mice displayed a decreased morphine dependence as observed by their
reduced withdrawal behaviors evoked by naloxone and attenuated the enhancement of
baseline ﬁring rates of locus coeruleus neurons induced by chronic morphine treatment
[380,381]. AC5 is highly co-expressed with µ, δ, and κ opioid receptors in the straitum.
Genetic ablation of AC5 markedly attenuated all major behavioral eﬀects in response
to morphine exposure including analgesia, tolerance, reward, dependence, withdrawal,
and locomotion [358, 382].

40

2. INVOVLMENT OF DELTA OPIOID RECEPTORS IN
ALCOHOL WITHDRAWAL-INDUCED MECHANICAL
ALLODYNIA IN MALE C57BL/6 MICE
As published in
Drug and Alcohol Dependence (2016) 167:190-8.

2.1

Introduction
Alcohol use disorder (AUD) poses signiﬁcant health, social and economic burdens

on individuals and society. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), in 2013, about 17 million or 7.2 percent of Americans reportedly had an AUD [383]. Chronic alcohol exposure can cause neuronal
degeneration in the peripheral and central nervous systems [218, 384, 385] resulting
in painful small ﬁber peripheral neuropathy [386, 387]. The hallmarks of neuropathic
pain are allodynia (pain responses to normally innocuous stimuli) and hyperalgesia (a
heightened responses to noxious stimuli). Self-medication with alcohol for pain relief
is not uncommon and is associated with a drinking problem [388, 389]. Preclinical
studies have indicated that alcohol administration can reverse hyperalgesia during
alcohol withdrawal in rodents [390], but alcohol withdrawal can make the symptoms
of small ﬁber neuropathy worse [65, 221, 391]. These observations are consistent with
clinical studies showing exacerbated peripheral neuropathy in alcohol withdrawal patients [392, 393]. Chronic pain can dysregulate overlapping neural substrates of negative emotional states of alcohol addiction such as anxiety and depression [394, 395]
as well as the craving stage of the addiction cycle [218, 396]. The combination of
cravings, increased pain and anxiety during periods of alcohol abstinence is known
as the ‘alcohol withdrawal syndrome’ and is a negative factor contributing to alcohol
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relapse [397]. Currently, the available drug treatments for AUD rarely combat the
complexities of the withdrawal syndrome [398–400]. The mechanisms underlying alcohol withdrawal symptoms especially allodynia are still not well understood, limiting
the development of novel treatments for AUD that counter multiple components of
the alcohol withdrawal syndrome.
Protein kinase C (PKC), an intracellular protein kinase, is associated with the
alcoholic neuropathy and mechanical hyperalgesia [65, 386, 391, 401]. However, it is
diﬃcult to develop truly PKC isoform-selective inhibitors [402]. The delta opioid
receptor (DOR), which is a membrane localized G protein-coupled receptor, has been
shown to produce analgesia and interact with PKC [403, 404]. DORs are primarily
expressed in mechanical pain sensing neurons [161, 213] and play a crucial role in
touch and mechanical sensation [213, 405], making it a promising target to treat
withdrawal hyperalgesia that is generally associated with increased tactile sensation.
Moreover, alcohol exposure can elevate functional DOR expression in diﬀerent areas of
the central nervous system [161,162,236]. We, therefore, propose that DORs can be a
novel target for alcohol withdrawal-induced mechanical allodynia (AWiMA) therapy,
particularly considering that DOR agonists also reduce alcohol consumption [182] and
attenuate anxiety-like behaviors in alcohol-withdrawn mice [183]. To investigate our
hypothesis, we induced AWiMA by exposing mice to voluntary or forced alcohol for
three weeks. We used DOR knockout (KO) mice as well as the DOR-selective agonist
TAN-67 [406] and antagonist naltrindole [172] to study the role of DORs in AWiMA.
Our results obtained with the KO mice and DOR-selective drugs indicate that DORs
play an active role in AWiMA, speciﬁcally during the alcohol exposure phase.

2.2

Materials and methods

2.2.1

Animals

Adult (8-10 week old) wild-type (WT) or DOR KO C57BL/6 mice (male, 1823 g, Taconic) were housed (maximally 5 per cage) in ventilated plexiglass cages at
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ambient temperature (21◦ C) in a room maintained on a reversed 12L:12D cycle (lights
oﬀ at 9:00 AM, lights on at 9:00 PM). DOR KO mice were produced by removal of
exon 2 as previously described [182] and outbred to a C57BL/6 background (>10
generations). Knock-out mice were crossbred with WT mice every 3-4 generations
to prevent genetic drift. Food and water were provided ad libitum. Purchased mice
were given 1.5 week to acclimatize before the start of the experiments. All animal
procedures were performed in an AAALAC accredited facility and pre-approved by
the Purdue Institutional Animal Care and Use Committee and were in accordance
with National Institutes of Health Guide for the Care and Use of Laboratory Animals.

2.2.2

Chronic voluntary alcohol consumption

A two-bottle limited access (4 h/day, 5 days/week) drinking paradigm was employed for three weeks to train mice to increase their intake of a 10% alcohol solution
as previously described [182, 407]. The ﬁrst dose of TAN-67 was injected four days
after the last alcohol exposure to ensure that no alcohol was left in the mouses circulation, and mice returned to a stable nociceptive baseline.

2.2.3

Administration of alcohol by gavage

Mice received 2 or 3 g/kg of 20% (vol/vol) alcohol in water via oral gavage (o.g.)
for ﬁve consecutive days each week for three weeks.The ﬁrst dose of TAN-67 was
injected two days after the last alcohol exposure.

2.2.4

Measurement of mechanical sensitivity

One day prior to testing, mice were placed in plexiglass chambers on a suspended
wire mesh grid (25 cm above a table) for one hour for habituation. In these chambers
mice were conﬁned but free to move and could turn 360◦ . On the test day, mice
were placed in the chambers one hour before measurement of mechanical sensitivity.
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Mechanical sensitivity was measured as previously described [161] by stimulating the
plantar surface of the hind paw of the mouse with von Frey ﬁlaments (0.04, 0.07,
0.16, 0.4, 0.6, 1, 1.4, 2 g) three times for two seconds at a time. A paw withdrawal
at 2 g was considered the maximal response. The 0.4 g ﬁlament was always used
ﬁrst and depending on the response either a smaller or bigger ﬁlament was tested.
The lowest force that evoked a paw withdrawal response in two out of three tests was
recorded. Both paws were measured and the average was used for each animal. Data
is normalized to the mechanical sensitivity response in naive/water-treated mice.

2.2.5

Intrathecal injection

Mice were anesthetized with 5% isoﬂurane ﬁve minutes prior to injection. Intrathecal (i.t.) injection of opioid solutions (5 or 10 µl) was performed as previously
described [161, 408] by direct puncture of spinal lumbar region (L4-L6) using a luertipped 250 µl Hamilton (725LT) syringe to which a 28.5 gauge needle was attached.
Upon correct placement of the needle a clear tail ﬂick response could be observed.
Drug response was measured ten minutes after i.t. injection. Mice would generally
wake up from anesthesia 2-3 min after injections and would be fully awake, mobile
and responsive upon time of von Frey mechanical sensitiviy measurement. Prior to
injection a baseline of von Frey mechanical sensitivity measurement was performed.
Data is represented as the percentage maximal possible eﬀect (MPE) which is deﬁned
as [(measurement-baseline)/(cutoﬀ-baseline)]x100.

2.2.6

Drugs and solutions

Alcohol solutions were prepared in tap water using 100% (vol/vol) alcohol (200
proof, Sigma-Aldrich, St. Louis, MO, USA). Clonidine, TAN-67, and naltrindole were
purchased from Tocris Bio-science (Ellisville, MO). All compounds were dissolved in
saline; therefore, we used saline as vehicle in all of our experiments to allow comparison
across all treatment groups. All drugs were prepared immediately prior to injection,
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ﬁlter sterilized and were administered intrathecally except for natrindole that mice
received subcutaneously.

2.2.7

Alcohol withdrawal-induced anxiety

To study alcohol withdrawal-induced anxiety-like behaviors, mice were orally gavaged with 3 g/kg alcohol for ﬁve consecutive days each week for three weeks. Twentyfour hours after the last alcohol exposure anxiety levels in the withdrawn mice were
tested by using the open ﬁeld exploration test and the light-dark transition test by
measuring the general locomotor activity.

2.2.8

Anxiety-like behavior measurements

Open ﬁeld exploration test
Spontaneous activity was analyzed using automated activity chambers with 48
channel I/R controller (27.3 cm x 27.3 cm x 20.3 cm, W x L x H; Med Associates,
St. Albans, VT). Boxes were evenly illuminated with 31.4 lx using a shadow-free
illumination system. Home cages were brought to the testing room 30 min prior
to testing. Each mouse was placed in the center of a chamber. Mice location was
tracked for 5 min. Time, distance and entries into the center of the open ﬁeld box
were recorded. A decrease in the amount of time spent in the center as well as the
number of entries in the center area demonstrate anxiety-like behaviors. Mice were
allowed to freely explore the chamber for an additional 55 min, and their horizontal
locomotor activity (total distance traveled) was recorded using a photobeam-based
tracking system. The chamber was cleaned with isoproponol and dried before the
next mouse was tested. A decrease in locomotor activity may indicate a general sense
of malaise.
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Light-dark transition test
The light-dark apparatus was made up of an automated activity monitor with a
dark box insert (ENV-510; Med Associates, St. Albans, VT) to create an equally
spaced light and dark compartment (13.6 cm x 27.3 cm x 20.3 cm, W x L x H). The
entire apparatus was positioned in a sound-attenuating chamber. The light side was
illuminated to a degree of ∼60 lx (100 mA bulbs-SG-700A), compared with ∼5 lx in
the dark side. Each animal was placed facing the entrance of the dark area. Mice
were allowed to freely explore the chamber for 5 min. The light-dark transition box
was cleaned with isopropanol and dried before the next mouse was tested. A photo
beam-based tracking system was used to track the movement and locomotor activity
of the mice within the test box and calculate the time spent in each area and the
number of entries into each area. Anxiety-like eﬀects were indicated by increased
time spent in the dark compartment.

2.2.9

Statistical data analysis

All data are presented as mean ± standard error of the mean. The analysis of
pharmacological drug eﬀects over time was performed using one-way or two-way, repeated measures ANOVA for drug treatment and genotype, followed by a Bonferroni
post-hoc test to determine statistically signiﬁcant diﬀerences between groups using
GraphPad Prism5 software (GraphPad Software, LaJolla, CA, USA). Students unpaired t-test was used for analyzing less than two groups using GraphPad Prism 5. A
level of probability of p < 0.05 was deemed to constitute the threshold for statistical
signiﬁcance and marked with an asterisk. For transparency, results with a level of
probability of p < 0.01 were marked with **, p < 0.001 with ***.
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2.3

Results

2.3.1

DORs are protective against allodynia during withdrawal from voluntary moderate alcohol intake

Wild-type and DOR KO C57BL/6 male mice were trained to consume a 10% alcohol solution for three weeks using a limited access (4 h/day) two-bottle choice drinking in the dark paradigm of voluntary self administration. Wild-type and DOR KO
C57BL/6mice showed similar escalation of voluntary consumption of alcohol (Figure
2.1A). We found that the two genotypes rapidly developed AWiMA upon termination
of alcohol access, as measured by their hind paw withdrawal responses to noxious mechanical pressure using von Frey ﬁlaments (Figure 2.1B). Data was normalized to the
von Frey response obtained in mice prior to alcohol exposure (Figure 2.2). Analysis
by two-way ANOVA revealed that DOR KO mice exhibited more prolonged and exacerbated AWiMA than WT mice (signiﬁcant main eﬀect of genotype: F1,17 =5.505,
p < 0.05 and time: F5,85 =10.24, p < 0.001; Figure 2.2), and this was reﬂected in
P
the cumulative AWiMA data (measured as 14
day=0 (100 - area under the mechanical
sensitivity curve)day ; Figure 2.1C). The cumulative AWiMA was signiﬁcantly higher
in DORKO than in WT mice (p < 0.05).

2.3.2

Robust model of alcohol withdrawal using orally gavaged alcohol
administration

We next examined whether a more binge-like exposure to alcohol using orally
gavaged bolus injections would produce stronger AWiMA and withdrawal syndrome.
Wild-type C57BL/6 male mice were orally gavaged with water or 20% vol/vol alcohol
solution at 2 g or 3 g alcohol per kg of body weight once a day for three weeks.
AWiMA was measured at multiple time points (Figure 2.3A). We found that there
was a signiﬁcantly greater decrease in mechanical threshold in mice exposed to 3
g/kg alcohol compared to those treated with 2 g/kg alcohol (signiﬁcant main eﬀect of
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Fig. 2.1. Endogenous activity at delta opioid receptors attenuate alcohol withdrawal-induced mechanical
allodynia in a model of voluntary alcohol consumption. Wild-type (WT) or DOR knockout (KO) C57BL/6
mice were trained to drink in a limited-access, two-bottle choice paradigm for three weeks, and consumption
of the 10% alcohol solution was measured over a 4-h period (A). The mechanical sensitivity measured by using
von Frey ﬁlaments was assessed on days 1, 2, 4, 7 and 14 after alcohol withdrawal. Signiﬁcance between
groups was determined by two-way ANOVA (B). The cumulative alcohol withdrawal-induced mechanical
allodynia (AWiMA) (expressed in arbitrary units (AU)) in WT and DOR KO mice was calculated using the
trapezoidal rule (C). *p < 0.05 normalized versus day 0 (BL, baseline). Reprinted from [409].
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Fig. 2.2. Delta opioid receptors play a protective role against alcohol withdrawal-induced mechanical allodynia in a model of voluntary alcohol consumption. Wild-type (WT) or DOR knockout (KO)
C57BL/6 mice were trained to drink 10% alcohol solution in a 4 hour
limited-access, two-bottle choice paradigm for three weeks. The mechanical sensitivity measured by using von Frey ﬁlaments was assessed
before alcohol exposure (naive) and on days 1, 2, 4, 7 and 14 after alcohol withdrawal. Data were analyzed via unpaired t-test or two-way
ANOVA; ***p < .001; **p < .01; *p < .05. Reprinted from [409].
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alcohol concentration: F1,20 =8.655, p < 0.01; Figure 2.3B). This was also illustrated
by the cumulative AWiMA (p < 0.01) in Figure 2.3C. Data was normalized to the von
Frey response obtained in tap water-treated mice, which did not develop mechanical
allodynia (See Figures 2.4 and 2.5). We next intrathecally injected mice with 10
nmol/10 µl

2.3.3

Mice withdrawn from gavaged alcohol elicit signs of anxiety and
malaise

To investigate the physiological and translational relevance of the o.g. model in
more detail, we examined whether mice exposed to gavaged alcohol intake would
display other signs of withdrawal. We found that WT C57BL/6 mice exposed to 3
g/kg alcohol for three weeks showed an anxiogenic phenotype 24 h in withdrawal,
as measured by their behaviors in an open ﬁeld exploration test (Figure 2.6, A-B)
and light-dark transition box (Figure 2.6, E-H). The alcohol-withdrawn mice spent
signiﬁcantly less time in the center (p < 0.05) of the open ﬁeld test compared with
water-exposed mice (Figure 2.6A). Alcohol withdrawal also inﬂuenced the number of
entries into the center (p < 0.01) of the open ﬁeld (Figure 2.6B). Locomotor activity
in the ﬁrst 5 min bout of the open ﬁeld test was not signiﬁcantly diﬀerent between
alcohol- and water-exposed mice (Figure 2.6C). However, alcohol-withdrawn mice
displayed signiﬁcantly lower locomotor activity compared with their water controls
over a 60-min period (Figure 2.6C). This eﬀect was most pronounced after 24 h of
withdrawal and returned to control levels after 4 days of withdrawal (signiﬁcant main
eﬀect of alcohol treatment: F1,10 =5.225, p < 0.05; Figure 2.6D). Alcohol-withdrawn
mice also made signiﬁcantly fewer entries into the light side (p < 0.01) of the lightdark transition box compared with water controls (Figure 2.6E).The fewer entries in
alcohol-withdrawn mice were not caused by a generalized decreased locomotor activity
because there were no group diﬀerences (p = 0.44) in distance traveled (Figure 2.6H).
Additionally, alcohol-withdrawn mice showed a longer latency, albeit not signiﬁcant
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once daily for ﬁve consecutive days for a duration of three weeks, and
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cumulative alcohol withdrawal-induced mechanical allodynia (AWiMA) (expressed in arbitrary units (AU)) in 2 and 3 g/kg gavaged
alcohol mice was calculated using the trapezoidal rule (C). 3 g/kg
alcohol-withdrawn mice (24 h after last exposure) were injected intrathecally (i.t.) with 10 nmol/10 µl of 2A-adrenergic receptor agonist clonidine, a medication used for treatment of alcohol withdrawal
symptoms. Ten minutes after injection, mechanical antinociception
was measured by using von Frey ﬁlaments. Signiﬁcance was determined by one-way ANOVA (D). ***p < 0.001; **p < 0.01 normalized
versus water-treated group. Reprinted from [409].
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Fig. 2.5. Eﬀects of chronic naltrindole or saline administration on alcohol withdrawal-induced mechanical
allodynia. Wild-type C57BL/6 mice were divided into six groups (n = 7-8), and were subcutaneously injected
with 0.2 mg/kg NTI, 2 mg/kg NTI or saline. Thirty minutes after injection, each group was given 3 g/kg
alcohol or water by oral gavage once daily for ﬁve consecutive days/week for two weeks. The mechanical
sensitivity of all animals measured by using von Frey ﬁlaments was examined on days 1, 2, 4, 7, 14, 21, 28,
35 and 49 after alcohol withdrawal. Signiﬁcance between treatment groups including saline/water-, 2 mg/kg
NTI/water- (A), saline/water-, 0.2 mg/kg NTI/water- (B) and saline/alcohol-, and 0.2 mg/kg NTI/alcoholtreated mice (C) was determined by two-way ANOVA; ***p < .001; **p < .01; *p < .05. Reprinted
from [409].
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(p = 0.21), for their ﬁrst light-side entry compared with water controls (Figure 2.6F).
However, the two groups showed no clear diﬀerence (p = 0.58) in the amount of time
spent in the light side (Figure 2.6G).
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Fig. 2.6. Mice daily gavaged with 3 g/kg alcohol demonstrate
anxiolytic-related behaviors during alcohol withdrawal. Wild-type
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Reprinted from [409].
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2.3.4

DORs play a protective role in a model of gavaged heavy alcohol
intake

To investigate the role of DORs in AWiMA in our o.g. alcohol withdrawal model,
we compared the severity and duration of AWiMA in WT and DOR KO mice after
15 sessions (three weeks) of 3 g/kg o.g. alcohol exposure. Mechanical sensitivity was
measured prior to alcohol exposure (BL, baseline) and on days 1, 2, 4, 7, 14, 21 and 28
after alcohol administration (Figure 2.7A). AWiMA in mice exposed to o.g. alcohol
was more pronounced and lasted longer than that observed in mice exposed to voluntary alcohol consumption (Figures 2.1B and 2.7B). Whereas mechanical sensitivity
returned to baseline in 47 days for voluntary alcohol-exposed mice (Figure 2.1B),
AWiMA persisted for 4 weeks for alcohol-gavaged mice (Figure 2.7B). Again, DOR
KO mice showed prolonged duration of AWiMA compared to WT mice, with a clear
signiﬁcant main eﬀect of time (F6,60 =24.47, p < 0.001; Figure 2.5). No signiﬁcant
main eﬀect of genotype (F1,10 =1.532, p = 0.24; Figure 2.7B) was noted; however, the
P
cumulative AWiMA (measured as 21
day=0 (100 - area under the mechanical sensitivity
curve)day ) was signiﬁcantly higher in DOR KO than in WT mice after 21 days of
alcohol withdrawal (p < 0.01; Figure 2.7C). Data was normalized to the von Frey
response obtained in water-treated mice (Figure 2.4).

2.3.5

Blockade of DORs during alcohol exposure prolongs duration of
AWiMA

To further investigate the temporal aspect of involvement of DORs in the establishment of AWiMA, we pretreated mice with the DOR-selective antagonist naltrindole
(NTI) before alcohol gavage administration. The NTI dosage was based on the lowest
dose tested that did not induce mechanical allodynia in naive mice (F1,38 =7.333, p <
0.05; Figure 2.8A), as we found that administration of 2 mg/kg NTI acutely induced
mechanical hypersensitivity (Figure 2.8A) and its chronic exposure led to prolonged
hyperalgesia in naive mice (Figure 2.8B). In contrast repeated administration of 0.2
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mg/kg NTI did not cause hypersensitivity (signiﬁcant main eﬀect of NTI concentration: F1,12 =12.43, p < 0.01 and time: F7,84 =2.881, p < 0.01; Figure 2.8B). Data was
normalized to the von Frey response obtained in saline/water-treated mice (Figure
2.5). Wild-type C57BL/6 mice (n = 7-8) mice were subcutaneously injected with
0.2 mg/kg NTI or saline 30 min prior to gavage administration of 3 g/kg alcohol or
water for two weeks (ten doses of NTI and alcohol in total; Figure 2.8C). Data was
normalized to the von Frey response obtained in saline/water-treated mice (Figure
2.5). Mice that received NTI prior to each alcohol administration displayed prolonged
AWiMA compared to saline/alcohol-treated mice (Figure 2.8D and 2.8E). This was
P
also illustrated by the cumulative AWiMA (measured as 49
day=0 (100 - area under the
mechanical sensitivity curve)day , p < 0.01) in Figure 2.8E.

2.3.6

The DOR-selective agonist TAN-67 loses antinociceptive potency
during active alcohol withdrawal

We next determined if TAN-67 could produce analgesia in naive and alcoholwithdrawn WT mice. Intrathecal delivery of TAN-67 caused a dose-dependent decrease in mechanical sensitivity in mice exposed to either water or voluntary alcohol
(Figure 2.9A, Table 2.1). No signiﬁcant diﬀerence was observed in ED50 (F2,57 =0.113,
p = 0.89). However, intrathecal injection of TAN-67 in mice exposed to 15 sessions
(three weeks) of 3 g/kg o.g. alcohol followed by a 35 day withdrawal showed a rightward shift in analgesic potency (F2,53 =9.320, p < 0.001) compared to mice exposed
to water (Figure 2.9B, Table 2.1).

2.4

Discussion
Alcohol use disorder is deﬁned as a chronic, relapsing brain disease and as such

carries a large socioeconomic burden [410, 411]. Heavy alcohol use and withdrawal is
associated with neuropathy, hyperalgesia and tactile allodynia. Alcohol withdrawal
induced allodynia is a component of the alcohol withdrawal syndrome, consisting of

Fig. 2.8. Chronic naltrindole administration prior to each alcohol exposure prolongs duration of alcohol
withdrawal-induced mechanical allodynia. The acute subcutaneous (s.c.) injection of the DOR-selective
antagonist naltrindole (NTI) dose-dependently caused mechanical allodynia in naive mice (A). The chronic
administration of 2 mg/kg NTI also led to prolonged hyperalgesia in naive mice (B). Timeline for chronic
alcohol consumption and measurement of mechanical nociception of Figure 2.8B (C). Twenty-two wild-type
C57BL/6 mice were divided into three groups (n = 7-8), and were s.c. injected with 0.2 mg/kg NTI or
saline. Thirty minutes after injection, each group was given 3 g/kg alcohol or water by oral gavage once
daily for ﬁve consecutive days/week for two weeks. The mechanical sensitivity of all animals measured using
von Frey ﬁlaments was examined on days 1, 2, 4, 7, 14, 21, 28, 35 and 49 after alcohol withdrawal (D). The
cumulative alcohol withdrawal-induced mechanical allodynia (AWiMA) (expressed in arbitrary units (AU))
was calculated using the trapezoidal rule (E). Data was normalized to the mechanical sensitivity response in
saline/water-treated group. **p < 0.01; *p < 0.05. BL, baseline. Reprinted from [409].
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Table 2.1.
Extrapolated ED50 values (95% Conﬁdence Interval, nmol) for
antinociception produced by the DOR-selective agonist TAN-67 in
C57BL/6 mice exposed to water or alcohol in a voluntary or gavage
model.
TAN-67

ED50 (95% CI, nmol)

Water (voluntary)

61.0 (39.0-194)

Alcohol (voluntary)

78.5 (42.7-577)

Water (gavage)

131.5 (82.3-1023)

Alcohol (gavage)

659 (319-10111)

1000
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several separate symptoms including anxiety, tremors, depression or sleep disturbance
[164, 218, 412, 413]. These withdrawal symptoms are a large contributor to alcohol
relapse. Currently, we lack detailed insight into mechanisms underlying the alcohol
withdrawal syndrome, hampering development of novel medications that could treat
the withdrawal symptoms and reduce relapse. Here we developed and validated a
novel animal model of the alcohol withdrawal syndrome, with a strong mechanical
allodynia component and identiﬁed the DOR as a contributor and potential target
for AWiMA.
While models for alcohol withdrawal are available, they frequently rely on delivering alcohol to animals by inhalation or liquid diet, which is not necessarily related to
the manner by which humans consume and abuse alcohol [414]. We generated a novel
alcohol withdrawal syndrome model using daily o.g. of 3 g/kg alcohol, mimicking a
daily alcohol binge. Our model provided face validity as it rapidly produced severe
and prolonged AWiMA (Figure 2.3) as well as withdrawal-induced anxiety-like behaviors (Figure 2.6) on a timescale similar to alcohol withdrawal in humans [387,415,416].
A beneﬁt of our o.g. model is that AWiMA is more pronounced, longer-lasting and
stable when compared to mice withdrawn from alcohol administered on a voluntary basis (compare Figure 2.1 and Figure 2.7). Clonidine, a centrally acting 2Aadrenergic receptor agonist clinically used in the treatment of alcohol withdrawal
symptoms [417–420], produced potent analgesia in our alcohol withdrawal model,
thereby also providing our model with construct validity.
The underlying mechanisms for AWiMA are not well understood. Recent studies
have shown that DORs are expressed in neurons responding to mechanical stimulation and are heavily involved in the sensation of touch [405] even under naive
conditions [161, 213]. DORs have been eﬀective in reducing chronic pain, including
neuropathic pain [131, 421, 422] and thus are a logic plausible target for involvement
in AWiMA. Using DOR KO mice, we conﬁrm that DORs appear to play a protective
role in AWiMA. Our observations in DOR KO mice however did not inform us at
which stage DORs alleviate AWiMA. We therefore speciﬁcally blocked DORs only
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during alcohol exposure using the DOR-selective antagonist NTI (see methods). We
reduced the alcohol exposure time from 2 weeks to 3 weeks in hopes of better diﬀerentiating severity and not only duration, yet onset of AWiMA was still fast and robust.
Using this strategy, we revealed that without functional DORs, alcohol withdrawal
produced prolonged AWiMA (Figure 2.8D and 2.8E). Thus, the presence of functional
DORs may limit the emergence of algogenic factors following repeated alcohol exposure. One such an algogenic factor could be Toll-like receptor 4 (TLR4). TLR4s are
expressed on neuroglia and have recently been implicated in the paradoxical hyperalgesia associated with chronic morphine use [423, 424]. Activation of TLR4 causes
hyperalgesia [424, 425]. Importantly, alcohol exposure can increase TLR4 expression
and TLR4-facilitated secretion of pro-inﬂammatory mediators [426, 427]. One study
has shown that the activation of DORs through mechanisms involving β-arrestin 2
inhibit TLR4-induced release of tumor necrosis factor induced by the TLR4 agonist
lipopolysaccharide in mast cells [428]. It will be worthwhile to explore the role of
TLR4 and potential TLR4-DOR crosstalk in the expression of AWiMA.
Current drugs approved by the Food and Drug Administration for AUD treatment do not relieve alcohol withdrawal induced hyperalgesia or other components of
the alcohol withdrawal syndrome. The National Institutes of Health has therefore
declared that it is critically important to develop new and more eﬀective pharmacological therapies for AUD. Besides a role in antinociception, DORs are implicated
in alcohol consumption, depression and anxiety including alcohol withdrawal-induced
anxiety [183, 287, 429, 430]. We and others have shown in preclinical animal models
that the DOR-selective agonist TAN-67 can produce analgesia and reduce alcohol
intake, depression and anxiety [182,183,295,431]. Hence, we were interested in investigating whether TAN-67, speciﬁcally, would alleviate AWiMA. We have previously
shown that intrathecal administration of the DOR-selective agonists SNC80, DPDPE
and deltorphin potently reduce mechanical sensation in naive mice and that alcohol
exposure does not change the analgesic potency of these DOR-selective agonists in
mechanical allodynia, although DPDPE and deltorphin do show enhanced potency
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for thermal analgesia after alcohol exposure [161]. The intrathecal route was chosen
because primary and secondary neurons in the pain pathway are located in dorsal
root ganglion and spinal cord and highly express DORs [432]. Additionally, the
local administration would limit the TAN-67-induced-anxiolysis as a potential confounder. Consistent with our previous ﬁndings, TAN-67 dose-dependently reduced
mechanical sensation in naive mice and mice fully withdrawn from voluntary alcohol. However, we observed a signiﬁcant decrease in TAN-67 potency in mice withdrawn from o.g. alcohol (Table 2.1). It is important to note that mice exposed to
o.g. alcohol were injected with TAN-67 during active withdrawal (days 36; Figure
2.7), whereas mice, voluntarily exposed to alcohol, were injected with TAN-67 after
withdrawal, as there was not stable hyperalgesia during active withdrawal (days 47;
Figure 2.1). The loss of TAN-67 potency during withdrawal could potentially be
attributed to DOR desensitization and internalization following endogenous opioid
release due to the chronic exposure to 3 g/kg o.g. alcohol [433–436]. Previous reports have shown that chronic alcohol consumption signiﬁcantly elevates the levels of
methionine-enkephalin, an endogenous ligand for the DORs, with a peak after 7 days
of alcohol ingestion [251, 268, 437, 438]. Interestingly, pharmacological studies have
suggested the existence of two DOR subtypes, DOR1 and DOR2 [198, 439]. TAN-67
has frequently been labeled as a DOR1-selective agonist. The pharmacology underlying the subtypes is not well deﬁned, but our data suggests that TAN-67 may interact
with DOR-mu opioid receptor heteromers [182] and have strong G-protein signaling
bias, with limited eﬃcacy for β-arrestin 2 recruitment [295]. While our data would
support DORs as a drug target for prevention but not treatment of AWiMA, it is
important to consider that DOR agonists alleviate other components of the alcohol
withdrawal syndrome. Also, diﬀerent DOR agonists with an intermediate β-arrestin
2 recruitment eﬃcacy such as KNT-127 [206, 295, 440, 441] may be more capable of
reducing alcohol withdrawal induced hyperalgesia.
In conclusion, we have developed a robust mouse model of the alcohol withdrawal
syndrome including AWiMA, which can be used to investigate mechanisms underlying
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this phenomenon. Our results indicate that DORs play a protective role against
AWiMA; however, this role appears to be limited to the alcohol exposure stage. Our
data also suggests that once mice reside in a state of severe alcohol withdrawal, DORs
appear to be either desensitized or downregulated.
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3. INVESTIGATION OF A NOVEL INTERACTION SITE
OF THE DELTA/MU OPIOID RECEPTOR
HETEROMERS
3.1

Introduction
Heteromeric interactions between membrane-bound proteins are relatively com-

mon place, and thus not surprisingly G protein-coupled receptors (GPCRs) have been
argued to interact based on many diﬀerent studies [442–449]. However, the majority
of the evidence supporting GPCR heteromerization is obtained using in vitro studies, which are frequently met with skepticism due to methodological constraints. For
example, biochemical approaches, such as co-immunoprecipitation, may suﬀer from
non-speciﬁc aggregation. On the other hand, biophysical approaches, like bioluminescence and ﬂuorescence resonance energy transfer (BRET and FRET), require fusing
large ﬂuorescent proteins to receptors, potentially altering their properties and, ultimately, are only a measure of proximity not interaction [450]. For only a handful
of receptors has heteromerization been accepted to occur in vivo [451–454], and frequently in these cases heteromerization was required for function, allowing for easier
characterization.
For heteromers to be relevant they need to have a distinct function from the
individual homodimers [455], and several studies have found heteromers displaying unique pharmacology compared to the pharmacology of the individual homodimeric/monomeric receptors [313, 333, 446, 456–458]. Disruption of the heteromers,
or preventing them from forming should eliminate the unique pharmacological heteromer phenotype. Some of the ﬁrst evidences of potential GPCR heteromerization arose from studies investigating opioid receptors [310, 459]. Several reports
suggest that delta opioid receptors have a negative impact on mu opioid receptor
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function [214,215]. For example, genetic disruption of delta opioid receptors or pharmacological blockade using the DOR-selective antagonist naltriben attenuated morphine tolerance [311,354]. An increase in surface expression of DOR-MOR heteromers
exacerbated methadone analgesic tolerance [214]. Similarly, preventing DOR-MOR
heteromer formation using an interfering peptide (transmembrane (TM) domain 1 of
MOR) increased morphine analgesia and reduced morphine tolerance [215]. Still, the
mechanism by which MOR interacts with DOR is not well deﬁned.
Diﬀerent biochemical and computational studies have implicated TM1, 2, 4, 5
and 6, helix 8, as well as intracellular loop (ICL) 3 [215, 303, 307, 333, 460–462] in
the formation of the DOR-MOR heteromer interface. This rather large number of
TM domains may be attributed to the existence of multiple, simultaneous interaction
sites through the formation of higher order oligomeric structures, rather than mere
dimers. It is also possible that diﬀerent sites are important in the heteromer interface
depending on whether the receptors are unbound, or bound to an agonist or antagonist
[463]. The antagonist-bound mu opioid receptor was crystallized as homodimers
with TM5/6 interface as well as a TM1/2-helix (H) 8 interface [303]. Interestingly,
due to the relatively high TM homology between the MOR and DOR the TM5/6
interface has a high probability of occurring as well for the DOR-MOR heteromers
[303]. One study has previously identiﬁed a region of ICL3 close to TM5 as important
in formation of DOR-MOR heteromers, which may support that the TM5 domains
are in close proximity of each other [460].
In this study, we perform a detailed analysis of contribution of the amino acid
residues spanning TM5/6 of the DOR as well as the MOR on heteromer formation/stability using a multipronged approach, including functional complementation
assays, co-immunoprecipitation and computational modeling. We conﬁrmed a region containing serine, valine and arginine (SVR) in ICL3 as contact interface for
heteromer stability, and additionally identiﬁed Ile6.53 (amino acids are depicted by
Ballesteros-Weinstein numbering) [464] as a potential contact point. However most
revealing was the discovery of a region near the extracellular portions of TM5/6 of
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DOR (Tyr5.33 , Trp5.34 and Asp6.62 ) and MOR (Tyr5.33 , Thr6.62 ) to play an important
role in heteromer stability. It may be possible to design small molecules in the future
targeting this region to speciﬁcally disrupt heteromer formation. Such protein-protein
interaction inhibitors could be useful in studying the physiological role of the DORMOR heteromers and could potentially have clinical value as adjuvant to a MOR
agonist-based therapy to reduce development of analgesic tolerance.

3.2

Materials and methods

3.2.1

Mutagenesis of DOR and MOR and creation of chimeric proteins

We created 45 mutant DORs and MORs by site-directed mutagenesis. Using
the pcDNA3.1-FLAG-mDORh8 -Gqi4 construct [465] we performed mutagenesis using QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara,
CA) according to the manufacturer’s protocol. Because the receptors have N-terminal
aﬃnity tags, we opt to use the Ballesteros-Weinstein numbering system to designate
amino acids [464]. In this numbering scheme the most highly conserved amino acid
in each TM domain is assigned the number 50 (e.g. Pro6.50 ) for the conserved proline
in TM6. Amino acids that reside in intracellular loop 3 (ICL3) were associated with
the closest TM domain e.g. Ser5.67(ICL3) or Asp6.27(ICL3) . Custom-designed complementary primers carrying the desired point mutations (http://www.
genomics.agilent.com/primerDesignProgram.jsp, Table 3.1) were used in a PCR reaction using 2x PfuUltra Hotstart PCR Master Mix (Agilent Technologies, Santa
Clara, CA) according to the manufacturer’s protocol. A portion of the DOR containing the mutant was restricted using HindIII and AfeI and was swapped with the
same region in the wild-type DOR. Restriction enzymes, T4 DNA ligase, NEB 5-alpha
competent E. coli (high eﬃciency), and SOC outgrowth medium were obtained from
New England Biolabs (Ipswich, MA). The Tyr5.33 Ala, Thr6.62 Asp, Thr6.62 Val, and
Tyr5.33 Ala+Thr6.62 Val MOR mutants were created by GenScript (Piscataway, NJ)
through custom gene synthesis. The Tyr5.33 Asp, Thr6.62 Tyr, and Thr6.62 Trp MOR
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mutants were also constructed by site-directed mutagenesis using the Tyr5.33 Ala,
Thr6.62 Asp, and Thr6.62 Val as the starting templates, respectively. Custom-designed
complementary primers of MOR were shown in Table 3.2.

BiFC pairs, N-YFP

and C-YFP, were made by site-directed mutagenesis using the pBiFC-YFP cDNA
(kindly provided by Dr. Chang-Deng Hu, Purdue University) as the starting template [466]. DOR/N-YFP was made by inserting a stop codon at amino acid 156 of
YFP. MOR/C-YFP was made by inserting a BamHI site at amino acid 156 of the
YFP, followed by BamHI digest to remove amino acids 1-155 of the YFP, and subsequent re-ligation [466]. All receptor mutants, both the purchased and engineered
constructs, were validated by gene sequencing.

TGACCAAGATCTGTTTGCCTTCGTGG
CCAAGATCTGCGTTGCCTTCGTGGTG
CGTGTTCCTCTTTGGTGCCGATCCTC
GTGTTCCTCTTTGGATCCTCATCATC

Ala

Leu5.44 Phe

Ala

5.43

5.47

Val5.48 Phe

TCATCATCACGGTCTCATGCTACTGC
TCATCATCACGGTCATGCTACTGCGC
GTGTGCTATGGCCTACTGCGCCTGCG
GCTATGGCCTCATTGCGCCTGCGCAG
GTGCTATGGCCTCTTCCGCCTGCGCA

Tyr5.58 Ala

Phe

Met5.61 Ala

Phe

5.59

5.62

Leu5.63 Phe

Leu

Gly

GTGCCGATCCTCACTATGGCCTCATG

CTTCGTGGGTGCCGTCATCACGGTGTG

Phe

Thr

5.55

Leu5.52 Phe

Ile

5.51

Phe

Phe

CCTTCGTGGTGCCCCTCATCATCACG

GGACACTGTGACCGCGTGTTCCTCTT

Ile5.40 Phe

Phe

CCCAGCTGGTACTTCACCAAGATCTG

Phe

Val

CCAGCTGGTACTGACCAAGATCTGCG

CAGTCCCAGCTGGTACACGGACACTGTGACCAAG

5.37

Thr

CAGTCCCAGCTGGCACTGTGACCAAG

CCCAGTCCCAGCTGGACCTGGGACACTGTGAC

Thr5.36 Val

Trp

5.34

Trp5.34 Ala

Thr

CCCAGTCCCAGCTGGGACACTGTGAC

Tyr5.33 Ala

Tyr

TCCCCAGTCCCAGTACTGGGACACTG

Trp5.32 Ala

5.33

Forward primer (5’→3’)

DOR

continued on next page

TGCGCAGGCGGAAGAGGCCATAGCAC

CTGCGCAGGCGCAATGAGGCCATAGC

CGCAGGCGCAGTAGGCCATAGCACAC

GCGCAGTAGCATGACCGTGATGATGA

GCAGTAGCATGAGACCGTGATGATGA

CATGAGGCCATAGTGAGGATCGGCAC

CACACCGTGATGACGGCACCACGAAG

CGTGATGATGAGGGGCACCACGAAGG

GATGATGAGGATCCAAAGAGGAACAC

GAGGATCGGCACCAAAGAGGAACACG

CACCACGAAGGCAACGCAGATCTTGG

CCACGAAGGCAAACAGATCTTGGTCA

AAGAGGAACACGCGGTCACAGTGTCC

CAGATCTTGGTGAAGTACCAGCTGGG

CGCAGATCTTGGTCAGTACCAGCTGG

CTTGGTCACAGTGTCCGTGTACCAGCTGGGACTG

CTTGGTCACAGTGCCAGCTGGGACTG

GTCACAGTGTCCCAGGTCCAGCTGGGACTGGG

GTCACAGTGTCCCAGCTGGGACTGGG

CAGTGTCCCAGTACTGGGACTGGGGA

Reverse primer (5’→3’)

Table 3.1.: List of primers of DOR used in this study.
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CGCCTGCGCAGCGCGGCTCTGCTGTCCGGT

Val5.68 Ala+Arg5.69 Ala

CACGCGCATGGTGGTGGTGGTGGGCG
GGTGGGCGCCTTCGTGTGCTGGGCGC
CCTTCGTGGTGTGTCCACATCTTCGT
GGGCGCCCATCCACTTCGTCATCGTC
ATCCACATCTTCGGTCTGGACGCTGG
CACATCTTCGTCATGGACGCTGGTGG
CGTCATCGTCTGGGACATCAATCGGC
ATCGTCTGGACGCCATCAATCGGCGC
TGGACGCTGGTGGCATCAATCGGCGC

Phe

Val6.45 Phe

Phe

6.49

Ile6.53 Phe

Phe

6.56

Val6.57 Phe

Phe

6.38

6.60

Val6.61 Phe

6.62

Asp

6.62

Tyr

Asp6.62 Thr

Asp

Leu

Ile

Ala

Leu

TCTGGACGCTGGTGTACATCAATCGGCGC

GTCTGGACGCTGGTGACCATCAATCGGCGCGA

GCGGCGCATCACGCATGGTGCTGGTG

Arg6.35 Ala

Val

AGCCTGCGGCGCACATGGTGCTGGTG

Phe

6.34

Thr

GACCGCAGCCTGGCGCGCATCACGCG

Arg6.31 Ala

Asp
CCAAGGAGAAGGCCCGCAGCCTGCG

TGCGCCTGCGCACCGTGCGTCTG

Ser5.67 Thr

Ala

GCTACTGCGCCTGGCCAGCGTGCGTCTG

Arg5.66 Ala

6.27

Forward primer (5’→3’)

DOR

Table 3.1.: continued

GCGCCGATTGATGTACACCAGCGTCCAGA

TCGCGCCGATTGATGGTCACCAGCGTCCAGAC

GCGCCGATTGATGCCACCAGCGTCCA

GCGCCGATTGATGGCGTCCAGACGAT

GCCGATTGATGTCCCAGACGATGACG

CCACCAGCGTCCATGACGAAGATGTG

CCAGCGTCCAGACCGAAGATGTGGAT

GACGATGACGAAGTGGATGGGCGCCC

ACGAAGATGTGGACACACCACGAAGG

GCGCCCAGCACACGAAGGCGCCCACC

CGCCCACCACCACCACCATGCGCGTG

CACCAGCACCATGCGTGATGCGCCGC

CACCAGCACCATGTGCGCCGCAGGCT

CGCGTGATGCGCGCCAGGCTGCGGTC

CGCAGGCTGCGGGCCTTCTCCTTGG

ACCGGACAGCAGAGCCGCGCTGCGCAGGCG

CAGACGCACGGTGCGCAGGCGCA

CAGACGCACGCTGGCCAGGCGCAGTAGC

Reverse primer (5’→3’)
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Thr6.62 Trp

Thr6.62 Tyr

Asp

TGGAAAGTGGTTTCTGGAATCCAGATCAGTGCTTT
GATGATGAC

ACTTTCCA

TGATGA

CTTTC
GTCATCATCAAAGCACTGATCTGGATTCCAGAAACC

GAAAGTGGTTTCTGGAATGTAGATCAGTGCTTTGA

Genscript

Genscript

GCAGGTTCTCCCAGTCCCATGTGGGATGA

TCATCATCAAAGCACTGATCTACATTCCAGAAACCA

GenScript

Thr

GenScript

6.62

TCATCCCACATGGGACTGGGAGAACCTGC

Thr6.62 Val

Tyr

Asp

Genscript

Tyr5.33 Ala+Thr6.62 Val GenScript

5.33

Genscript

GenScript

Tyr5.33 Ala

Reverse primer (5’→3’)

Forward primer (5’→3’)

MOR

Table 3.2.: List of primers of MOR used in this study.
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3.2.2

Heteromer-selective calcium signaling assay

The heteromer-selective calcium signaling assay was performed in 384-well format as previously described [465]. In short, human embryonic kidney HEK-293 cells
(ATCC, Manassas, VA) were maintained at 37◦ C humidiﬁed in 5% CO2/% air atmosphere in Dulbecco’s Modiﬁed Eagle’s medium (DMEM, #11995-065 Life Technologies, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (#F0926
Sigma, St. Louis, MO). Cells were seeded in a 6-well plate (#353046 Fisher/Falcon,
Hampton, NH) and transfected when 90% conﬂuent with 1 µg of pcDNA3.1-FLAGmDORh8 -Gqi4 and 1 µg of pcDNA3.1-HA-mMOR using X-tremeGENE9 (#06365787001
Roche, Basel, Switzerland) in Opti-MEM (#31985-070 Life Technologies), following
the manufacturer’s protocol. The next day cells were detached and seeded (25,000
cells/25 µl) in a 384-well clear bottom black plate (#142761 Fisher/Nunc). The following day, cells were loaded with 25 µl of FLIPR calcium 6 dye (#10048-806 VWR,
Radnor, PA) for one hour before cells were stimulated with increasing concentrations
of [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO, Sigma). Calcium mobilization
was measured for two minutes using a FlexStation 3 (Molecular Devices, Sunnyvale,
CA), with the read starting 10 seconds before the addition of DAMGO. Data is represented in relative ﬂuorescence units as the peak calcium response/baseline calcium
response x 1,000. If not otherwise speciﬁed.

3.2.3

Bimolecular Fluorescence Complementation (BiFC) assay

Cath.a diﬀerentiated (CAD) cells (generously provided by Dr. Dona M. Chikaraishi,
Duke University) were seeded (10,000 cells/well) in a poly-D-lysine (Sigma) pretreated
96-well clear bottom black plates in regular DMEM and were transfected the following
day with equal amounts (200 ng each) of WT or mutant DOR/N-YFP+MOR/C-YFP,
along with 40 ng of Mem-mCherry plasmid (generously provided by Dr. Catherine
Berlot, Geisinger Medical Center [467]) using X-tremeGENE9 according to the manufacturer’s protocol. The following day cells were washed twice with PBS and replaced
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with 100 µl of FluoroBrite DMEM Medium (#A1896701 Life Technologies). Fluorescence was measured using a Cytation 3 cell imaging multi-mode plate reader (Biotek,
Winooski, VT) using a Texas Red channel (Ex 586, Em 647, LED = 6, Integration
time = 346, Gain = 15.6) and a YFP channel (Ex 500, Em 542, LED = 6, Integration
time = 100, Gain = 14.4). Mem-mCherry ﬂuorescence was used to identify transfected
cells and as a marker of transfection eﬃciency. Positive BiFC was observed as complementation of the N-YFP and C-YFP halves to restore YFP ﬂuorescence. Negative
BiFC was observed as a lack of YFP ﬂuorescence in transfected cells co-expressing
the Mem-mCherry plasmid.
For a small subset of receptors, we also measured BiFC by confocal microscopy.
Cells (40-45,000 cells/600 µL) were seeded into one chamber of a four chamber 35 mm
glass bottom tissue culture dish. Once 60-80% conﬂuent cells were transfected with
equal amounts (600 ng each) of WT or mutant DOR/N-YFP+MOR/C-YFP, along
with 120 ng of Mem-mCherry plasmid using X-tremeGENE9. Twenty-four hours after
transfection, images were acquired via Nikon Eclipse Ti-E inverted microscope (Nikon
Instruments, Mellville, NY) at 20x and 60x magniﬁcation using oil immersion. Gain
and exposure were standardized. For each transfection, approximately 50-100 cells
were used for quantiﬁcation. Images were processed using NIS-Elements Advanced
Research (Version 4.20.01) analysis software (Nikon Instruments).

3.2.4

Co-immunoprecipitation assay and Western blot analysis

HEK-293 cells were grown to 80-90% conﬂuency in 10-cm dishes (Thermo Fisher
Scientiﬁc, Waltham, MA) and transfected with 2.5 µg FLAG-mDOR and 2.5 µg
HA-mMOR with 15 µl X-tremeGENE9. Two days after transfection, medium was
removed and cells were detached with a cell scraper using 800 µl ice-cold lysis buﬀer
[20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100 (Sigma), 1X HALT protease inhibitor (ThermoFisher)] and incubated for 1 hour at 4◦ C before centrifugation
(14,000 g, 10 minutes, 4◦ C). The supernatant was removed and incubated with 20
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µl protein G plus agarose beads (#SC-2002 Santa Cruz Biotechnology, Dallas, TX)
for 30 minutes at 4◦ C on a nutator. Following a 1 minute 1,000 g centrifugation at
4◦ C, the supernatant was collected (40 µl [5%] of the supernatant was separated for
analysis) and 1,000 µg (determined using a Bradford assay) was immunoprecipitated
with 2 µl mouse anti-FLAG M2 (#F1804, lot# SLBG5673V Sigma) for overnight at
4◦ C on a nutator and isolated by incubation with 30 µl protein G plus agarose beads
for overnight at 4◦ C on a nutator. Following a 1 minute 1,000 g centrifugation at 4◦ C,
the beads were removed, washed three times with lysis buﬀer and resuspended with 60
µl of 2x Laemmli buﬀer (Bio-Rad, Hercules, CA). Samples were heated for 5 minutes
at 95◦ C and loaded onto NuPAGE 4-12% Bis-Tris gel (#NP0321BOX Life Technologies). Proteins were transferred onto nitrocellulose membrane (Bio-Rad). Following
blocking in Odyssey blocking buﬀer (#927-40000 Li-Cor Biosciences, Lincoln, NE)
for 1 hour at room temperature, membrane was incubated with a 1:1,000 dilution of
the mouse anti-FLAG M2 for 1 hour at room temperature, the rabbit anti-actin (#sc7210, lot# L1812 Santa Cruz Biotechnology) for 2 hours at room temperature, or the
rabbit anti-HA (#3724, lot# 8 Cell Signaling Technology, Danvers, MA) overnight at
4◦ C. Membranes were washed four times for 10 minutes with PBS + 0.1% Tween-20
(#SLBH5836V Sigma) and incubated with a 1:10,000 dilution of IRDye 800CW goat
anti-mouse IgG (#926-32210, lot# C31021-01 Li-Cor Biosciences) or IRDye 800CW
goat anti-rabbit IgG (#926-32211, lot# C61103-06 Li-Cor Biosciences) for 1 hour
at room temperature. Membranes were washed four times for 10 minutes with PBS
+ 0.1% Tween-20. The ﬂuorescent signal was detected using Odyssey CLx imager
(Li-Cor Biosciences) according to the manufacturer’s instructions.

3.2.5

GloSensor cAMP assay

Inhibition of forskolin-stimulated cAMP accumulation was using a GloSensor
cAMP assay as previously described [295]. HEK-293 cells were transfected with wildtype or mutant DOR or MOR DNA and pGloSensor22F-cAMP plasmids (Promega,
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Madison, WI) in a 3:7 ratio using X-tremeGENE9 according to the manufacturer’s
protocol. On day 2 cells were dislodged, counted, and 7.5 µl of cell suspension was
seeded (30,000 cells/well) in a low volume, round bottom, white 384-well microplate
(PerkinElmer, Waltham, MA). Three hours later, cells were stimulated with 7.5 µl
4% GloSensor reagent (Promega) in Hank’s Balanced Salt Solution (HBSS) with 20
mM Hepes buﬀer (both Life Technologies) and incubated for 90 minutes at room
temperature. Cells were stimulated for 20 minutes with the 5 µl/well of increasing concentrations of either the MOR agonist DAMGO or the DOR agonist SNC80
(Tocris, Bristol, UK). Each dilution was performed in triplicate. Following stimulation, cells were incubated for 20 minutes with 5 µl 100 µM forskolin (Sigma) and
luminescence was measured on a FlexStation3.

3.2.6

Fluorescence-activated cell sorting

HEK-293 cells were transfected with cDNAs encoding wild-type or mutant FLAGtagged DOR or HA-tagged MOR. Forty-eight hours after transfection, cells were harvested and ﬁxed in PBS containing 4% paraformaldehyde for 10 minutes at 37◦ C. Cells
were then washed twice with FACS incubation buﬀer (0.5% BSA in PBS). Brieﬂy, 6 x
105 cells were incubated with a 1:50 dilution of the Alexa Fluor 488-conjugated rabbit
anti-FLAG antibody (#5407, lot#12 Cell Signaling Technology) or the Alexa Fluor
488-conjugated mouse anti-HA antibody (#2350, lot# 19 Cell Signaling Technology)
in 100 µl of FACS incubation buﬀer for 1 hour at room temperature. Cells were then
washed once with FACS incubation buﬀer and subjected for analysis of cell-surface
expression using BD Accuri C6 Cytometer (BD Biosciences, San Jose, CA) equipped
with a 488-nm laser and a 533/30-nm band-pass ﬁlter. Cells with the light scatter
properties were analyzed using BD Accuri C6 software (BD Biosciences).
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3.2.7

Statistical analysis

Data was plotted using GraphPad Prism5 software (GraphPad Software, La Jolla,
CA). Each experiment was performed a minimum of three independent times. One
way ANOVA was carried out on the data sets and if a diﬀerence in the mean was
observed, the ANOVA was followed by a Bonferroni post-hoc analysis to determine if
there was a statistically signiﬁcant diﬀerence between wild-type receptors and mutant
receptors.

3.3

Results

3.3.1

Mutagenesis approach to investigate the DOR TM5/6 domain in
DOR-MOR heteromer stability

The inactive, antagonist-bound MOR crystal structure was resolved as homodimers with a TM5/6 contact interface [303,468]. Based on the high homology between
DOR and MOR in this region (Figure 3.1A), it is plausible for the DOR and MOR
to interact with each other as a heterodimer using the same TM5/6 interface (Figure
3.1B). To investigate the importance of this region and individual amino acids within
it in relation to heteromer formation and/or stability we created 18 mutants in TM5, 5
mutants in ICL3, and 12 mutants in TM6. The SVR and Arg6.31 were used as positive
controls, based on previous reports [460, 469–471] (Figure 3.1C). In most instances
residues were mutated to alanine. However, only Thr5.36 and Asp6.62 were mutated to
valine as the immediate neighboring residues (Val5.37 and Val6.61 ) were valines, suggesting that a valine would be tolerated well. In cases where the original residue was
relatively small and not charged (Gly, Ala, Val, Leu, Ile, or Thr) we opted to mutate
the residue into the much bulkier uncharged amino acid, phenylalanine (Tables 3.1
and 3.2).
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Fig. 3.1. Prediction of potential amino acids in the TM5/6 domain that could disrupt the DOR-MOR
heteromers by crystal structure and computational model. (A) Sequences of the DOR and MOR shown
with potential twenty-eight mutants in black font spanning TM5/6 of the DOR in green and MOR in pink
highlights (reproduced from [303]). (B) Computational model of the DOR-MOR heteromers shown with
potential TM5/6 dimer interface of the MOR in pink and DOR in green. (C) Snake plot representation of
DOR shown with thirty-ﬁve mutation points in green circles spanning TM5/6 and ICL3 of the DOR that
were tested in the current study.
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3.3.2

Identiﬁcation of regions of interest within DOR TM5/6 that reduce
heteromer activation

We used a heteromer-selective signaling assay to quickly characterize the 28 mutants. The heteromer signaling is detected by a calcium-mobilization assay in which
the DOR is truncated after helix 8 and fused to a chimeric Gqi4 protein [465, 472].
This DORh8 -Gqi4 does not produce a strong calcium response upon activation. This
can be rescued when co-expressed with wild-type MOR, which is a Gi-coupled receptor that cannot induce calcium release by itself [465] (Figure 3.2A-B) . As previously shown by our group [465], the potency of DAMGO to induce calcium release
in cells expressing DORh8 -Gqi4 + MOR [pEC50 = 5.9 (5.7-6.2, 95% CI), maximal
eﬀect set to 100%] is uniquely diﬀerent from those of MOR + Gqi4 [pEC50 = 7.0
(6.8-7.3, 95% CI), maximal eﬀect = 131% of DORh8 -Gqi4 + MOR] or DORh8 -Gqi4
[pEC50 = 4.9 (4.4-5.4, 95% CI), maximal eﬀect = 20% of DORh8 -Gqi4 + MOR]
(Figure 3.2B). Each mutant was created as a truncated, Gqi4-fused receptor and in
our initial characterization of the DOR mutants we measured calcium release induced
by a single concentration of DAMGO (100 µM) when the mutant was co-expressed
with wild-type MOR. In this primary screen, we identiﬁed six regions of interest
(Tyr5.33 Ala/Trp5.34 Ala, Phe5.47 Ala, Thr6.34 Phe, Ile6.53 Phe and Asp6.62 Val) where mutations attenuated the calcium release observed by >70% compared to that observed
with the WT DOR (Figure 3.2C-D).
Next, we decided to move forward characterizing those DORs that carry amino
acids in the identiﬁed regions of interest, and use DORs with mutated residues that
are neighboring or nearby the disruptive mutants as negative controls. Because 100
µM of DAMGO can induce a small amount of calcium release for the DORh8 -Gqi4
(Figure 3.2B), we retested the mutants at 10 µM of DAMGO this time to ensure that
the DORh8 -Gqi4 itself did not aﬀect the calcium release. The SVR region in ICL3
and Arg6.31 served as our positive controls and also attenuated calcium release (Figure 3.3A). We determined full dose-response curves for DAMGO on the “disruptive”
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Fig. 3.2. Identiﬁcation of regions of interest within DOR TM5/6 that reduce signal transduction in heteromerselective calcium signaling assay. (A) Schematic representation of calcium signaling assay used for measuring
heteromeric interactions. DOR (in green) is truncated and fused to a chimeric Gqi4 protein that exclusively
induces calcium release. Steric hindrance and lack of fused Gqi4 protein only allows the heteromers of
DOR and MOR (in pink) to signal. (B) Dose-response curves for calcium release induced by the MORselective agonist DAMGO in HEK-293 cells expressing wild-type full-length MOR with the Gqi4 or the
wild-type DORh8 -Gqi4 proteins. DAMGO does not induce calcium release when the DORh8 -Gqi4 or MOR
is expressed alone. (C-D) Calcium release induced by 100 µM of DAMGO in cells expressing wild-type
MOR with DORh8 -Gqi4 that has a single amino acid mutation in transmembrane domain (C) 5 or (D) 6.
Residues important for the DOR-MOR heteromerization are highlighted in green. The data were normalized
by deﬁning the calcium levels from WT DORh8 Gqi4 + MOR as 100% and WT DORh8 Gqi4 - MOR as 0%. All
data shown represent the average and SEM at least three independent experiments conducted in triplicate.
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mutations (Figure 3.3B, Table 3.3). We expected that with increased disruption of
the DOR-MOR heteromers, we would see a decrease in pEC50 and maximal eﬀect
of the DAMGO until it is approximately equal to that observed at the DORh8 -Gqi4
expressed alone (Figure 3.3B). The Ile6.53 Phe mutant showed a rightward shift in
potency of DAMGO, but not a decrease in eﬃcacy, which could indicate that the mutation at this site may aﬀect DOR conformation following DAMGO binding. Because
the c-terminal tail of the DOR is shortened and fused to the chimeric Gqi4-protein,
we are unable to characterize the wild-type or mutant receptors in a typical functional assay such as a [35 S]GTPγS binding assay or a cAMP assay as the free ﬂowing
Gi-proteins may not be able to compete against the fused Gqi4 protein and our
previous paper has shown attenuated signal transduction when the receptor is truncated [161]. However, we tested the ability of the DOR-selective agonist SNC80 to
inhibit forskolin-induced cAMP accumulation via the full-length, non-fused mutant
receptors and found that mutant receptors behaved as wild-type (Figure 3.3C, Table
3.3), suggesting that the binding pocket of the mutant receptor is intact. Additionally, the cAMP assay was run on whole cells, indicating that the mutation did not
result in a misfolded DOR trapped in the Golgi apparatus or endoplasmic reticulum.
Because each DOR construct has an engineered amino-terminal FLAG sequence, we
assessed surface expression of the DORh8 -Gqi4 mutants using Alexa Fluor 488 conjugated FLAG-tag antibody and ﬂuorescence activated cell sorting (FACS). We found
that all receptors were expressed on the plasma membrane albeit to varying degrees
(Figures 3.3D and 3.4A). We did not ﬁnd a signiﬁcant correlation between DOR
surface expression and calcium signaling (p=0.59); some mutants with poor surface
expression still strongly induced calcium release (e.g. Val6.57 Phe), and some mutants
with high surface expression inhibited calcium release (e.g. Phe5.47 Ala).

Fig. 3.3. Conﬁrmation of disruptive mutations within DOR TM5/6 in a heteromer-selective calcium signaling
assay. (A) HEK-293 cells transfected with wild-type or mutated DORh8 -Gqi4 and wild-type MOR were
stimulated with 10 µM of DAMGO. Calcium mobilization was measured using a FLIPR assay. Mutants
highlighted in blue are potential sites important for the heteromer interface. Signiﬁcance between groups
was determined by one-way ANOVA. (B) Dose-response curves for calcium release induced by DAMGO in
HEK-293 cells expressing seven representative DORh8 -Gqi4 mutants and MOR are shown. (C) HEK-293
cells transfected with glosensor and wild-type or mutated DOR were incubated with the DOR-selective
agonist SNC162 and 100 µM of forskolin. Alterations of cAMP levels were measured using a luminescencebased assay. The data were normalized to the percentage of forskolin-stimulated cAMP accumulation under
matched transfection conditions. (D) Correlation between mean ﬂuorescence intensity of HEK-293 cells
expressing wild-type or mutated DORh8 -Gqi4 fused to a small FLAG epitope tag measured by a ﬂuorescenceactivated cell sorting (FACS) and calcium release measured by a FLIPR assay are shown (p > 0.05). The
data on the x-axis of (A) and the y-axis of (D) were normalized by deﬁning the calcium levels from WT
DORh8 Gqi4 + MOR as 100% and WT DORh8 Gqi4 - MOR as 0%. The data on the x-axis of (D) were
normalized by deﬁning the mean ﬂuorescence intensity from WT DORh8 Gqi4 as 100% and empty vector as
0%. All data shown represent the average and SEM of at least three independent experiments conducted in
triplicate. ***p < 0.001, ****p < 0.0001 compared to WT DORh8 Gqi4 + MOR.
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Table 3.3.
Potency and maximal eﬀects for the MOR-selective agonist DAMGO
tested for calcium release in HEK-293 cells expressing wild-type MOR
and either wild-type or mutated DORh8 -Gqi4. Potency for the DORselective agonist SNC162 tested for inhibition of forskolin-stimulated
cAMP accumulation in HEK-293 cells expressing wild-type or mutated DOR. Data represent an average of at least three independent
experiments. For pEC50 and pIC50 values, the 95% conﬁdence interval is shown in parentheses. Maximal eﬀects are shown as a percentage
of wild-type DORh8 -Gqi4’s maximal response, and SEM is shown in
parentheses. N/A, not applicable.
Receptor

Calcium signaling assay [DAMGO]

cAMP assay [SNC162]

pEC50 (M)

Max Eﬀect (% WT DORh8 -Gqi4)

pIC50 (M)

WT DOR

5.9 (5.7-6.2)

100 (±4)

7.3 (6.9-7.8)

Tyr5.33 Ala

6.4 (6.1-6.7)

62 (±3)

8.2 (7.7-8.8)

5.34

6.8 (5.9-7.7)

18 (±2)

7.9 (7.5-8.3)

5.6 (5.3-5.9)

40 (±2)

6.8 (6.4-7.3)

5.7 (5.4-6.0)

80 (±5)

7.4 (6.9-7.8)

4.6 (4.5-4.8)

116 (±4)

7.1 (6.6-7.6)

5.0 (4.7-5.4)

36 (±3)

7.6 (6.9-8.2)

Ser5.67 Thr+Asp6.62 Val

5.2 (3.6-6.8)

17 (±6)

7.0 (6.6-7.4)

-MOR

4.9 (4.4-5.4)

20 (±2)

N/A

Trp

Ala

Phe5.47 Ala
5.68

Val

5.69

Ala+Arg

Ala

Ile6.53 Phe
Asp

6.62

Val
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Fig. 3.4. Cell surface expression of wild-type and mutated FLAGtagged DORh8 -Gqi4 and DOR-Vn as detected by ﬂow cytometry.
HEK-293 cells transfected with wild-type or mutated (A) DORh8 Gqi4 or (B) DOR-Vn fused to a small FLAG epitope tag were stained
with Alexa Fluor 488-conjugated anti-FLAG antibody. The receptor
expression was measured using a ﬂuorescence activated cell sorting.
Mutants highlighted in red had poor membrane expression and were
excluded from the study. The data were normalized by deﬁning the
mean ﬂuorescence intensity from WT DORh8 Gqi4 or WT DORVn as
100% and empty vector as 0%. All data shown represent the average and SEM of at least three independent experiments conducted
in triplicate. Signiﬁcance between groups was determined by oneway ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
compared to WT DORh8 Gqi4 or WT DORVn highlighted in black.
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3.3.3

Conﬁrmation of disruptive mutations in a bimolecular ﬂuorescence
complementation assay

We next decided to use bimolecular ﬂuorescence complementation (BiFC) as a
secondary assay to conﬁrm the disruptive ability of the DOR mutations in TM5 and
TM6. Based on the location of the disruptive mutants we were particularly interested in those located near the extracellular side of the TM domains i.e. Tyr5.33 ,
Trp5.34 , Ile6.53 and Asp6.62 . The Val5.68 Ala/Arg5.69 Ala and Arg6.31 Ala were used as
positive controls and several negative controls (Trp5.32 Ala, Gly5.59 Phe, Arg5.66 Ala,
Val6.45 Phe, and Ala6.49 Phe) were also included. For the BiFC assay, we fused the untruncated carboxyl terminal tail of the DOR mutant to the amino-terminal portion
of a split Venus yellow ﬂuorescent protein (Vn), and fused the wild-type MOR to
the carboxyl remaining fragment of the Venus ﬂuorescent protein (Vc). We expected
that if DOR-MOR heteromers were formed we would observe functional complementation of the Venus protein and detect its ﬂuorescence in the absence of ligand
activation (Figure 3.5A). Using cells only expressing MOR-Vc as baseline we found a
similar pattern of heteromer disruption for the mutants identiﬁed as observed in the
heteromer signaling assay (Figure 3.5B). The negative controls, i.e. those mutants
that did not signiﬁcantly attenuate calcium release in the heteromer signaling assay,
also did not show a reduction in BiFC (Figure 3.5B), whereas our positive controls
did (Val5.68 Ala/Arg5.69 Ala and Arg6.31 Ala in Figure 3.5B). Due to the large number
of mutants that we created the BiFC screen was performed in medium-throughput
screening using a Cytation 3 cell imaging multi-mode reader (Figure 3.5B-C). However, when we analyzed these receptors using the more sensitive confocal microscope
technique, we observed an identical pattern of disruption (Figure 3.5D-E), suggesting
that the Cytation method was acceptable for screening. Similar to the Gqi4 fused
receptors, we did ﬁnd diﬀerences in surface expression, as measured by FACS (Figures
3.5F and 3.4B), but again the correlation between surface expression and BiFC was
not signiﬁcant (p=0.25; Figure 3.5F).
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Fig. 3.5. Conﬁrmation of disruptive mutations within DOR TM5/6
in a bimolecular ﬂuorescence complementation (BiFC) assay. (A)
Schematic representation of BiFC assay. Venus ﬂuorescent protein
is separated in two fragments, Vn155 and Vc155, that are fused to
DOR in green and MOR in pink, respectively. When the DOR-MOR
heteromers are formed, the ﬂuorescent fragments will be in close proximity to reconstitute an intact Venus ﬂuorescent protein. (B-E) CAD
neuronal cells were transfected with wild-type or mutated DOR-Vn
and wild-type MOR-Vc in the presence of Mem-mCherry used to label
plasma membrane. Mutants highlighted in blue caused a signiﬁcant
loss of BiFC detected by using a (B) BioTek Cytation 3 and (D) Nikon
confocal microscope with representative images shown in (C) and (E),
respectively. Heteromerization between wild-type or Gly5.59 Phe DORVn and MOR-Vc produces clear BiFC (white arrows). Lack of interaction between Asp6.62 Val DOR-Vn and MOR-Vc causes absence of
BiFC (blue arrows). The merged image (overlapping signal in yellow) represents an overlap of mCherry (red signal) with Venus (green
signal). Magniﬁcation images were obtained by using the 10x ocular
lens in combination with a 20x objective lens. (F) Correlation between receptor expression of wild-type or mutated DOR-Vn fused to
a FLAG epitope tag measured by FACS and ﬂuorescence intensity of
DORVn + MORVc measured by BiFC is shown (p > 0.05). The data
on the x-axis of (B) and the y-axis of (F) were normalized by deﬁning
the YFP intensity/number of cells from WT MORVc + DORVn as
100% and WT MORVc - DORVn as 0%. The data on the x-axis of
(F) were normalized by deﬁning the mean ﬂuorescence intensity from
WT DORVn as 100% and empty vector as 0%. The BiFC eﬃciency
is calculated by dividing the median BiFC-mCherry ratio from the
MORVc + DORVn pair by that of the MORVc - DORVn (negative
control). All data shown represent the average and SEM of at least
three independent experiments conducted in triplicate. Signiﬁcance
between groups was determined by one-way ANOVA. *p < 0.05, **p
< 0.01, ***p < 0.001, ****p < 0.0001 compared to WT DORVn +
MORVc. YFP, yellow ﬂuorescent protein.
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3.3.4

Mutations of the extracellular portions of TM5/6 disrupt DORMOR heteromers

Next, we investigated if mutations of MOR at parallel locations of TM5/6 of DOR
would be equally disruptive. Based on computational modeling, we found that Tyr5.33
of the MOR may interact with Asp6.62 of the DOR and that Thr6.62 of the MOR may
interact with Tyr5.33 of the DOR (Figure 3.6A). Thus, we created Tyr5.33 Ala and
Thr6.62 Val mutations in non-truncated, non-fused MOR. The mutant MORs inhibited
cAMP accumulation following DAMGO and forskolin stimulation identical to the
wild-type, suggesting that they were functional (Figure 3.6B, Table 3.4). When coexpressed with wild-type DORh8 -Gqi4 we found that Tyr5.33 Ala and Thr6.62 Val of the
MOR strongly reduced calcium signaling of the heteromers (Figure 3.6C-D, Table
3.4) particularly the Tyr5.33 Ala/Thr6.62 Val double mutant which showed a further
decrease in calcium release when compared with the single mutation (Figure 3.6CD, Table 3.4). As further evidence for the physical disruption of the DOR-MOR
heteromers we performed a co-immunoprecipitation assay using the amino-terminal
FLAG tag on the DOR (wild-type, non-truncated, non-fused) and the amino-terminal
HA tag on the MOR. When precipitating DORs using anti-FLAG beads we were
able to detect wild-type HA-MOR in the lysate by Western blot analysis (FLAGDOR/HA-MOR co-express in Figure 3.6E), while we did not ﬁnd HA-MOR in the
precipitate when we mixed HEK-293 cells expressing only FLAG-DOR with cells only
expressing HA-MOR (FLAG-DOR+HA-MOR mix in Figure 3.6E). The HA-MOR
was also co-immunoprecipitated with the Gly5.59 Phe mutant of DOR (Gly5.59 Phe/HAMOR co-express in Figure 3.6E), which we used as an additional control as we had
found this mutant to have no eﬀect on the DOR-MOR heteromer formation in both
the heteromer signaling and BiFC assays. In contrast, the Asp6.62 Val DOR mutant
and in particular the Tyr5.33 Ala/Thr6.62 Val MOR double mutant showed reduced coimmunoprecipitation of HA-MOR with FLAG-DOR (Asp6.62 Val/HA-MOR co-express
and FLAG-DOR/Tyr5.33 Ala/Thr6.62 Val co-express, respectively in Figure 3.6E).
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Fig. 3.6. Identiﬁcation of extracellular portions of TM5/6 that disrupt
DOR-MOR heteromers. (A) Computational model of the heteromer
extracellular interface between TM5/6 shown with six potential disruptive amino acids of the DOR in pink and MOR in green. (B) HEK293 cells transfected with glosensor and wild-type or mutated MOR
were incubated with DAMGO and 100 µM of forskolin. Alterations
of cAMP levels were measured using a luminescence-based assay. The
data were normalized to the percentage of forskolin-stimulated cAMP
accumulation under matched transfection conditions. (C) HEK-293
cells transfected with wild-type DORh8 -Gqi4 and wild-type or mutated MOR were stimulated with diﬀerent doses of DAMGO. Calcium
mobilization was measured using a FLIPR assay. (D) Bar graphs
represent calcium response after stimulation of cells with 10 µM of
DAMGO. The data were normalized by deﬁning the calcium levels
from WT DORh8 Gqi4 + MOR as 100% and WT DORh8 Gqi4 - MOR
as 0%. (E) Co-immunoprecipitation of wild-type or mutated fulllength DOR and MOR using an anti-FLAG antibody to precipitate
DOR followed by anti-HA immunoblot. Control immunoprecipitations were performed using untransfected cells or FLAG-tagged DOR
mixed with HA-tagged MOR expressing cell lysates. FLAG-DOR coprecipitates with HA-MOR and is reduced in Tyr5.33 Ala+Thr6.62 Val
and Asp6.62 Val but not Gly5.59 Phe transfected HEK-293 cells. Approximate molecular weight markers are shown on the right, and representative images are shown. Quantiﬁcation of HM levels from immunoblots normalized to β-actin by densitometry. All data shown
represent the average and SEM of at least three independent experiments conducted in triplicate. Signiﬁcance between groups was
determined by one-way ANOVA. ****p < 0.0001 compared to WT
DORh8 Gqi4 + MOR. **p < 0.01 compared to untransfected cells.
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Table 3.4.
Potency and maximal eﬀects for DAMGO tested for calcium release
in HEK-293 cells expressing wild-type DORh8 -Gqi4 and either wildtype or mutated MOR. Potency for DAMGO tested for inhibition of
forskolin-stimulated cAMP accumulation in HEK-293 cells expressing
wild-type or mutated MOR. Data represent an average of at least
three independent experiments. For pEC50 and pIC50 values, the
95% conﬁdence interval is shown in parentheses. Maximal eﬀects are
shown as a percentage of wild-type MOR’s maximal response, and
SEM is shown in parentheses. N/A, not applicable.
Receptor

Calcium signaling assay [DAMGO]

cAMP assay [DAMGO]

pEC50 (M)

Max Eﬀect (% WT MOR)

pIC50 (M)

WT MOR

5.8 (5.4-6.2)

100 (±6)

7.2 (6.5-7.8)

Tyr5.33 Ala

5.1 (4.8-5.4)

39 (±2)

7.7 (7.3-8.1)

Thr6.62 Val

5.1 (4.9-5.3)

43 (±2)

6.9 (6.4-7.3)

Tyr5.33 Ala+Thr6.62 Val

4.8 (4.5-5.1)

28 (±2)

7.0 (6.5-7.5)

-MOR

5.1 (4.2-5.9)

21 (±4)

N/A
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3.3.5

Creation of reciprocal mutations at the extracellular regions of
TM5/6 of DOR and MOR

To further investigate the interaction site of the DOR-MOR heteromers particularly at the extracellular regions of the TM5/6 we decided to mutate DOR
and MOR simultaneously and create reciprocal mutations (Figure 3.7). Not surprisingly DAMGO did not induce strong calcium release in HEK-293 cells expressing DOR-Tyr5.33 Ala/MOR-Thr6.62 Val, DOR-Trp5.34 Ala/MOR-Thr6.62 Val, or DORAsp6.62 Val/MOR-Tyr5.33 Ala (Figure 3.8A-B, Table 3.5).

Interestingly the DOR-

Asp6.62 Thr mutant did not attenuate DAMGO-induced calcium release to the same
degree as the other reciprocal mutants, although the MOR-Thr6.62 Asp mutant did
(Figure 3.8A-B, Table 3.5). Finally, we still observed a decrease in DAMGO-induced
calcium release in HEK-293 cells expressing DOR-Tyr5.33 Thr/MOR-Thr6.62 Tyr, DORTrp5.34 Thr/MOR-Thr6.62 Trp, or DOR- Asp6.62 Tyr/MOR-Tyr5.33 Asp (Figure 3.8A-B,
Table 3.5), suggesting that the reduced calcium release of the heteromers may result
from an interference with the overall protein structure. The mutated MOR receptors
inhibited cAMP accumulation when activated by DAMGO and forskolin similar to
the wild-type receptor (Figure 3.8C, Table 3.6).

3.4

Discussion
In order to develop new tools to study the physiological relevance of DOR-MOR

heteromers we investigated the potential interacting residues in the regions spanning
TM5/6 of these receptors. We identiﬁed several novel potential contact points, of
which the most promising region was near the extracellular side of TM5/6 of both
the DOR and MOR, validated by using multiple complementary approaches.
Many GPCRs have been suggested to form heteromers in vitro [442–449]; however,
establishing their existence in vivo has been a more daunting task. It is crucial for
heteromers to have a unique function, and thus one approach to study a mechanism
that connects the heteromers with their observed pharmacological eﬀect is to disrupt
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Fig. 3.7. Schematic overview of reciprocal mutations at the extracellular regions of TM5/6 of DOR and
MOR used in Figure 6A-B. Mutations to alanine at Tyr5.33 and Trp5.34 , and to valine at Asp6.62 of the
DORs caused signiﬁcant loss of heteromerization, as shown in Figure 3.3A, 3.5B, and 3.6E. Also, mutations
to alanine at Tyr5.33 , and to valine at Thr6.62 of the MORs disrupted the heteromerization, as shown in
ﬁgure 3.6D-E. To assess the importance of these residues to selectivity, the reciprocal mutant pairs were
constructed, namely Asp6.62 Thr and Thr6.62 Asp, Tyr5.33 Thr and Thr6.62 Tyr, Trp5.34 Thr and Thr6.62 Trp, and
Asp6.62 Tyr and Tyr5.33 Asp of DOR and MOR, respectively.
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Fig. 3.8. Reciprocal mutations at the extracellular regions of TM5/6 of DOR and MOR show loss of signal
transduction in the heteromers. (A) HEK-293 cells transfected with DORh8 -Gqi4 and MOR reciprocal
mutants were stimulated with diﬀerent doses of DAMGO. Calcium mobilization was measured using a
FLIPR assay. (B) Bar graphs represent calcium response after stimulation of cells with 10 µM of DAMGO.
The data were normalized by deﬁning the calcium levels from WT DORh8 Gqi4 + MOR as 100% and WT
DORh8 Gqi4 - MOR as 0%. All data shown represent the average and SEM of at least three independent
experiments conducted in triplicate. Signiﬁcance between groups was determined by one-way ANOVA.
****p < 0.0001 compared to WT DORh8 Gqi4 + MOR. (C) HEK-293 cells transfected with glosensor and
wild-type or mutated MOR were incubated with DAMGO and 100 µM of forskolin. Alterations of cAMP
levels were measured using a luminescence-based assay. The data were normalized to the percentage of
forskolin-stimulated cAMP accumulation under matched transfection conditions.
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Table 3.5.
Potency and maximal eﬀects for DAMGO tested for calcium release in
HEK-293 cells expressing DORh8 -Gqi4 and MOR reciprocal mutants.
Data represent an average of at least three independent experiments.
For pEC50 and pIC50 values, the 95% conﬁdence interval is shown in
parentheses. Maximal eﬀects are shown as a percentage of wild-type
DORh8 -Gqi4 and MOR’s maximal response, and SEM is shown in
parentheses. N/A, not applicable.
Receptor

Calcium signaling assay [DAMGO]
pEC50 (M)

Max Eﬀect (% WT DORh8 -Gqi4+MOR)

DORGqi4 + MOR

7.0 (6.7-7.3)

100 (±5)

DORGqi4 - MOR

4.9 (4.4-5.4)

37 (±5)

Tyr5.33 AlaGqi4 + Thr6.62 Val

5.2 (4.3-6.0)

13 (±2)

Trp5.34 AlaGqi4 + Thr6.62 Val

N/A

N/A

Asp6.62 ValGqi4 + Tyr5.53 Ala

5.5 (2.9-8.0)

13 (±5)

Asp6.62 ThrGqi4 + MOR

5.4 (5.0-5.8)

57 (±5)

DORGqi4 + Thr6.62 Asp

5.5 (5.0-6.0)

43 (±4)

Tyr

4.7 (2.9-6.5)

19 (±8)

Trp5.34 ThrGqi4 + Thr6.62 Trp

6.1 (4.3-7.8)

18 (±3)

N/A

N/A

5.33

Tyr

ThrGqi4 + Thr

6.62

Asp

6.62

5.53

TyrGqi4 + Tyr

Asp

Table 3.6.
Potency for DAMGO tested for inhibition of forskolin-stimulated
cAMP accumulation in HEK-293 cells expressing wild-type or mutated MOR. Data represent an average of at least three independent
experiments. For pEC50 and pIC50 values, the 95% conﬁdence interval is shown in parentheses.
Receptor

cAMP assay [DAMGO]
pIC50 (M)

WT MOR
6.62

Thr

7.7 (7.5-8.0)

Asp

7.6 (7.0-8.1)

Thr6.62 Tyr

6.6 (5.8-7.4)

Thr6.62 Trp

7.2 (6.8-7.7)

Tyr5.53 Asp

7.4 (6.5-8.3)
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or prevent the heteromer formation. A frequently used method to disrupt heteromers
is through the expression of competing transmembrane peptides [215]. Depending on
the diﬀerent types of GPCR heteromers, diﬀerent TM domains have been used. For
example, TM4 has been shown to disrupt D2R homodimers [473,474], while TM1 has
been used for the DOR-MOR heteromers [215]. However, the large TM peptides are
rather unwieldy and thus are not easily transformed into drug therapies. Several nonTM domains have been implicated in heteromer stability including regions in ICL3,
such as a SVR region in the DOR-MOR heteromers [460] and an arginine-rich stretch
in the A2A-D2R heteromers [470, 471]. Similarly, we found that Val5.68 +Arg5.69 and
Arg6.31 mutations in the DOR could disrupt the DOR-MOR heteromers. Yet, it is
hard to target the intracellular location of the receptor with exogenous drugs. Pepducins could potentially reach these regions and disrupt the heteromers; however, the
pepducin technology is still relatively in its infancy and often involves at a minimum
octapeptides to allow for the inhibition of protein-protein interactions. Thus pepducins could be problematic to study GPCR heteromers in the CNS as the pepducins
would have a hard time crossing the blood brain barrier. Previous studies have also
not detected pepducin in brain besides other vascularized tissues after injections of
P4pal-10 pepducin [475, 476]. Here we identiﬁed a novel interaction site in TM5/6
of DOR and MOR. The importance of this region in heteromer formation/stability
was validated in three diﬀerent cellular assays, by mutations in both DOR and MOR
and by using not only chimeric proteins but also regular/full length receptors. The
mutations did not interfere with receptor expression and function as determined by
FACS and cAMP functional assays, respectively.
Prior to the crystallization of the DOR, a homology model of DOR using the
beta-adrenergic 2 receptor crystal structure was used to investigate the homodimer
interface of DORs. In this study, Johnston et al. employed a multipronged approach
including BRET, crosslinking, and molecular modeling and identiﬁed that mutation
of residues in TM4 (Cys4.48 ) and TM5 (Cys5.41 ) decreased crosslinking-induced dimerization, while mutation of Val4.58 Cys and Thr5.38 Cys increased dimerization, suggest-
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ing that these amino acids are in close proximity of an interaction interface [477].
Interestingly, a recent study using molecular dynamics simulations compared with
crystal structures of MOR, DOR, and KOR has suggested that the TM4/5 interface
is only formed in the DOR-DOR homodimers [478]. For the DOR-MOR heteromers
TM5/TM5 interface is the most abundant, followed by TM1-2/H8 interacting with
either TM1-2/H8, TM5/6, or TM4/5 [478]. In this study TM4/5-TM5/6 or TM5/6TM5/6 contact interfaces were not detected for the DOR-MOR heteromers. It is
possible that the formation of those interfaces may require more time to be formed
and were not captured in their simulations during the 10 µs [478].
It has been suggested that the TM domains involved in dimer formation may
change depending on the activation state of the receptor(s) [479, 480].

For the

dopamine D2R it has been shown that diﬀerent residues in TM4 are involved in
the homodimer interface depending on whether the receptor is bound to the D2R
antagonist sulpiride or the agonist dopamine [479]. Similarly, for the mGluR2 it appears that TM4/5 form the contact interface in the inactive state, but TM6 is the
predominant interface for the activated mGluR2 [480]. Our Co-IP and BiFC studies
were performed in the absence of ligand, and thus our ﬁndings indicating a role for
TM5/6 for the unbound DOR-MOR heteromers would ﬁt the observations for the
mGluR2. Additionally, while we used agonists in the heteromer-selective calcium
signaling assay, the receptors had been allowed to exist in the absence of agonists
for roughly 48 hours before stimulation. Thus, the observed loss of calcium release
may be the result of the initial decrease in heteromer formation while the DORs and
MORs were in their inactive states.
In this study we also created reciprocal mutants between DOR and MOR (Asp6.62 Thr
and Thr6.62 Asp, Tyr5.33 Thr and Thr6.62 Tyr, Trp5.34 Thr and Thr6.62 Trp, and Asp6.62 Tyr
and Tyr5.33 Asp, respectively) and anticipated them to rescue the interaction of DORMOR heteromers. However the results still showed the disruption of the DOR-MOR
heteromers in cells expressing these reciprocal mutants, providing additional support
for the importance of these regions and indicating that the interactions at the dimer
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interface of TM5/6 DOR-MOR are not the mirror image interaction. Based on the
crystal structures [303] and the molecular dynamics simulations [478], it is conceivable that a region near the extracellular side of TM1/2 could be another interesting
region to study as a target for dimer disruption. We are currently unaware of studies
of the DOR-MOR heteromer disruption by speciﬁcally mutating residues on the top
of TM1/2 of either DOR or MOR.
In summary, using a multipronged approach we isolated a speciﬁc region of TM5/6
of DOR and MOR that is important in the formation and/or stabilization of the
DOR-MOR heteromers. Because this region is located on the extracellular side of
the receptor complex it would provide an opportunity to develop small molecules
that could disrupt the heteromers and probe their functions. Based on the reported
negative eﬀects of the DOR-MOR heteromers on mu opioid analgesia, such a proteinprotein interaction inhibitor could have a therapeutic value in this regard.
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4. IDENTIFICATION OF A SELECTIVE
SMALL-MOLECULE INHIBITOR OF TYPE 1
ADENYLYL CYCLASE ACTIVITY WITH ANALGESIC
PROPERTIES
As adapted from
Science Signaling (2017) 10(467).

4.1

Introduction
Chronic pain is a major health concern and costs the US more than $635 bil-

lion per year [481]. Unfortunately, the currently available drugs including opioids
and antidepressants can cause side eﬀects, such as opioid dependence, withdrawal,
and constipation, and are often ineﬀective to return patients to their normal activity
level. The development of novel agents acting on unique targets for the management of chronic pain with fewer side eﬀects is thus needed. Recent neurobiological
and preclinical studies have suggested that neuronal adenylyl cyclase type 1 (AC1)
may be that new target [369]. AC1 is highly expressed in neuronal tissues associated
with nociception including the anterior cingulate cortex (ACC) and spinal dorsal
horn neurons [369–371], and somatic withdrawal including locus coeruleus and periaqueductal gray area [373, 381, 482]. Mice lacking AC1 showed a marked decrease in
pain responsiveness compared to wild-type animals in neuropathic and inﬂammatory
pain models [369, 372, 380, 381] and attenuated somatic signs associated with opioid
withdrawal [380, 381]. This is consistent with the potential of the small molecule
AC1 inhibitor NB001 that also exerts analgesic properties in inﬂammatory and neuropathic pain model [372,374] and prevents the opioid antagonist naltrexone-induced
reinstatement of hyperalgesia in mice [483].
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ACs are a family of enzymes that catalyze conversion of adenosine triphosphate
(ATP) to cyclic adenosine monophosphate (cAMP) upon G protein-coupled receptor
(GPCR) activation [357]. The GPCR activation that couples to diﬀerent types of
G proteins can diﬀerentially modulate the activity of AC. For example, coupling to
Gαi/o protein decreases the AC activity, while coupling to Gαs protein increases the
AC activity. Coupling to Gαq protein or activation of ion channels can either inhibit or
stimulate the AC activity [357, 484]. To date, nine isoforms of membrane-bound ACs
and one isoform of soluble AC have been discovered in humans. Each AC has distinct
regulation and tissue distribution, which allow them to serve discrete functions [358].
The membrane-bound ACs are all stimulated by Gαs and are categorized into four
groups [357, 358]. Group 1 ACs are stimulated by Ca2+ /calmodulin including AC1,
3, and 8. Group 2 ACs are insensitive to Ca2+ but are activated by Gβγ subunit
including AC2, 4, and 7. Group 3 ACs are inhibited by Ca2+ and Gαi/o including
AC5 and 6. Group 4 AC is solely AC9 and unique from the others because it is not
activated by the AC activator forskolin [357, 358, 484].
As mentioned above, inhibition of AC1 can result in antinociceptive eﬀects, which
involve cAMP for changes in synaptic plasticity. One of the forms of persistent synaptic plasticity is long-term potentiation (LTP) which produces an increase in synaptic
strength [362,369,374]. LTP has been proposed to be associated with the development
of chronic pain as well as the cellular process underlying memory formation [362,369].
AC1 and AC8 are widely expressed in hippocampus which is responsible for learning and memory [358, 362]. AC1 and AC8 double knockout mice displayed abolished
long-term learning and memory in passive avoidance and contextual fear conditioning
paradigms [365]. However single genetic ablation of either AC1 or AC8 in mice did
not markedly alter the long-term memory [365], implying that AC1 and AC8 may
play their own unique roles in learning and memory. This also suggests that AC1 inhibitors used for pain management need to have higher selectivity of AC1 over AC8.
Interestingly, NB001 prevented the induction of LTP in neurons from the ACC and
spinal dorsal horn but not the hippocampus [374], highlighting the importance of AC1
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in nociception and to a lesser extent in learning and memory. However NB001 has
some limitations for selectivity of AC1 over AC8 and does not directly target AC1 to
decrease cAMP levels [374, 485].
In collaboration with Dr. Val J. Watts’s laboratory, they had screened the NDL3000 Natural Derivatives Library and discovered novel AC1 inhibitors. The most
potent small molecule AC1 selective inhibitor found in this study was ST034307, a
chromone derivative (IC50 = 2.3 µM, 95% CI = 1.2-4.5 µM). ST034307 was shown
to signiﬁcantly abolish the AC1 activity stimulated by forskolin or isoproterenol in
AC1 expressing cells. The AC1 inhibition by ST034307 occurred through a direct
target on the AC1 but not the Gβγ or the Gαi/o as evidenced by an inability to alter
ST034307-inhibited AC1 activity when Gβγ subunits was sequestered by βARKCT or Gαi/o signaling was inactivated by pertussis toxin. ST034307 also needed
membrane-bound proteins to function as it was shown to inhibit the calmodulinstimulated AC1 activity in cellular membranes prepared from HEK or Sf9 cells and
hippocampal homogenates. The Watts group further explored the eﬀect of ST034307
on MOR signaling due to the fact that AC is an important second messenger of MORmediated analgesia, that signals through the Gαi/o protein [369–371, 483, 486–488].
They revealed that ST034307 imitated the cellular and physiological consequences
of Gαi/o activation in response to µ-opioid receptor despite no eﬀects on β-arrestins
recruitment. Additionally chronic MOR activation can lead to so-called heterologous
sensitization which is characterized by the superactivation of AC [489, 490]. The
heterologous sensitization of AC is linked to cellular and behavioral opioid tolerance
and withdrawal-induced hyperalgesia [491, 492]. Notably, ST034307 prevented both
the development and maintenance of heterologous sensitization of AC1 in a dosedependent manner [493], suggesting that ST034307 may be useful for the treatment
of opioid withdrawal.
Thereafter I explored the potential of ST034307 for the treatment of inﬂammatory pain and opioid withdrawal in in vivo contexts. Animal models of inﬂammatory
pain evoked by Complete Freunds Adjuvant (CFA) and morphine withdrawal precip-

101
itated by naloxone were used in this study. I demonstrated that ST034307 produced
analgesic eﬀects in the inﬂammatory pain model and showed a strong trend, but not
signiﬁcant, towards the reduction of morphine withdrawal symptoms. Collectively
the Watts group has identiﬁed and characterized the potent AC1 selective inhibitor
ST034307 and I have elucidated its analgesic properties in the mouse model of inﬂammatory pain and its mild or moderate, but not signiﬁcant, reduction of opioid
withdrawal signs.

4.2

Materials and methods

4.2.1

Compounds and other chemicals used

6-chloro-2-(trichloromethyl)-4H -chromen-4-one (ST034307) was purchased from
TimTec (Newark, DE), and the structure of the compound was conﬁrmed by nuclear
magnetic resonance spectroscopy. (D-alanine2,N-methylphenylalanine4,glycine3-ol)
enkephalin (DAMGO), morphine sulfate and naloxone hydrochloride were purchased
from Sigma-Aldrich (St. Louis, MO) and were dissolved to the desired concentration
in normal saline. Forskolin was purchased from Tocris (Bristol, UK).

4.2.2

Animals and housing

Male wild-type C57BL/6 mice aged 5 weeks (18 to 23 g) were obtained from
Taconic (Cambridge City, IN). The mice were grouped 4-5 per cage and housed in
single-grommet ventilated plexiglass cages at ambient temperature (21◦ C) in a room
maintained on a reversed 12-hour light/12-hour dark cycle (lights oﬀ at 10:00, lights
on at 22:00) in our animal facility approved by the Association for Assessment and
Accreditation of Laboratory Animal Care. Food and water were provided ad libitum.
The mice were given ∼7 days to acclimatize to the housing conditions and reverse
light cycle before the start of the experiments. Mice were then habituated to the
containment boxes for the von Frey assay. All animal procedures were preapproved
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by our Institutional Animal Care and Use Committee and were in accordance with
the National Institutes of Healths Guide for the Care and Use of Laboratory Animals.

4.2.3

Inﬂammatory pain behavioral assay

Mice were individually placed in a plexiglass chamber on a suspended wire mesh
grid (25 cm above a table) and were allowed to acclimate for 1 hour before testing.
Next, a baseline measurement of mechanical sensitivity was performed by stimulating
the plantar surfaces of the left and right hindpaws with three applications of von
Frey ﬁlaments (0.04, 0.07, 0.16, 0.4, 0.6, 1, 1.4, 2 mN; Stoelting, Wood Dale, IL)
as previously described [161, 483]. A paw withdrawal at 2 mN was considered the
maximal response. The 0.04 mN ﬁlament was always used ﬁrst and depending on the
response either a smaller or bigger ﬁlament was tested. The lowest force that evoked
a paw withdrawal response in two out of three tests was recorded. Immediately after
baseline measurements, the mice were injected with undiluted CFA (10 µl, Sigma, St.
Louis, MO) into the intraplantar surface of the left hindpaw to induce inﬂammation
[483]. Mechanical sensitivity was then reassessed one day following the induction of
inﬂammation. All compounds were intrathecally injected into the mice. Intrathecal
injection was performed by direct puncture of spinal lumbar region (L4-L6) using
a 28.5 gauge needle attached to a luer-tipped 250 µl Hamilton (725LT) syringe as
previously described [161]. Upon correct placement of the needle a quick ﬂick of the
tail would be observed. All injections were in a volume of 10 µl. Drug response was
measured 10 minutes after intrathecal injection using von Frey ﬁlaments. Data are
represented as a percentage of the average baseline response.

4.2.4

Morphine withdrawal assay

To generate opioid withdrawal in mice, the mice received two subcutaneous morphine injections separated by 6 hours daily for 7 consecutive days for a total of 14
injections. Mice were injected with escalating doses of morphine; 20 mg/kg on day
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1, 40 mg/kg on days 2-3, 80 mg/kg on days 4-5, and 100 mg/kg days 6-7. ST034307
was then intraperitoneally injected with doses of 1 or 3 mg/kg on day 7, 30 minutes after the second dose of morphine. ST034307 was dissolved in 2% DMSO in
saline. The control mice received the equivalent volume of 10 mL/kg vehicle. Opioid
withdrawal was precipitated 30 minutes after the compound treatment by a subcutaneous injection of 10 mg/kg naloxone. Immediately after the naloxone injection,
mice were placed individually in plexiglass container and observed for 20 minutes (5
minute blocks). The somatic signs of withdrawal such as jumping, wet dog shake,
fecal dropping, rearing, or paw tremor were monitored and quantiﬁed. Mice were
weighed before and after withdrawal testing as withdrawal can induce substantial
weight loss from increased metabolism, defecation, and urination. A global score was
calculated as the sum of all the activities. Statistical analyses of behavioral tests by
time bins was performed using two-way ANOVA followed by Bonferroni test when
comparing among groups receiving 1 or 3 mg/kg of ST034307 or vehicle.

4.2.5

Data and statistical analyses

All data and statistical analyses were performed using GraphPad Prism 6 (GraphPad Software). Statistical signiﬁcance obtained using either one-sample t test or oneway or two-way analysis of variance (ANOVA) was described in text or ﬁgure legends
where appropriate.

4.3

Results

4.3.1

Analgesic properties of ST034307 in a mouse model of inﬂammatory
pain.

To investigate the potential of ST034307 in analgesia, a mouse model of inﬂammatory pain was employed. As shown in ﬁgure 4.1A and 4.2A, intraplantar injection
of CFA to the mice produced inﬂammatory pain hypersensitivity in response to stim-
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ulation of the ipsilateral but not contralateral hindpaw with applications of von Frey
ﬁlaments. Intrathecal injections with either 0.25 µg ST034307 or 50 ng MOR-selective
agonist DAMGO (positive control) caused a signiﬁcant decrease in CFA-induced inﬂammatory pain at the ipsilateral but not contralateral hindpaw (ﬁgure 4.1A and
4.2A). No signiﬁcant changes were seen in saline-treated mice, indicating that inhibition of AC1 is critical to mediate behavioral allodynia. In the limited dose-response
experiments, ST034307 revealed an estimated ED50 value for analgesic eﬀect equal
to 0.28 µg (95% CI = 0.13 to 0.43; ﬁgure 4.1B). Moreover, in view of the hypothesis that inhibition of AC1 is a mechanism of spinal antinociception by ST034307,
agents which activate adenylyl cyclase activity or increase cAMP levels such as the
non-selective AC activator forskolin would reduce the analgesic action of ST034307. I
thus performed intrathecal injections of forskolin in mice at one day after CFA injection. The mice showed hypersensitivity to a non-noxious stimulus at the ipsilateral
but not contralateral hindpaw in response to the coinjection of 10 µg of forskolin and
0.5 µg of ST034307 (Figure 4.1C and 4.2B). The injections of saline or forskolin alone
did not signiﬁcantly alter the mechanical sensitivity, indicating that an increase in
cAMP levels has inhibitory eﬀect on ST034307-induced analgesia in mice.

4.3.2

Eﬀects of ST034307 on somatic signs of morphine withdrawal in
mice

To determine the role of AC1 in opioid withdrawal, I monitored opioid withdrawal
behaviors in mice chronically treated with morphine and then intraperitoneally injected with 1 or 3 mg/kg of ST034307 or vehicle (littermate controls). The withdrawal
signs were precipitated by a subcutaneous injection of 10 mg/kg of the opioid receptor
antagonist naloxone. Several standard opioid withdrawal signs including jumps, wet
dog shakes, rearings, paw tremors, and global withdrawal score trended toward a decrease, but did not reach statistical signiﬁcance, in male mice treated with 1 mg/kg of
ST034307 when compared to the control mice. In particular the number of jumps for
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Fig. 4.1. Analgesic properties of ST034307 in a mouse model of inﬂammatory pain. (A) On day 0, baseline
(BL) measurements of mechanical sensitivity of C57BL/6 mice to von Frey ﬁlaments were recorded, and
inﬂammatory hypersensitivity was induced by injection of CFA to the hindpaw. On day 1, inﬂammatory
hypersensitivity was measured using von Frey ﬁlaments. Animals received intrathecal injections with saline (n
= 10), 50 ng of MOR-selective agonist DAMGO (n = 11), or 0.5 µg of ST034307 (n = 11), and inﬂammatory
hypersensitivity was measured again. *P < 0.05 compared to saline injection at 10 min, analyzed by oneway ANOVA. (B) Dose-response experiments with ST034307 (n = 6 for each condition). Estimated ED50
value of ST034307 for analgesia equals to 0.28 µg (95% CI, 0.13 to 0.43). (C) One day after CFA-induced
inﬂammatory pain, animals received intrathecal injections with saline (n = 9), 10 µg of forskolin (n = 8), 0.5
µg of ST034307 (n = 9), or 10 µg of forskolin + 0.5 µg of ST034307 (n = 8), and mechanical hypersensitivity
was measured using von Frey ﬁlaments 10 minutes after injections. *P < 0.05, **P < 0.01 compared to each
corresponding treatment, analyzed by one-way ANOVA with Tukeys test. The data shown represent the
average and SEM of each group of measurements to stimulation of the ipsilateral hindpaw of the mice. All
data were normalized by deﬁning the baseline measurements as 100% and the CFA-induced hypersensitivity
as 0%. Reprinted from [493].
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of CFA-induced inﬂammatory pain 10 minutes after injections on the
contralateral paw, analyzed by one-way ANOVA. (B) One day after
CFA-induced inﬂammatory pain, mice received intrathecal injections
of compounds and revealed that neither saline (n = 9), nor 10 µg
of forskolin (n = 8), nor 0.5 µg of ST034307 (n = 9), nor 10 µg of
forskolin + 0.5 µg of ST034307 (n = 8) produced analgesic eﬀects
10 minutes after injections on the contralateral paw, analyzed by oneway ANOVA. The data shown represent the average and SEM of each
group of measurements to stimulation of the contralateral hindpaw of
the mice.
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the ﬁrst ﬁve minutes of the test session was signiﬁcantly decreased. However, no eﬀect
of ST034307 on fecal droppings was observed. In male mice treated with 3 mg/kg of
ST034307, only a trend to reduction of the number of jumps for the ﬁrst ﬁve minutes
of testing and the total number of rearings were found. Behavioral responses to morphine were also assessed in female mice. Female mice treated with 1 or 3 mg/kg of
ST034307 showed only a non-signiﬁcant trend towards reduction of the total number
of jumps or rearings. The global withdrawal score observed in both male and female
mice was thus mostly driven by the number of jumps which predominantly occurred
in the ﬁrst ﬁve minutes of testing and rearing behaviors (Figure 4.3).
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Fig. 4.3. Somatic signs of morphine withdrawal in mice treated with
ST034307. Male and female mice chronically treated with ascending
doses of morphine (20-100 mg/kg) were injected with 1 or 3 mg/kg of
ST034307 (n = 8 to 9) or vehicle (n = 12). The withdrawal syndrome
was precipitated by a subcutaneous injection of 10 mg/kg of the opioid
receptor antagonist naloxone. Opioid withdrawal signs including (A)
jump, (B) wet dog shake, (C) paw tremor, (D) fecal dropping, and (E)
rearing were monitored for 20 minutes and (F) a global withdrawal
score was calculated. There was a trend for ST034307 treatment to
reduce the total number of withdrawal signs, particularly in male mice
treated with 1 mg/kg of ST034307 showing a signiﬁcant reduction in
the number of jumps during the ﬁst ﬁve minutes of testing. The data
shown represent the average and SEM of each group. *p < 0.05 for
treatment over time bin, analyzed by two-way ANOVA followed by
Bonferroni test.
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4.4

Discussion
Previous studies have revealed the potential of AC1 as a drug target for the

treatment of chronic pain and opioid withdrawal [372–375, 380, 381]. Inhibition of
AC1 activity by either genetic deletion in mice or pharmacological blockade using the
small molecule AC1 inhibitor NB001 was shown to markedly reduce inﬂammatory
and neuropathic pain [373, 374]. However NB001 has limitations in its selectivity for
AC1 over AC8 (nearly 10 fold) and appears not to directly inhibit the AC1 activity.
Thus, the Watts group screened for additional AC1 inhibitors and discovered a more
potent and selective AC1 inhibitor ST034307 which had been characterized by several
models and stimulation paradigms. The eﬀects of ST034307 on inﬂammatory pain
and opioid withdrawal animal models were subsequently examined in this study.
The development of chronic pain is associated with LTP through a persistent
strengthening of synaptic connection in the ACC and the spinal dorsal horn [362,369].
It is hypothesized that the activation of NMDA (N-methyl-D-aspartate) receptor
causes inﬂux of Ca2+ ions, activation of AC1, and subsequently production of cAMP,
a crucial modulator of LTP [369]. LTP is also an important cellular process of learning
and memory formation [362, 369]. As discussed earlier, inhibition of AC1 activity
can be exploited for achieving pain management despite the fact that those used
AC1 inhibitors need to be highly selective for AC1 versus AC8 to avoid the side
eﬀect of memory impairments. The Watts lab has shown that ST034307 selectively
inhibits AC1 but not AC8 at doses up to 30 µM, indicating pronounced selectivity
for inhibition of AC1 over AC8. Furthermore ST034307 was not shown to inhibit
any other membrane-bound AC isoforms. The results of unchanged AC1 inhibition
in response to ST034307 when Gβγ was sequestered or Gαi/o signaling was blocked
also conﬁrmed that ST034307 suppressed the cAMP signaling through the inhibition
of AC1 and not the G protein subunits.
One limitation of the AC1 inhibitor NB001 is that it does not inhibit AC1 activity
in intact cell membranes [485], suggesting that NB001 may not inhibit AC1 directly
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and may have its own unique mechanism to inhibit AC1 activity [485]. Unlike NB001,
ST034307 was able to inhibit AC1 activity in cell membranes prepared from AC1expressing HEK or Sf9 cells.
MOR is widely expressed in the ACC and spinal dorsal horn where AC1 is also
located.

Activation of MOR leads to diverse downstream coupling, resulting in

diﬀerent physiological functions [494, 495]. Upon MOR activation, Gαi/o and Gβγ
subunits dissociate. Gαi/o then inhibits the activity of ACs, while Gβγ subunits
regulate the activation of G protein-coupled inwardly rectifying potassium (GIRK)
channels [301]. Interestingly, activation of either Gαi/o or Gβγ subunits inhibits the
activity of AC1 [357, 496]. These cellular mechanisms are known to be associated
with antinociceptive eﬀects of MOR agonists [376, 497–499]. Despite the canonical
pathway MORs can also signal through β-arrestins [494, 496, 500] that is believed to
be connected with deleterious side eﬀects of opioids such as tolerance and respiratory
depression [376,497–499]. Therefore agonists used for pain therapy should bias signaling to activate G protein and inhibit AC, and not activate β-arrestins to limit the side
eﬀects [369–371, 483, 486–488]. The Watts group investigated the eﬀects of ST034207
on MOR signaling. They observed that ST034307 and the MOR-selective agonist
DAMGO had additive eﬀects for AC1 inhibition at submaximal concentrations, suggesting that ST034307 at least may have similar eﬀect on Gαi/o protein activation as
MOR. Notably ST034307 did not have an impact on β-arrestin recruitment to MOR
indicating a promising sign of ST034307 for the avoidance of side eﬀects.
Prolonged G protein activation in response to MOR agonists can contribute to
neuroadaptive changes called heterologous sensitization [501] that is associated with
opioid dependence [376, 377, 483]. One key feature of heterologous sensitization is
a signiﬁcant increase in AC activity [376, 377, 501, 502]. Genetic deletion of AC1 in
mice attenuated several behaviors related to morphine dependence [380, 381]. This is
consistent with previous studies determining the role of NB001 in heterologous sensitization and the opioid antagonist naltrexone-precipitated hyperalgesia [483]. The
Watts group demonstrated that ST034307 prevented the development and mainte-
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nance of heterologous sensitization of AC1, indicating that AC1 inhibition can inhibit
the cellular consequences following repeated MOR activation.
Next I investigated the potential of ST034307 for analgesia in an animal model
of inﬂammatory pain evoked by an intraplantar injection of CFA. ST034307 was
capable of reducing the inﬂammatory pain in a dose-dependent manner. To assure
that mechanisms underlying AC1-mediated inﬂammatory pain is a result of AC1
inhibition and decreased cAMP levels, coinjections of the AC activator forskolin and
ST034307 into mice after the induction of inﬂammatory pain were then performed.
We anticipated that forskolin would increase cAMP levels and counteract the analgesic
eﬀects of ST034307. As expected, ST034307 failed to decrease inﬂammatory pain in
the presence of forskolin. These results further illustrate that AC1 inhibitors may be
beneﬁcial for inﬂammatory pain therapy as either standalone treatment or adjuvant
to minimize opioid doses and prevent side eﬀects associated with opioids.
AC1, AC5, and AC8 have been shown to be involved in chronic morphine actions
as demonstrated in genetic deletion of these adenylyl cyclase isoforms in mice causing
an attenuation of some somatic withdrawal signs [381, 382]. This is consistent with
cells chronically exposed to morphine showing the superactivation of AC1, AC5, and
AC8 [490, 503]. I therefore explored the potential of ST034307 for treating morphine
withdrawal symptoms by injecting mice with escalating doses of morphine twice daily
for consecutive 7 days, and then treating the mice with 1 or 3 mg/kg of ST034307.
The intraperitoneal administration was chosen to test the eﬀect of ST034307 on morphine withdrawal as opioid withdrawal symptoms are mediated by adaptations in the
central and peripheral nervous system [504] and the substance administered would
primarily absorb into the mesenteric vessels before undergo the systemic circulation [505]. The opioid withdrawal symptoms were precipitated by an injection of
the opioid receptor antagonist naloxone at 10 mg/kg. I observed sex diﬀerences in
the withdrawal behaviors following the ST034307 treatment which may be reconciled
by diﬀerences in their severity of withdrawal symptoms. Previous ﬁnding indicates
that female C57BL/6 mice have more somatic signs of withdrawal and their global
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withdrawal scores last longer than the male mice [506]. Moreover male mice treated
with 1 mg/kg of ST034307 reduced some distinct withdrawal symptoms. This is in
agreement with earlier reports showing that AC1 knockout mice display the overlap
of attenuated morphine withdrawal symptoms [380]. However, it is important to note
that our pilot studies used only 4-5 mice per treatment group. Further research is
needed to include a larger number of animals for verifying our preliminary ﬁndings
as well as to elucidate optimal dose-response relationships.
Here we used the small molecule AC1 inhibitor to reduce concerns about the
confounds associated with using a genetic knockout mouse. The incomplete blockade of somatic withdrawal signs may be because of the presence of other adenylyl
cyclase isoforms (e.g. AC5 and AC8 as described above) and phosphorylated-CREB
(pCREB). pCREB is implicated in morphine actions as demonstrated in mice treated
with CREB antisense oligonucleotide infusion [507] or CREB knockout mice [508] exhibiting some attenuated withdrawal behaviors. The phosphorylation of CREB is
mediated by several kinases including cAMP-activated protein kinase A (regulated
by ACs) or calcium/calmodulin- or mitogen-activated protein kinases [509]. Thus the
residual withdrawal behaviors following the ST034307 treatment indicates that AC1
is not the sole mediator responsible for the morphine withdrawal behaviors. Further study on the downstream targets of ACs and cellular pathways involving the
morphine response is needed. Since this study only showed the role of AC1 in the
expression of morphine withdrawal, it will be worthwhile to also investigate the eﬀect
of ST034307 on the establishment of morphine withdrawal.
Collectively, the Watts group identiﬁed and characterized a potent small-molecule
AC1 selective inhibitor ST034307 of which I further explored the role in in vivo
contexts. ST034307 displayed analgesic properties in an inﬂammatory pain model
and was able to relieve the morphine withdrawal syndrome to some extent. Future
studies that examine the eﬀect of ST034307 on learning and memory are also necessary
as AC1 inhibition has been reported to cause memory impairments to a certain extent
[365, 366].
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5. CONCLUSIONS AND FUTURE DIRECTIONS
To date, mu opioid receptor (MOR) agonists, including morphine and oxycodone
are still amongst the most potent and eﬀective painkillers. While they are eﬀective
for acute pain, they are not useful for chronic pain and produce several adverse
eﬀects such as opioid addiction, tolerance, and respiratory depression. In 2015, an
estimated 33,091 people in the US died because of opioid overdose [510]. Therefore,
it is critical that we discover novel and better targets for chronic pain relief. Here
we have examined diﬀerent promising targets including delta opioid receptor (DOR),
DOR-MOR heteromers and adenylyl cyclase type I (AC1) which have all been shown
to be involved in chronic pain processing [131, 214, 215, 369].
In chapter 2, we have studied one of the hallmarks of chronic pain which is mechanical allodynia (pain responses to normally innocuous stimuli). Mechanical allodynia
is also a component of the alcohol withdrawal syndrome, consisting of several separate
symptoms additionally including anxiety and depression, that can facilitate alcohol
relapse [164, 218, 397]. The currently available drug treatments for alcoholism rarely
combat the complexities of the withdrawal syndrome [398,399]. Yet, the mechanisms
underlying alcohol withdrawal symptoms speciﬁcally allodynia are still not well understood, hampering development of novel medications that could treat the alcohol
withdrawal syndrome and reduce relapse.
Recent studies have shown that DORs are expressed in neurons responding to
mechanical stimulation and are heavily involved in the sensation of touch [213, 405].
Alcohol exposure can elevate functional DOR expression in diﬀerent areas of the
central nervous system [161,162]. Moreover, DOR agonists have been shown to reduce
chronic pain [131]. We therefore propose that the DOR could be a novel target
for alcohol withdrawal-induced mechanical allodynia (AWiMA) therapy, particularly
considering that DOR agonists also reduce alcohol consumption [182] and attenuate
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anxiety and depression in alcohol-withdrawn mice [183]. To study AWiMA, adult
male wild-type and DOR knockout C57/BL6 mice were exposed to alcohol by either a
voluntary drinking or oral gavage exposure. The DOR-selective agonist TAN-67 [406]
and antagonist naltrindole [172] were also used to examine the involvement of the
DOR in AWiMA, which was measured using a von Frey nociception test.
We have generated a novel animal model of the alcohol withdrawal syndrome,
which can be used for further research to address its underlying mechanisms and
treatments. Additionally, we found that AWiMA was exacerbated and prolonged in
DOR knockout mice compared to control mice, indicating a protective role of the DOR
in the establishment of AWiMA. Using the DOR-selective antagonist naltrindole, we
also showed that the mice exhibited prolonged AWiMA. However, analgesia induced
by TAN-67 was attenuated during withdrawal in alcohol-gavaged mice, suggesting
that DORs appear to be either desensitized or downregulated once mice reside in
a state of severe alcohol withdrawal. It is possible that the presence of DORs may
intervene the function of algogenic factors like Toll-like receptor 4 (TLR4) following
chronic alcohol exposure. TLR4s are highly expressed in the glial cells and primary
sensory neurons. Activation of TLR4 participates in opioid-induced hyperalgesia and
neuropathic pain [423–425]. Interestingly, alcohol consumption leads to an increase in
TLR4 expression and TLR4-evoked release of inﬂammatory mediators [426, 427]. It
would be of interest to examine the contribution of TLR4 and possibly the crosstalk
between TLR4 and DOR in AWiMA by investigating the eﬀects of genetic deletion of
TLR4 or TLR4-selective antagonists in our animal model of the alcohol withdrawal
syndrome.
We have employed the DOR-selective agonist TAN-67 and shown its analgesic
property during the AWiMA expression. However, the potency of TAN67 was reduced in the mice withdrawn from o.g. alcohol compared to naive mice. Previous
reports have demonstrated that TAN-67 has strong G-protein signaling bias, with limited β-arrestin 2 recruitment [295]. As discussed earlier, cellular signaling pathways
implicated in the AWiMA may be associated with the algogenic mediator TLR4 [427].
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The activation of DORs could inhibit the ampliﬁcation of proinﬂammatory signaling
evoked by TLR4, which may be responsible for hyperalgesia, through mechanism
involving β-arrestin 2 [428]. It is plausible that having β-arrestin 2 signaling may
help to treat AWiMA. Thus future studies that explore the eﬀects of diﬀerent DORselective agonists with eﬃcacy for β-arrestin 2 recruitment on AWiMA are of interest.
However, there should be concern with the use of DOR agonists that strongly recruit
β-arrestin 2 as they can elevate alcohol consumption [295] and may lead to alcohol
relapse. DOR agonists with an intermediate β-arrestin 2 recruitment eﬃcacy such
as KNT-127 [206, 295, 440, 441] would be considered as another potential therapy for
AWiMA for future studies.
We are also aware of reports illustrating that TAN-67 may interact with DORMOR heteromers [182]. A recent study has reported that electro-acupuncture attenuates thermal hyperalgesia in alcohol withdrawn rats through MORs in the lateral
habenula [511], suggesting that MORs may play a protective role against alcohol withdrawal induced hyperalgesia. Previous studies have revealed the contradictory eﬀects
of DOR-MOR in nociception. Some have demonstrated that DOR-MOR heteromers
have negative eﬀects on MOR-mediated analgesia [214,215], while others have shown
that activation of DOR-MOR by ligand combinations of MOR agonists and DOR
antagonists can augment MOR antinociception [311, 354]. The role of DOR-MOR
heteromers in nociception remains unclear thereby making the use of DOR-MOR
heteromer-active ligands for AWiMA therapy debatable.
Our results have also indicated that administration of the DOR-selective antagonist naltrindole during alcohol exposure periods prolongs AWiMA expression in mice,
suggesting that leu-enkephalin, a putative endogenous ligand for DORs, may be beneﬁcial for AWiMA treatment. Thus another promising strategy for future studies
on AWiMA therapy could be increasing basal tones of leu-enkephalin by using positive allosteric modulators (PAMs) [512] or enkephalinase inhibitors which inhibit
enkephalinase enzymes that break down the endogenous enkephalin. Enkephalinase
inhibitors have been shown to exert antinociceptive eﬀects [513]. PAMs or enkephali-
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nase inhibitors could also be used in combination with MOR agonists to curtail overdose issues. However, enkephalins have been reported to either increase or decrease
alcohol intake which can be explained by opioid reward- or opioid compensationhypotheses of alcoholism, respectively [244]. These inconsistent results regarding the
role of the endogenous opioids in alcohol consumption mean that we should be careful
to consider enhancing enkephalin levels as a therapeutic strategy. The discovery of
novel PAMs that engender the signaling bias toward desired pathways [514] (possibly favor Gi protein activation with a low-intermediate recruitment of β-arrestin 2
for AWiMA therapy) would be valuable based on studies highlighting the negative
impact of β-arrestin 2 recruitment on alcohol use [295].
In order to design the most eﬀective drugs for AWiMA and alcohol withdrawal
syndrome, it is necessary to understand detailed mechanisms underlying alcohol withdrawal. As we have shown in our current study that DOR can be a drug target for
AWiMA therapy, it will be worthwhile to determine dynamics of protein and mRNA
expression of the DOR signal transduction machinery during the establishment and
expression of AWiMA. The expression of DORs is highly dynamic. Most of newly
synthesized DORs reside in vesicles under the plasma membrane in naive conditions
and can be translocated to the cell surface during chronic alcohol exposure [161].
DORs can also be activated by their endogenous ligands, enkephalins, which play an
important role in the basal homeostasis of nociceptive signal transduction. The expression of enkephalins is enhanced under chronic stress conditions including chronic
inﬂammation and chronic alcohol exposure [251, 268, 437, 438] or by inhibition of
enkaphalinases [515, 516]. Also, alcohol withdrawal has been shown to reduce mRNA
expression levels of enkephalinases, conﬁrming increased enkephalin levels in this condition [517]. Knockout of the enkephalin precursor gene (preproenkephalin) decreases
the levels of enkephalin and has been shown to modulate anxiety-like behaviors assessed in an open ﬁeld and elevated O-maze test [518]. This is consistent with the
observed anxiety-like behaviors in DOR knockout mice [287], highlighting the potential of targeting DORs in alcohol withdrawal as anxiety disorder is one of the
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major alcohol withdrawal symptoms. The expression of β-arrestin 2 is another important factor modulating DOR pharmacology that requires additional investigation
as the eﬃcacy of DOR agonists to recruit β-arrestin 2 is positively associated with
their ability to enhance alcohol consumption [295]. The levels of β-arrestin 2 are
also shown to be diﬀerent in alcohol preferring and alcohol non-preferring rats [519].
Thus more research needs to be done to determine the dynamic expression patterns
of DOR, preproenkephalin, enkephalin-degrading enzymes like alanyl aminopeptidase
and neprilysin, and β-arrestin 2 in AWiMA by using quantitative RT-PCR and western blot analysis. Although our current data supports the DOR as a drug target
for prevention but not treatment of AWiMA, it is important to consider that DOR
agonists alleviate other components of the alcohol withdrawal syndrome and decrease
the risk of relapse.
In chapter 3, we have identiﬁed which amino acids in the DOR-MOR heteromer
interface are important in forming and maintaining the heteromers. Previous studies
have suggested that DORs can physically interact with MORs at the transmembrane domain ﬁve and six (TM5-6) interface [303] to form so-called DOR-MOR heteromers [310]. DOR-MOR heteromers appear to display unique function relative to
MOR monomer/homodimers and may contribute to adverse eﬀects of long-term opioid therapy for chronic pain [214,215]. The disruption of heteromeric complexes may
therefore be useful to lessen the side eﬀects of MOR agonists. Yet, there are still lack
of tools that target DOR-MOR heteromers for investigating their role in preclinical
and clinical models. Based on previously published studies of crystal structures of
the DOR and MOR [303,304], we created nearly ﬁfty mutants spanning TM5-6 of the
DOR. The interface mutants located in the intracellular loop 3 (IL3) which connects
TM5 with TM6 were also generated and used as positive controls since they have
been established as the potential sites important for heteromer interface [460]. Using
a heteromer-selective calcium signaling assay by fusing a chimeric Gqi4 protein to a
truncated DOR and co-expressing it with a wild-type MOR [465], we demonstrated
that single mutations at amino acid positions Tyr5.33 , Trp5.34 , Phe5.47 , Ile6.53 , and
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Asp6.62 and at IL3 inhibited the DOR-MOR heteromer function. These promising
interface sites were then validated using a bimolecular ﬂuorescence complementation
(BiFC) assay for which we fused the DOR and MOR to complementary fragments of
a ﬂuorescent protein [520]. The BiFC data veriﬁed the results for mutations at amino
acid positions Tyr5.33 , Trp5.34 , Ile6.53 and Asp6.62 to be disruptive and conﬁrmed that
IL3 also played a role in the heteromer formation.
The combined data from all of the mutants were employed to optimize a computational model of DOR-MOR heteromers. The optimized computational model further
identiﬁed reciprocal amino acids in the MOR that could be crucial for the formation
of the DOR-MOR heteromers. We constructed those additional reciprocal mutants
and subsequently tested them in signaling and biochemical assays. The results have
shown that amino acid positions Tyr5.33 and Thr6.62 are crucial in the heteromer formation. To strengthen the claims of the heteromer disruption, we also performed a
third biochemical co-immunoprecipitation assay [182]. With respect to the reports on
the crystal structures [303,304] and the molecular dynamics simulations [478] showing
the importance of TM1/2 in the DOR-MOR heteromer formation, it will be worthwhile to study those regions by mutating residues in the TM1/2 of either MOR and
DOR and investigate their eﬀects on the dimer disruption. In conclusion, using a
multipronged approach, the results suggest that amino acid, in particular near the
extracellular side of TM5-6, positions Tyr5.33 , Trp5.34 , and Asp6.62 appear to be crucial
in forming and maintaining the heteromers. These studies will move us closer to the
development of protein-protein interaction inhibitors that can be used with opioid
analgesics to prevent or delay adverse eﬀects of chronic opioid therapy.
Currently a major hurdle to overcome when aiming to disrupt heteromer function
relates to the ability to obtain functional inhibitors of the DOR-MOR heteromers
that can block the DOR-MOR heteromers without aﬀecting either the MOR- or
DOR-homodimers so that they can be employed to precisely dissect each receptors
role in opioid analgesia. Unlike targeting a known orthosteric binding site, targeting an allosteric protein-protein interaction site may require more examination into
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the optimal length and targeted site of the inhibitors. Based on the hypothesis that
DOR-MORs are a contributing factor in the development of morphine tolerance, it
will be useful to develop a DOR-MOR protein-protein interaction inhibitor and test
it in morphine tolerant or in combination with morphine in naive mice to elucidate
the drug potential to reverse or prevent morphine tolerance. Besides tolerance, the
role of DOR-MORs in opioid induced respiratory depression and opioid addiction are
also worth exploring as chronic morphine exposure enhanced DOR-MOR heteromer
expression in the rostral ventral medulla (RVM), nucleus accumbens (NAcc), and
ventral tegmental area (VTA) [326]. The RVM is a brain region implicated in opioid
induced respiratory depression [521]. The NAcc and VTA are brain regions associated
with opioid addiction [522]. Another hurdle that still remains in the DOR-MOR heteromer ﬁeld is identifying their existence and physiological function in vivo because
most evidence on GPCR heteromers have been reported in artiﬁcial cell systems. The
development of DOR-MOR heteromer-selective inhibitors, especially systemically active small molecule inhibitors, will also aid in overcoming this hurdle. Understanding
protein interfaces that have unique amino acid composition and mimicking the types
of binding interactions can provide insights into targeting such protein-protein interactions and help to accelerate the development of DOR-MOR inhibitors.
The methods used in the heteromer study could also be used for the development of protein-protein interaction inhibitors for other GPCR oligomers involved in
nociceptive and opioid related pharmacology such as heteromers of MOR1D splice
variant and gastrin-releasing peptide receptor associated with opioid-induced pruritis [523], obligatory homodimers of GABAB implicated in neuropathic pain [524]. To
measure the interaction of either homodimer or heteromer formation simultaneously,
the multi-color BiFC technique can be exploited by using diﬀerent N terminal halves
of venus YFP (Vn) and cerulean CFP (Cn) which are able to complement with a
C terminal half of cerulean CFP (Cc). The diﬀerent ﬂuorescent signals from BiFC
complexes including vYFP (Vn+Cc) or cCFP (Cn+Cc) can be simply detected by
ﬂuorescence microscopy [525] (Figure 5.1).
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Fig. 5.1. Simultaneous detection of GPCR homomers and heteromers
by multi-color BiFC. Upon interactions of diﬀerent receptors, receptors tagged with venus N termini (Vn) and receptors tagged with
cerulean C termini (Cc) reconstitute a yellow ﬂuorescent protein,
whereas receptors tagged with Cc and receptors tagged with cerulean
N termini (Cn) reconstitute cerulean CFP.
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In chapter 4, we revealed that a selective small-molecule inhibitor of type 1 adenylyl cyclase activity ST034307 was able to reduce pain associated with inﬂammation
and had a tendency to prevent morphine withdrawal symptoms. AC1 is highly expressed in neuronal tissues associated with pain processing and is the enzyme that
synthesizes cAMP which functions as a critical second messenger in opioid receptor
signaling [526]. cAMP and its signaling pathways are known to be involved in nociception [527]; elevated cAMP levels typically lead to enhanced nociception, while
decreased cAMP levels by AC inhibitors or other agents contribute to antinociception. For example our studies have revealed that the AC1 inhibitor ST034307 exerts
analgesic eﬀects in inﬂammatory pain [493]. This corresponds to previous data showing that administration of either the AC activator forskolin or phosphodiesterase
inhibitors, to prevent cAMP breakdown, prolong inﬂammatory hyperalgesia [528]. It
is feasible that AC1 inhibitors can be used as a standalone pain management in future studies. Activation of either MOR or DOR can couple to inhibitory G-protein Gi
and inhibit ACs, resulting in diminished cAMP-induced nociceptor excitability [529].
However in vitro repeated stimulation of MORs can lead to so-called cAMP superactivation [489, 490]. It has also been shown that in vivo prolonged opioid exposure
and opioid withdrawal paradoxically upregulate the activity of ACs particularly AC1,
AC5, and AC8 [530] that subsequently contributes to opioid-induced abnormal pain
sensitivity and tolerance [491,492]. AC1 knockout mice showed a signiﬁcant decrease
in chronic pain responses, providing supportive evidence for linkage between AC1
and chronic pain [369]. Our results have demonstrated that a recently identiﬁed AC1
inhibitor ST034307 is able to produce analgesia in a Complete Freunds Adjuvant
model of acute inﬂammatory pain [493]. The in vitro data has also suggested the additive/synergistic interaction between AC1 inhibition and opioid receptor activation
in preventing cAMP formation [493]. It will be of interest to further investigate the
eﬃcacy of AC1 inhibitors in other models of chronic pain like arthritic pain because
arthritis which occurs in 20% of US adults is a major source of chronic inﬂammatory pain [531]. Currently opioids are not recommended for use in treating arthritic
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pain [532], but AC1 inhibitors either alone, or co-administered with a MOR painkiller
could prove to be a novel strategy. Animal models exist to induce an arthritic-pain
like state; for example, injecting mice with collagen or kaolin/carrageenan [533]. Using AC1 inhibitors as adjuvants to MOR analgesics may be useful to lower opioid
dose and prevent opioid dependence or withdrawal as evidenced by reduced opioid
withdrawal behaviors in AC1 and AC8 knockout mice [381]. To provide additional
support for the clinical relevance of AC1 inhibitors, they can be investigated in three
clinically relevant scenarios: 1) as a standalone therapy in opioid-naive animals, 2)
in combination with an opioid analgesic, and 3) in opioid-tolerant mice. Broadly
these studies can support the development of more selective AC1 inhibitors for the
treatment of chronic inﬂammatory pain and studies into the mechanisms by which
AC1 and opioid receptors are interacting under inﬂammatory conditions.
It will also be of interest to use AC1 inhibitors in conjunction with DOR agonists
to minimize opioid dose and the risk of adverse eﬀects for pain management because
the main hurdle for the clinical development for DOR agonists is their ability to
produce convulsion [534,535]. It is hypothesized that cellular mechanisms underlying
DOR agonist-induced convulsion may be associated with a forebrain hyperexcitability
[203, 536, 537]. AC-mediated cAMP levels are crucial signaling pathways involved
in maintaining the excitability of central nervous system [538]. Animal study has
shown that overexpression of AC1 in the forebrain leads to hyperactive behaviors
[539], whereas genetic deletion of AC1 and AC8 displays hypoactive behaviors. This
indicates that inhibition of AC1 may help to reduce the hyperactivity in the forebrain
and potentially convulsion.
Studies employing AC1 knockout mice suggest that AC1 may be beneﬁcial of
treating opioid withdrawal [380,381]. Our results have also shown that ST034307 has
a tendency to inhibit morphine withdrawal symptoms. Yet, it is unclear whether the
complicated neuroadaptive changes in opioid withdrawal are caused by an inhibition of
a single AC isoform as multiple signaling pathways besides AC inhibition are involved
in opioid withdrawal [530]. Future studies that explore the potential of selective
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inhibitors of other single AC isoforms or in combination with AC1 to decrease opioid
withdrawal symptoms are essential.
AC1 and AC8 double knockout mice exhibited impaired long-term memory and
late phase LTP [365], implying that non-selective inhibition of ACs may cause some
detrimental side eﬀects. However the inhibition of a single AC1 isoform may not
result in serious memory impairments as evidenced by lack of LTP inhibition in the
hippocampus and eﬀects on contextual fear memory [374] observed in mice treated
with the AC1 inhibitor NB0001. Since AC1 is widely expressed in the hippocampus,
future studies that investigate the eﬀect of ST034307 on learning and memory are
necessary. The mice treated with ST034307 could be tested on various types of
learning and memory including the Morris water maze, the novel object recognition,
the contextual learning, or the passive avoidance tests [365].
Altogether our studies have provided signiﬁcant insights into mechanisms and eﬃcacy of DOR, DOR-MOR heteromers, and AC1 for development of drugs for chronic
pain with few observable side eﬀects (Figure 5.2).
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Fig. 5.2. Summary diagram of novel therapeutic targets for chronic
pain. The novel therapeutic targets for chronic pain discussed in this
study include DOR-MOR heteromers, DOR, and AC1. Activation
of DOR-MOR leads to downstream coupling of Gz and β-arrestin 2
which is believed to cause side eﬀects of opioids. Activation of DOR
contributes to downstream coupling of β-arrestin 2 and dissociation of
Gαi/o and Gβγ subunits. Gαi/o protein is then able to inhibit the AC
activity, reduce cAMP levels, and subsequently decrease nociception.
Collectively DOR-MOR inhibitors, DOR biased ligands (favor Gαi/o
signaling pathway), and AC1 inhibitors should be considered for the
development of new drugs for the treatment of chronic pain with few
side eﬀects.
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